3051_Seifer_00FM 11/27/01 3:41 PM Page i
Office-Based Infertility Practice
3051_Seifer_00FM 11/27/01 3:41 PM Page ii...
106 downloads
2473 Views
8MB Size
Report
This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form
3051_Seifer_00FM 11/27/01 3:41 PM Page i
Office-Based Infertility Practice
3051_Seifer_00FM 11/27/01 3:41 PM Page ii
3051_Seifer_00FM 11/27/01 3:41 PM Page iii
David B. Seifer, M.D.
Robert L. Collins, M.D.
Director, Division of Reproductive Endocrinology and Infertility and Professor and Vice-Chair of Academic Affairs Department of Obstetrics, Gynecology and Reproductive Sciences UMDNJ-Robert Wood Johnson Medical School New Brunswick, New Jersey
Medical Director, The Reproductive Center Youngstown, Ohio and Associate Professor Department of Obstetrics and Gynecology Northeast Ohio University College of Medicine Rootstown, Ohio
Editors
Office-Based Infertility Practice With 58 Figures
3051_Seifer_00FM 11/27/01 3:41 PM Page iv
David B. Seifer, M.D. Director, Division of Reproductive Endocrinology and Infertility and Professor and Vice-Chair of Academic Affairs Department of Obstetrics, Gynecology and Reproductive Sciences UMDNJ-Robert Wood Johnson Medical School 303 George Street New Brunswick, NJ 08901, USA
Robert L. Collins, M.D. Medical Director Reproductive Endocrinologist The Reproductive Center Youngstown, OH 44514, USA and Associate Professor Department of Obstetrics and Gynecology Northeast Ohio University College of Medicine Rootstown, OH 44272, USA
Cover illustration: Bottom illustration represents the profile of a 20 week-old fetus. © Department of Prenatal Diagnosis and Therapy, Chairman: G. Bernaschek, University of Vienna, Austria.
Library of Congress Cataloging-in-Publication Data Office-based infertility practice / editors, David B. Seifer, Robert L. Collins p. cm. Includes bibliographical references and index. ISBN 0-387-98390-2 (hbk : alk. paper) 1. Infertility. 2. Office practice. 3. Human reproductive technology. I. Seifer, David B., 1955– II. Collins, Robert L. RC889 .O35 2001 616.6.9206—dc21 00-053200 Printed on acid-free paper. © 2002 Springer-Verlag New York, Inc. All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Springer-Verlag New York, Inc., 175 Fifth Avenue, New York, NY 10010, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use of general descriptive names, trade names, trademarks, etc., in this publication, even if the former are not especially identified, is not to be taken as a sign that such names, as understood by the Trade Marks and Merchandise Marks Act, may accordingly be used freely by anyone. While the advice and information in this book are believed to be true and accurate at the date of going to press, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein. Production managed by Jenny Wolkowicki; manufacturing supervised by Joseph Quatela. Typeset by Matrix Publishing Services, Inc., York, PA. Printed and bound by Edwards Brothers, Inc., Ann Arbor, MI. Printed in the United States of America. 9 8 7 6 5 4 3 2 1 ISBN 0-387-98390-2
SPIN 10660187
Springer-Verlag New York Berlin Heidelberg A member of BertelsmannSpringer Science+Business Media GmbH
3051_Seifer_00FM 11/27/01 3:41 PM Page v
This book is dedicated to our children Ben Joseph Seifer, Charlie Max Seifer, Denise Collins, and Robbie Collins, for the joy, love and promise they represent.
This page intentionally left blank
3051_Seifer_00FM 11/27/01 3:41 PM Page vii
Preface The practice of clinical reproductive medicine has gradually moved from its initial 1980–90 hospital base to its present (circa 2001) office site of operation. With this transition have been improvements in efficiency of practice often in response to increased pressure to provide the most patient satisfaction. An added challenge of office-based practice has been taking on many of the responsibilities of what had been traditionally the hospital’s domain. Some of these new responsibilities have included the ordering of operative supplies and equipment, the establishment of quality control programs, construction and maintenance of special laboratory spaces, redesigning efficient methods of
practice in the era of managed care and coordinating ancillary offsite medical personnel. The objective of this text is to assist in this ongoing endeavor by presenting in a clear, concise manner many of the topics relevant to contemporary office-based infertility practice. The initial half of this text addresses topics which focus upon general concepts of infertility evaluation and practice. The latter half is a practical approach to the execution of specific office-based infertility procedures. We hope this book will assist all medical personnel who dedicate their clinical effort in achieving what is most coveted by our patients, the birth of a healthy newborn. DAVID B. SEIFER, M.D. UMDNJ-Robert Wood Johnson Medical School ROBERT L. COLLINS, M.D. The Reproductive Center, Youngstown, Ohio October 2001
vii
This page intentionally left blank
3051_Seifer_00FM 11/27/01 3:41 PM Page ix
Contents
Preface . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Contributors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
vii xi
1 Evaluation of the Female for Infertility . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Bryan D. Cowan
1
2 Evaluation of the Male for Infertility . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Kevin A. Spear
10
3 Detection and Therapeutic Approaches to Age-Related Infertility . . . . . . . . . . . . . . . . . . . . Fady I. Sharara, Richard T. Scott, Jr., and David B. Seifer
24
4 Role of Ultrasonography in Infertility . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Theresa Widrich
39
5 Coping with Infertility: Practical Psychosocial Issues . . . . . . . . . . . . . . . . . . . . . . . . . . . . Dorothy Greenfeld
49
6 Impact of Managed Care on Office-Based Infertility Practice . . . . . . . . . . . . . . . . . . . . . . Richard E. Blackwell
58
7 Basics of Laboratory Set-Up in the Office . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Dean E. Morbeck
63
8 Office Anesthesia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Angeline N. Beltsos
77
9 Ovulation Induction and Controlled Ovarian Hyperstimulation with Intrauterine Insemination . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100 Robert L. Collins 10 Diagnostic and Therapeutic Hysteroscopy in the Office . . . . . . . . . . . . . . . . . . . . . . . . . . . 116 David A. Grainger, Bruce l. Tjaden, and Arjav Shah 11 Endoscopic Evaluation of the Fallopian Tube . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127 Eric S. Surrey 12 Transcervical Tubal Cannulation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 137 Jacek W. Graczykowski and David B. Seifer 13 Microlaparoscopy for Infertility in the Office . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 141 Steven F. Palter 14 Treatment of Cervical Stenosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 147 Gary N. Frishman 15 Treatment of Male Reproductive Dysfunction in the Office . . . . . . . . . . . . . . . . . . . . . . . . 150 Hossein Sadeghi-Nejad and Robert Oates
ix
3051_Seifer_00FM 11/27/01 3:41 PM Page x
x
Contents
16 In Vitro Fertilization in the Office Setting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 161 Glen K. Adaniya and Bradford L. Bopp 17 Unstimulated In Vitro Fertilization and In Vitro Oocyte Maturation . . . . . . . . . . . . . . . . . . 174 Phillip E. Patton and Don P. Wolf 18 Intratubal Gamete Transfer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 184 Kristin Sinnock Friel and Alan S. Penzias 19 Complications of Ovulation Induction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 195 Janee A. Fonslick and David B. Seifer Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 203
3051_Seifer_00FM 11/27/01 3:41 PM Page xi
Contributors
Glen K. Adaniya, P.h.D., Midwest Reproductive Medicine, 8081 Township Live Road, Indianapolis, IN 46260, USA Angeline N. Beltsos, M.D., Suite 195, 135 North Arlington Heights Road, Buffalo Grove, IL 60089, USA Richard E. Blackwell, M.D., University of Alabama at Birmingham, Department of Obstetrics and Gynecology, 1918 University Boulevard, Birmingham, AL 35294-0005, USA Bradford L. Bopp, M.D., Midwest Reproductive Medicine, 8081 Township Live Road, Indianapolis, IN 46260, USA Robert L. Collins, M.D., Medical Director, The Reproductive Center, Youngstown, OH 44514 and Associate Professor of Obstetrics and Gynecology, Northeast Ohio College of Medicine, Rootstown, OH 44272, USA Bryan D. Cowan, M.D., Professor, Department of Obstetrics and Gynecology, University of Mississippi Medical Center, Jackson, MS 39216-4505, USA Janee A. Fonslick, M.D., Abington Obstetrical and Gynecological Associates, Building 2, 300 Welsh Road, Horsham, PA 19044, USA Kristin Sinnock Friel, Lehigh Valley Hospital Allentown, PA 18103, USA Gary N. Frishman, Women’s and Infant’s Hospital, Brown Medical School, 101 Dudley Street, Providence, RI 02 905-0000, USA Jacek W. Graczykowski, Reproductive Health and Fertility Center, 973 Featherstone Road, Suite 100, Rockford IL 61107, USA David A. Grainger, M.D., Director, Division of Reproductive Endocrinology, 9220 E., 29th N Suite 102, Wichita, KS 67226, USA Dorothy Greenfeld, M.S.W., Yale University School of Medicine, Department of Obstetrics and Gynecology WP-402, PO Box 208063, New Haven, CT 06520-8063, USA Dean E. Morbeck, Ph.D., Midwest Center for Reproductive Health, Oakdale Medical Building, 3366 Oakdale Ave North #550, Minneapolis, MN 55422, USA Robert D. Oates, M.D., Department of Urology, Boston University Medical Center, 720 Harrison Avenue, Suite 606, Boston, MA 02118-2334, USA Steven F. Palter, Yale University School of Medicine, Department of Obstetrics and Gynecology, WP402 PO Box 208063, New Haven, CT 06520-8063, USA Phillip E. Patton, M.D. and Professor, University Fertility Consultants Department of Obstetrics and Gynecology, Oregon Health Services University, 1750 SW Harbor Way, Suite 100, Portland, OR 97201, USA
xi
3051_Seifer_00FM 11/27/01 3:41 PM Page xii
xii
Contributors
Alan S. Penzias, M.D., Boston IVF, 40 Second Avenue Suite 300, Waltham MA 02451, USA Hossein Sadeghi-Nejad, Director, Center for Male Reproductive Medicine, UMD-New Jersey Medical School and Hackensack University Medical Center, 20 Prospect Ave, Suite 711, Hackensack NJ 07601, USA Richard T. Scott, Jr., M.D., Reproductive Medicine Associates, 111 Madison Avenue Suite 100, Morristown, NJ 07962, USA David B. Seifer, M.D., Director, Division of Reproductive Endocrinology and Infertility, and Professor and Vice-Chair of Academic Affairs, Department of Obstetrics, Gynecology and Reproductive Sciences, UMDNJ–Robert Wood Johnson Medical School, 303 George Street, Suite 250, New Brunswick NJ 08901, USA Arjav Shah, M.D., Orange Park Medical Center, 1605 Kinsley Avenue, Orange Park, FL 32073, USA Fady I. Sharara, M.D., The Fertility and Reproductive Health Center, 4316 Evergreen Lane, Annandale, VA 22003, USA Kevin A. Spear, M.D., Advanced Urology Associates, Professional Center North, 75 Arch Street, Suite 101, Akron, OH 44304, USA Eric S. Surrey, Colorado Center for Reproductive Medicine, 799 East Hampden Ave. Suite 300, Englewood, CO 80110, USA Bruce L. Tjaden, M.D., Center for Reproductive Medicine, 2903 E. Central, Wichita, KS 67214, USA Theresa Widrich, M.D., Department of Obstetrics and Gynecology, Landeskrankenhaus Mödling, Sr. M. Restitutag 12, A-2340, Mödling, Austria Don P. Wolf, Ph.D., Division of Reproductive Sciences, Oregon Regional Primate Research Center, 505 NW 185th Avenue, Beaverton, OR 97006-3448, USA
3051_Seifer_01_p1-9 11/5/01 3:04 PM Page 1
1 Evaluation of the Female for Infertility Bryan D. Cowan
Evaluation of women with infertility is an increasingly important part of the primary care practitioner’s role. Reproductive dysfunction affects more than 2 million married couples during their reproductive lives, and approximately 10–15% of women between the ages of 25 and 45 seek office consultation concerning reproductive dysfunction. As a perspective, the fertility rate in the United States has remained nearly constant for more than a decade at 2.1 live births per reproductive-age female. This is coincident with the ideal fertility rate that maintains a population profile consistent with “zero population growth.” Because our society has this population growth philosophy, there is great pressure on couples to have their families at a time that is convenient for them personally and professionally. Thus many couples seek fertility services to overcome acquired diseases, enhance natural decreasing fertility associated with age, and accommodate life style agendas.
Confirmation of Infertility Infertility is established when a couple attempts a pregnancy for 12 months or longer and conception fails. It is important to remember that the natural fertility rate is expressed in two ways. The overall cumulative pregnancy rate is the expected probability of conception within a population when all the pregnancies have occurred. The second important factor to consider is the occurrence of pregnancy with each opportunity (ovulation) for conception. In young, unencumbered couples, this fecundity rate is approximately 20% per month. Three important factors are associated with infertility. They are represented by major disturbances in male gamete production, female gamete pro-
duction, and female tuboperitoneal diseases. Although the distribution of these defects varies with infertility populations, it is convenient to consider that about 40% of couples have male factor dysfunction, ovulatory dysfunction occurs in 20%, and anatomic abnormalities are present in 30% (Table 1–1). Ten percent of couples have no identifiable cause of their reproductive dysfunction after a thorough infertility evaluation.
Strategy for Infertility Testing Once the diagnosis of infertility is confirmed, a thorough evaluation correctly classifies the cause of infertility in 85–90% of patients. Most of the evaluation is conducted in an office environment and usually requires no more than 60–90 days to complete. The timing of the tests is generally coordinated with the female ovarian menstrual cycle. Figure 1–1 illustrates the hormone levels during the menstrual cycle. It is usually convenient to schedule tests throughout the course of two cycles to avoid disruption of the ovarian menstrual cycle and potential errors in interpretation if tests conflict.
Male Factor Evaluation The history from the male partner should include important information concerning a history of previously fathered pregnancies, testicular trauma or infection, environmental exposure to toxins or heat, and coital and sexual performance. If a physical examination can be performed, the genitalia are inspected and the developmental stage classified. The scrotum is evaluated for masses, varicocele, or inguinal hernia.
1
3051_Seifer_01_p1-9 11/5/01 3:04 PM Page 2
2
B.D. Cowan TABLE 1–1. Causes of Infertility
TABLE 1–2. Semen Analysis Parameters
Cause
%
Male factor Ovulation defect Pelvic diseases Unexplained
40 20 30 10
Volume pH Concentration Count Motility Morphology Vitality
Semen analysis is the single most important laboratory test for male factor evaluation. Although many parameters can be measured, the volume, total number of ejaculated sperm, percent motility of the sperm, and percent normal forms (Table 1–2) represent the major and most important parameters. It is important to remember that the time required to complete a cycle of sperm production is 70–80 days. Thus if antecedent illness, stress, or injury has occurred, it is advisable to repeat the semen analysis after an appropriate interval of time has elapsed that would ensure measurement of an unaffected sperm cycle. Adjuncts to the traditional semen analysis have been sought to assess the fertilizing capability of the semen or the fertility of the man. These adjuncts include a postcoital test, zona-free hamster pene-
2 ml 7.2–8.0 20 106 spermatozoa/ml 40 106 spermatozoa/ejaculate 50% forward progression or 25% rapid progression 30% normal forms 75% live
Source: WHO, 1992.
tration, zona binding assays, cervical mucus penetration assays, and seminal antibody detection. Detecting antibody on sperm has been associated with the prediction of infertility, particularly if the antibody is recognized to be a head-to-head agglutinating antibody of the immunoglobulin G class. Unfortunately, except for antibody testing, other adjunctive tests are less helpful, difficult to perform, and expensive. In particular, most authorities recommend that routine use of the postcoital test be abandoned. This test is difficult to interpret and dependent on female cervical mucus production during the ovarian menstrual cycle; moreover, uniform norms have not been established. Additionally, critical evaluation of reported case series reveal an inability of the test to predict fertility. Thus we believe that semen analysis represents the single and most important test for evaluating the man. When necessary, this test should be repeated at 2- to 3-week intervals to encompass a complete 70- to 80-day sperm cycle. Other than seminal antisperm antibodies, other routine adjunctive tests of sperm function are not justifiable and should be used only for special indications.
Assessment of Ovulation
FIGURE 1–1. Hormone levels during the menstrual cycle. During the proliferative phase (days 1–14) estrogen levels progressively rise. Ovulation (day 14) is preceded by an increase in the gonadotropins and is signaled by a sharp rise in luteinizing hormone (LH). During the secretory phase (days 15–28) the corpus luteum produces increasing levels of progesterone. In the absence of fertilization, menstruation (days 1–5) occurs as the endometrium is shed.
The history of the female partner should include the time of menarche, the interval between menstrual cycles, the presence or absence of molimina, the duration of menstrual flow, and the presence or absence of dysmenorrhea. Women with regular, predictable cycles (26–34 days) can be predicted to be ovulatory with a high degree of certainty (99.8%). In perspective, only two to three of every 1000 women who offer a history of regular, predictable cycles are discovered to be anovulatory. It is important to remember that the menstrual history reflects subjective information, and confirmation of ovulatory status should be determined by appropriate laboratory tests. Three office-based procedures are used to confirm that ovulation has
3051_Seifer_01_p1-9 11/5/01 3:04 PM Page 3
1. Evaluation of the Female for Infertility TABLE 1–3. Assessment of Ovulatory Status Test BBT Serum progesterone Endometrial biopsy Sonography LH testing
Timing Complete cycle Mid-luteal Late luteal Late follicular Late follicular
BBT, basal body temperature; LH, luteinizing hormone.
occurred, and two additional office-based procedures are used to determine that ovulation will occur in the immediate future. To determine that ovulation has occurred, most clinicians use basal body temperature (BBT) chart monitoring, luteal phase serum progesterone measurements, or secretory phase endometrial biopsy. BBT chart monitoring typically reveals a temperature below 98°F during the follicular phase (Table 1–3). After ovulation the temperature rises 0.2°– 0.6°F and is sustained for 9–13 days during the luteal phase. Immediately before or coincident with the onset of menses, the temperature falls below 98°F. This typical “biphasic” profile is demonstrated repeatedly in ovulatory women. Use of BBT chart monitoring to determine dysfunctional ovulation (in contrast to the absence of ovulation) is generally not helpful. Unfortunately, parameters such as the number of temperature-elevated days and the magnitude of the temperature rise have correlated with other measures of luteal function (progesterone, endometrial biopsy) and have not been used reliably to initiate therapy. Thus BBT chart monitoring can establish ovulation but is unable to determine the presence or absence of ovulatory disturbances. Serum progesterone concentrations are higher than 5 ng/ml during the luteal phase. Most clinicians use the luteal phase progesterone level to establish both ovulation and the quality of ovulation. If the serum progesterone is higher than 5 ng/ml, ovulation is confirmed. This measurement can apply to any day of the luteal phase. When more rigorous criteria are set for the time of progesterone measurement (6–8 days prior to the onset of menses—typically day 20–22 of the cycle), several investigators have reported that the “quality” of ovulation can be determined. The precise threshold value of progesterone is controversial, but most agree that a mid-luteal progesterone level of less than 10 ng/ml is consistent with luteal dysfunction. Additionally, most authors agree that a serum progesterone level higher than 20 ng/ml is consistent with adequate luteal function. There is no consensus on what a serum progesterone level of 10–20
3
ng/ml indicates about luteal function, but it clearly means that ovulation has occurred. Endometrial biopsy is typically performed during the late luteal phase to classify the morphologic transformation of the secretory endometrium. The “luteal phase defect” has been defined as endometrium that is more than 48 hours “out of phase” with the cycle. The proper interpretation of this test requires three pieces of information: (1) the date the test was performed; (2) the date natural menstruation occurred; and (3) the morphologic dating of the endometrial specimen. For example, a specimen obtained on day 26 of a 28-day cycle that was interpreted as consistent with day 23 endometrium would be considered out of phase, but a specimen obtained 6 days before the onset of menstruation consistent with day 23 secretory endometrium would be considered in phase. Finally, interest has emerged concerning adjunctive measurement of endometrial peptides. In particular, some integrins are known to be expressed at unique times during the secretory phase. Measurement of these factors may increase the accuracy of properly classifying endometrial specimens. Endometrial biopsy is inconvenient to the patient, is associated with mild discomfort, and is approximately four to six times more expensive than serum progesterone measurements. Unfortunately, there is a mixed degree of agreement regarding serum progesterone measurements and endometrial maturity. Hence these two tests currently stand at the “discretion of the practitioner” as independent but not correlated tests. Follicular measurements (sonography) have been used to predict ovulation. In general, a naturally growing follicle expands at approximately 2–3 mm per day and ruptures after the follicular diameter approaches 20–22 mm. In contrast, a clomiphene citrate-stimulated follicle ruptures when the diameter approaches 24–26 mm. After rupture the follicle generally collapses, and fluid collects in the cul-de-sac. Commonly, a luteal structure can be observed in the ovary. Finally, urinary measurements of mid-cycle luteinizing hormone (LH) can detect the preovulatory LH surge. Because urinary LH measurements are done infrequently (usually once or twice daily), it is reasonable to estimate that ovulation will occur 24–36 hours after detection of the surge.
Anatomic Defects Figure 1–2 reviews the anatomy of the female pelvic organs. Two principal anatomic defects deserve evaluation for couples with infertility. Uter-
3051_Seifer_01_p1-9 11/5/01 3:04 PM Page 4
4
B.D. Cowan TABLE 1–4. Assessment of Tuboperitoneal/ Anatomic Status Test Hysterosalpingography Laparoscopy Hysteroscopy Sonohysterography Sonography
FIGURE 1–2. Female pelvic organs. (A). The relations between uterus, bladder, colon, and great vessels are noted in the transverse plane. (B) These relations are emphasized in the sagittal plane.
ine abnormalities (malformations, uterine fibroids, endometrial polyps) and tuboperitoneal factors (pelvic scarring from infection or prior surgery, endometriosis, congenital tubal abnormalities) can be evaluated by several techniques (Table 1–4). A time-honored test for evaluating uterine and tubal factors is hysterosalpingography. It is a contrast study performed under fluoroscopy, where radiopaque solutions are injected into the uterus to define the outline of the uterus and fallopian tubes.
Comment High false-negative rate Confirms peritoneal disease Confirms intrauterine disease Visualizes mural and intrauterine lesions Identifies uterine and endometrial contour
Currently, both aqueous and oil-based contrast solutions are available for use. Studies have provided evidence concerning the value of hysterosalpingography. If the hysterosalpingogram is normal (normal uterine contour with bilateral tubal fill and spill), it has a negative predictive value of only about 60%. This is principally because the infertility population has a high incidence of endometriosis, which typically represents peritoneal disease but not tubal disease. Therefore the tubes appear open on the hysterosalpingogram, but the disease remains unrecognized by this limited study. Similarly, proximal tubal occlusion has a 50% positive predictive value. At the time of further diagnostic studies (below) proximal tubal occlusion cannot be demonstrated, probably related to the presence of tubal spasm or another technical problem associated with the procedure. However, the hysterosalpingogram has a high positive predictive value if distal tubal occlusion is detected. When distal tubal occlusion is detected, untreated patients are at increased risk for pelvic infection. Therefore these patients should be treated with an outpatient course of antibiotics. We recommend doxycycline 100 mg bid for 5 days. The efficacy of antibiotic treatment for patients without hydrosalpinx has not been demonstrated convincingly. The presence of acute cervical or pelvic infections represents a contraindication. Most clinicians use water-based contrast material for hysterosalpingography. The use of oil-based contrast material has been associated with an intravasation syndrome. The oil-based droplets are absorbed into the circulation and then wedge in the microcapillary spaces throughout the body. This syndrome presents as respiratory difficulty (pulmonary involvement) and changes in mental status (cerebral involvement). The syndrome typically appears a few hours after the procedure. Deaths have been reported. The diagnosis is relatively easy, usually based on a chest radiograph demonstrating contrast dispersed throughout the lung. Treatment is supportive.
3051_Seifer_01_p1-9 11/5/01 3:04 PM Page 5
1. Evaluation of the Female for Infertility
Sonography is a valuable tool for detecting uterine structural lesions such as uterine fibroids and adnexal pathology. Although the role of sonography has been limited by its inability to evaluate tubal status and subtle abnormalities of the endometrium (polyps, small fibroids), it is emerging as a relatively simple office-based procedure that can provide the clinician with extra details concerning the pelvic anatomy. The inclusion of sonohysterography has expanded our view of the endometrium to detect intrauterine abnormalities that may go undetected. However, even with sonohysterography, demonstration of tubal patency is difficult. Some authors have reported using special solutions, adding microspheres, and color-flow Doppler to demonstrate flow into the fallopian tubes. Despite the problems, sonography and sonohysterography currently are best applied to the evaluation of the uterus and endometrium. Endoscopy is currently considered the most thorough, comprehensive tool for evaluating pelvic anatomy. Laparoscopy allows visualization of the peritoneum to detect endometriosis and to assess tubal status. Hysteroscopy can be used to evaluate the endometrium and the tubal ostia. Additionally, when disease is detected, therapy can be provided. These therapies include adhesiolysis, neosalpingostomy, and adnexal surgery.
Evaluation Strategy The strategy for female infertility evaluation has evolved into an efficient, cost-effective investigation that can usually be performed during two cycles. Figure 1–3 shows the usual timing of the
major tests to evaluate male factor, tuboperitoneal status, and ovulation status. Invasive procedures such as hysterosalpingogram and laparoscopy are scheduled during the proliferative phase of the cycle to avoid the risk of a procedure during a concomitant pregnancy. Serum progesterone measurements are timed for 6–8 days before the onset of menses, and endometrial biopsy is performed 2–3 days prior to the onset of menses. Semen analysis can be performed at any time during the cycle. In general, we recommend hysterosalpingography, serum progesterone, and semen analysis during the first month. An office visit can be scheduled at the conclusion of these studies to review the data and to advance to laparoscopy based on any detected abnormalities (below). If no explanation is discovered after these initial studies, endoscopy (hysteroscopy and laparoscopy) is performed to exclude endometriosis and nonobstructive tubal adhesions (found in approximately 50% of cases with negative basal studies) and occult intrauterine lesions (fewer than 1% of patients).
Treatment Treatment strategy is based on the level of clinical care available for the couple. Three levels of care have evolved, classified as basic, complex level I, and complex level II. The basic level of care is based on treating anovulation. Patients with more complex disorders are referred to higher levels. As seen in Table 1–5, women more than 35 years of age should be considered to have a complex problem and so be referred to a higher level of evaluation. Only women less than 35 years of age with ovulation dysfunction are candidates for basic levels of treatment. If ovulation defects exist, clomiphene citrate is initiated for up to four cycles. Thyroid and prolactin screening should exclude correctable endocrine dysfunction.
TABLE 1–5. Levels of Complexity of Reproductive Care
FIGURE 1–3. Usual timing of fertility testing during the female ovarian menstrual cycle. HSG, hysterosalpingogram; P, progesterone; Bx, endometrial biopsy; PCT, postcoital test; surgery, laparoscopy, and/or hysteroscopy.
5
Basic level 35 years old Anovulation No male or tubal factors Complex level I 35 years old Tubal disease Male factor No conception at basic level Complex level II Gamete technologies
3051_Seifer_01_p1-9 11/5/01 3:04 PM Page 6
6
B.D. Cowan
TABLE 1–6. Outcome of ART Procedures (1997*) Procedure IVF IVF ICSI GIFT ZIFT Donor Cryopreserved cycle
# of Cycles
Deliveries (%)
Ectopic (%)
33,032 18,312 1,943 1,104 4,616 10,181
28.4 27.1 30.0 28.0 35.7 16.9
0.9 0.6 1.0 1.2 0.5 0.7
*Fertil Steril 2000;74:641–654.
Complex level I is a level of care designed to treat diagnosis-related conditions of male gamete production, tuboperitoneal disease, and complex anovulation. Complex level I treatment facilities have the ability to treat couples with insemination, advanced follicular stimulation, and advanced endoscopic management. It makes little sense to perform expensive, time-consuming diagnostic procedures (e.g., laparoscopy) if the operating surgeon does not have the skill to treat the conditions detected properly. Complex level II facilities provide gamete technologies to correct infertility. An array of assisted reproductive technology (ART) (Table 1–6) can be used under the umbrella “gamete technologies.” Commonly, patients who receive these treatments have failed conservative therapies at the basic and complex level I or are of advanced maternal age when seeking fertility treatment. Therapeutic options are classified as diagnosisrelated or empiric. Diagnosis-related treatments are provided for couples affected by disordered male factors, tubal factors, or ovulation defects. Empiric therapy is provided to couples with unexplained infertility.
Male Factor Treatment Male factor treatment is principally insemination. Two types of insemination are provided: homologous and donor. In general, homologous intrauterine insemination has a per-cycle fecundity (see
below) that ranges from 3% to 9% and a cumulative probability of conception that approaches 30% over 8–12 inseminations. Donor insemination has an expected fecundity of 12–18% and a cumulative success rate that approaches 70% after 8–10 treatment cycles. In special cases, retrograde ejaculation, electrostimulatory ejaculation, and testicular aspiration/biopsy have allowed acquisition of sperm for use in insemination or ART.
Tubal Disease Pelvic adhesions and endometriosis represent diseases of the pelvis that impair fertility. Laparoscopic adhesiolysis produces a pregnancy success rate of nearly 50%. On the other hand, women who require neosalpingostomy for hydrosalpinx have an overall expected maximum probability of pregnancy of less than 20%. Endometriosis is classified into stages based on the extent of disease. In women with early disease (stage I–II) the cumulative probability of pregnancy is 60%. In contrast, women with stage III or IV disease benefit from surgery, but the cumulative probability of pregnancy is only 35% for these women.
Ovulation Defects Women with estrogenized/androgenized chronic anovulation are typically treated successfully with
TABLE 1–7. Fecundity and Cumulative Probability of Conception for Various Infertility Treatment Options Treatment option Unexplained and untreated Anovulatory with clomiphene Surgery for adhesiolysis Surgery for neosalpingostomy Surgery for stage I–II endometriosis Surgery for stage III–IV endometriosis hMG for hypothalamic amenorrhea Normal hMG, human menopausal gonadotropin.
Fecundity
Cumulative conceptions (%)
0.08 0.12 0.04 0.02 0.06 0.06 0.30 0.20
50 65 40 12 65 35 90 90
3051_Seifer_01_p1-9 11/5/01 3:04 PM Page 7
1. Evaluation of the Female for Infertility
7
these parameters. Two models are commonly used today to estimate fecundity and cumulative probability. Life-table analysis and logistic regression allow analysis of time-dependent data. Table 1–7 demonstrates fecundity and cumulative probability of conception for various treatment options, and Figure 1–4 illustrates the logistic analysis using these parameters.
Impact of Age on Reproduction
FIGURE 1–4. Logistic regression demonstrating the cumulative probability of conception for common infertility conditions.
clomiphene citrate: 85% of patients on this therapy ovulate. Of those who ovulate, 65% achieve a pregnancy within 4–6 months. Human menopausal gonadotropin (hMG) (Metrodin, Pergonal, Humegon, Fertinex) has been used to treat women with hypogonadotrophic hypogonadism and estrogenized/androgenized chronic anovulatory patients who fail to respond to clomiphene citrate. Curiously, those with hypogonadotrophic hypogonadism have an excellent response to hMG therapy. Approximately 90% of these patients achieve a pregnancy within 6 months of therapy. This remarkable response represents the highest fertility treatment option available to clinicians. In contrast, chronically anovulatory patients refractory to clomiphene citrate fare much worse: Their expected maximum probability of pregnancy is only 30% despite the high ovulatory rates established with hMG.
Measures of Fertility Treatment Success Fertility treatment measurements require an analysis of time-dependent events. As such, two expressions are used to discuss fertility success. Fecundity is the measure of pregnancy occurrence per single ovulatory cycle. The cumulative probability of pregnancy represents the expectations of conception in a population over time. That expectation is time-dependent and may occur within 6 months or 6 years, depending on the duration of the measurement. Analytic tools have been developed to assess
No discussion of female fertility would be complete without considering ovarian maturity. Two detrimental reproductive events affect oocyte development over time. Increased occurrence of nondisjunction leads to genetic abnormalities associated with trisomy. Table 1–8 demonstrates the agedependent association of Down syndrome (trisomy 21). Reproductive efficiency is also dramatically influenced by age. Two important examples must be considered. A 40-year-old population undergoing donor insemination demonstrated a 50% preg-
TABLE 1–8. Age-Dependent Association of Down Syndrome Maternal age (years)
Risk of Down syndrome
Risk for all chromosome abnormalities
20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49
1/1923 1/1695 1/1538 1/1408 1/1299 1/1205 1/1124 1/1053 1/990 1/935 1/885 1/826 1/725 1/592 1/465 1/365 1/287 1/225 1/177 1/139 1/109 1/85 1/67 1/53 1/41 1/32 1/25 1/20 1/16 1/12
1/526 1/526 1/500 1/500 1/476 1/476 1/476 1/455 1/435 1/417 1/384 1/384 1/322 1/285 1/243 1/178 1/149 1/123 1/105 1/80 1/63 1/48 1/39 1/31 1/24 1/18 1/15 1/11 1/8 1/7
3051_Seifer_01_p1-9 11/5/01 3:04 PM Page 8
8
B.D. Cowan
FIGURE 1–5. Historic population analysis of female fertility rate by age from Morman genealogic data. Modified from Mineau G and Trussell J, Demography, 1982.
nancy occurrence and a 50% miscarriage rate, for a take-home pregnancy success rate of 25%. This population was compared to a 30-year-old group who demonstrated an 80% chance of pregnancy and a 20% chance of miscarriage, resulting in a 65% take-home pregnancy rate. Lastly, historic populations have demonstrated profound aberrations of the fertility rate after age 35 (Fig. 1–5). Historic populations are of interest because contraception was unknown, and in some (e.g., Mormans) large families were desired. Thus women after age 35 are at increased risk for nondisjunction events leading to trisomy and decreased reproductive efficiency. Fertility evaluation and treatments become urgent in this population.
Suggested Reading Diagnosis Baker HWG, Burger HG, de Krester DM, et al. Testicular vein ligation and fertility in men with varicoceles. BMJ 1985;291:1678–1680. Barnea ER, Holford TR, McInnes DRA. Long-term prognosis of infertile couples with normal basic investigations: a life-table analysis. Obstet Gynecol 1985;66: 24–26. Barratt CLR. On the accuracy and clinical value of semen laboratory tests. Hum Reprod 1995;10:250–252. Chalmers TC, Celano P, Sacks H, Smith H Jr. Bias in treatment assignment in controlled clinical trials. N Engl J Med 1983;309:1358–1361. Dunphy BC, Scudamore I, Cooke ID. Falloposcopy, a
technological gimmick or a clinical tool? J Soc Obstet Gynecol Can 1993;15:25–32. Eggert-Kruse W, Leinhos G, Gerhard I, et al. Prognostic value of in vitro sperm penetration into hormonally standardized human cervical mucus. Fertil Steril 1989; 51:317–323. ESHRE Capri Workshop Group. Male sterility and subfertility: guidelines for managements. Hum Reprod 1994;9:1260–1264. Forti G, Krausz C. Clinical review 100: evaluation and treatment of the infertile couple. J Clin Endocrinol Metab 1998;83:4177–4188. Griffith CS, Grimes DA. The validity of the postcoital test. Am J Obstet Gynecol 1990;162:616–620. Gwatkin RBL, Collins JA, Jarrell JF, et al. The value of semen analysis and sperm function assays in predicting pregnancy among infertile couples. Fertil Steril 1990;53:693–699. Hanson MA, Dumesic DA. Initial evaluation and treatment of infertility in a primary-care setting. Mayo Clin Proc 1998;73:681–685. Hughes EG, Fedorkow DM, Collins JA. A qualitative overview of controlled trials in endometriosis-associated infertility. Fertil Steril 1993;59:963–970. Kremer J, Jager S. The significance of antisperm antibodies for sperm-cervical mucus interaction. Hum Reprod 1992;7:781–784. Opsahl MS, Miller B, Klein TA. The predictive value of hysterosalpingography for tubal and peritoneal infertility factors. Fertil Steril 1993;60:444. Shalev J, Meizner I, Bar-Hava I, et al. Predictive value of transvaginal sonography performed before routine diagnostic hysteroscopy for evaluation of infertility. Fertil Steril 2000;73:412–417. Taylor PJ, Lewinthal D, Leader A, et al. A comparison of dextran 70 with carbon dioxide as the distention medium for hysteroscopy in patients with infertility or requesting reversal of a prior tubal sterilization. Fertil Steril 1987;47:861–863. Wentz AC, Kossoy LR, Parker RA. The impact of luteal phase inadequacy in an infertile population. Am J Obstet Gynecol 1990;162:937–945. Yoder IC, Hall DA. Hysterosalpingography in the 1990s. AJR 1991;157:675–683.
Treatment Adamson GD, Pasta DJ. Surgical treatment of endometriosis-associated infertility: meta-analysis compared with survival analysis. Am J Obstet Gynecol 1994; 171:1488–1505. American Fertility Society. The American Fertility Society classification of adnexal adhesions, distal tubal occlusion, tubal occlusion secondary to tubal ligation, tubal pregnancies, müllerian anomalies and intrauterine adhesions. Fertil Steril 1988;49:944–955. Chung CC, Fleming R, Jamieson ME, et al. Randomized comparison of ovulation induction with and without intrauterine insemination in the treatment of unexplained infertility. Hum Reprod 1995;10:3139–3141. Collins JA, Burrows EA, Willan AR. The prognosis for
3051_Seifer_01_p1-9 11/5/01 3:04 PM Page 9
1. Evaluation of the Female for Infertility live birth among untreated infertile couples. Fertil Steril 1995;64:22–28. Crosignani PG, Walters DE, Soliani A. The ESHRE multicentre trial on the treatment of unexplained infertility: a preliminary report. Hum Reprod 1991;6:953– 958. Dlugi AM, Reddy S, Saleh WA, et al. Pregnancy rates after operative endoscopic treatment of total (neosalpingostomy) or near total (salpingostomy) distal tubal occlusion. Fertil Steril 1994;62:913–920. Edvinsson A, Forssman L, Milsom I, et al. Factors in the infertile couple influencing the success of artificial insemination with donor semen. 1990;53:81–87. Friedman AJ, Juneau-Norcross M, Sedensky B, et al. Life table analysis of intrauterine insemination pregnancy rates for couples with cervical factor, male factor, and idiopathic infertility. Fertil Steril 1991;55:1005–1007. Gysler M, March CM, Mishell DR Jr, et al. A decade’s experience with an individualization of clomiphene treatment regimen including its effect on the postcoital test. Fertil Steril 1982;37:161–167. Haan G. Effects and costs of in-vitro fertilization. Int J Technol Assess Health Care 1991;7:585–593. Hammond MG, Hlame JK, Talbert LM. Factors affecting the pregnancy rate in clomiphene citrate induction of ovulation. Obstet Gynecol 1983;62:196–202. International Federation of Fertility Societies, Montpellier, pp 1–43. International Working Group for Registers on Assisted Reproduction. World Collaborative Report 1993. Lindheim SR, Kavic S, Shulman SV, Sauer MV. Operative hysteroscopy in the office setting. J Am Assoc Gynecol Laparosc 2000;7:65–9. Mineau G, Trussell J. A specification of marital fertility by parents’ age, age at marriage, and marital duration. Demography 1982;19:335–350. Office of Technology, US Congress. Infertility: Medical and Social Choices. US Government Printing Office, Washington, DC, pp 3–402.
9
Pal L, Lapensee L, Toth TL, Isaacson KB. Comparison of office hysteroscopy, transvaginal ultrasonography, and endometrial biopsy in evaluation of abnormal uterine bleeding. J Soc Laparoendosc Surg 1997;1:125–30. Reiss H. Management of tubal infertility in the 1990s. Br J Obstet Gynaecol 1991;98:619–623. Saidi MH, Sadler RK, Theis VD, Akright BD, Farhart SA, Villanueva GR. Comparison of sonography, sonohysterography, and hysteroscopy for evaluation of abnormal uterine bleeding. J Ultrasound Med 1997; 16:587–91. Saravelos, et al. Microsurgery versus laparoscopic adhesiolysis for fertility. Hum Reprod 1995;10:2887–2928. Schlesinger MH, Wilets IF, Nagler HM. Treatment outcome after varicocelectomy: a critical analysis. Urol Clin North Am 1994;21:517–529. Society for Assisted Reproductive Technology and the American Society for Reproductive Medicine. Assisted reproductive technology in the United States: 1997 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology Registry. Fertil Steril 2000;74: 641–654. Speroff L. The effect of aging on fertility. Curr Opin Obstet Gynecol 1994;6:115–120. Toner JP, Glood JR. Fertility after the age of 40. Obstet Gynecol Clin North Am 1993;20:261–272. Valli E, Zupi E, Marconi D, Solima E, Nagar G, Romanini C. Outpatient diagnostic hysteroscopy. J Am Assoc Gynecol Laparosc 1998;5:397–402. Van Steirteghem A, Liu J, Joris H, et al. Higher success rate by intracytoplasmic sperm injection than by subzonal insemination: report of a second series of 300 consecutive treatment cycles. Hum Reprod 1993;8: 1055–1060. Zullo F, Pellicano M, Stigliano CM, DiCarlo C, Fabrizio A, Nappi C. Topical anesthesia for office hysteroscopy. A prospective randomized study comparing two modalities. J Reprod med 1999;6:331–6.
3051_Seifer_02_p10-23 11/27/01 3:43 PM Page 10
2 Evaluation of the Male for Infertility Kevin A. Spear
The purpose of this chapter is to give a concise but practical overview of the in-office evaluation of the infertile man. Women have traditionally sought consultation and treatment for infertility, so the focus of therapy for many years has been on female factors. Because approximately 40% of infertility cases involve male factors, it is imperative that the couple be considered as a unit and the infertility evaluation proceed in a parallel manner. Also, significant medical pathology can be uncovered by a comprehensive infertility evaluation of the man. Additionally, with advances in the diagnosis and treatment of male factor infertility, and the refinement of assisted reproductive techniques, many men whose problems were once untreatable are now excellent candidates for therapy. As economic issues are becoming increasingly important, it is evident that treatment of male factor infertility is cost-effective. The man must not be ignored, and the following is a guide to his evaluation.
Evaluation The initial workup begins whenever the patient presents. This is predicated by the fact that the longer a couple remains infertile the less chance there is for cure. A rapid, noninvasive, cost-effective evaluation is essential.
History The cornerstone of the evaluation of the infertile man is the history and physical examination. Table 2–1 outlines the complete pertinent history. The sexual history is paramount. Some of the problems most commonly encountered in this patient population are related to the timing of intercourse, with it being too frequent or too infrequent. Often nei10
ther husband nor wife understands the menstrual cycle and does not know the optimal time for intercourse. Because sperm survive in the female reproductive tract for approximately 2 days, the most effective frequency of intercourse is every 48 hours around the ovulatory peak, which ensures that viable spermatozoa are present during the 12- to 24-hour period when the egg is in the fallopian tube and capable of being fertilized. Lubricant use should be investigated. Commonly used substances such as K-Y Jelly, Lubifax, Surgilube, Keri Lotion, and saliva have been shown to decrease sperm motility in vitro. If lubricant use is necessary, couples should be instructed to use a minimal amount of one that does not impair motility. Substances that do not impair in vitro motility include petroleum jelly, vegetable oil, and peanut oil. The history of an undescended testicle is significant. In a patient with a history of unilateral cryptorchidism, regardless of the time of orchidopexy, overall semen quality is considerably less than that found in normal men. Despite this fact, most men with one undescended testis are able to initiate a pregnancy without difficulty. Bilateral cryptorchidism is extremely important. Progressive damage occurs to the germinal epithelium if the testicle is not in its proper position in the scrotum. It has been shown that orchidopexy should be performed prior to 2 years of age to maintain a significant level of spermatogenic function. Any previous surgery of the retroperitoneum, bladder neck (prostate), pelvis, inguinal region, or scrotum should be assessed. Retroperitoneal lymph node dissection with interruption of the sympathetic chain causes anejaculation with resultant azoospermia. Today nerve-sparing techniques allow more than 90% of patients to retain ejaculatory function after retroperitoneal lymph node dissection. Any
3051_Seifer_02_p10-23 11/27/01 3:43 PM Page 11
2. Evaluation of the Male for Infertility TABLE 2–1. Infertility History Sexual history Duration of infertility Prior pregnancies, with present and any previous partners Previous treatments Evaluation and treatment of female partner Potency Use of lubricants Timing and frequency of intercourse Frequency of masturbation Past medical history, including childhood Undescended testicles Testicular torsion Testicular trauma Delayed puberty Pelvic injury Diabetes, multiple sclerosis Previous or current therapy Viral and febrile illness history Postpubertal mumps orchitis Sexually transmitted diseases Urinary tract infections Cystic fibrosis, or family history of it Past surgical history Orchiectomy Orchidopexy Retroperitoneal surgery Pelvic, inguinal, or scrotal surgery Herniorrhaphy Medications and gonadotoxins Chemotherapeutic agents Therapeutic drugs: cimetidine, sulfasalazine, nitrofurantoin Chemicals (pesticides) Recreational drugs: smoking, marijuana, cocaine Androgenic steroids Thermal exposure (hot tubs) Radiation
surgery on the bladder neck may cause retrograde ejaculation. Inguinal surgery such as herniorrhaphy, undertaken when an infant or an adult, may have caused vasal occlusion or vascular insufficiency to the testicle. Fever can cause impaired testicular function. The ejaculate may not be affected for more than 3 months after the event, as spermatogenesis takes about 74 days. Therefore events that have occurred during the previous 3–6 months are important. Postpubertal mumps may cause mumps orchitis, which results in an atrophic testis. Fifty percent of patients with testicular cancer have subnormal sperm densities prior to therapy. A history of diabetes or multiple sclerosis should raise questions about potency and ejaculatory function. Exposure to drugs and toxins should be detailed. Withdrawal of the medications listed under gonadotoxins in Table 2–1 may allow the return of normal spermatogenesis. The routine use of hot tubs or saunas should be discontinued, as elevated temperatures impair spermatogenesis.
11
A family history of cystic fibrosis is important owing to associated vasal agenesis and epididymal abnormalities. Finally, a history of anosmia (lack of smell) indicates the possibility of hypogonadotropic hypogonadism. Galactorrhea, headaches, and impaired visual fields suggest the presence of a central nervous system tumor. It is useful to use a preprinted history form filled out by the patient. It ensures that all pertinent historical data are obtained prior to the physical examination.
Physical Examination The physical examination must be thorough, with special attention to the genitalia. Figure 2–1 depicts the pertinent male reproductive anatomy. The penile curvature and location of the urethral meatus should be assessed, as abnormalities may result in improper delivery of the ejaculate. Testicular size and consistency must be recorded, with the length
FIGURE 2–1. Pertinent male reproductive tract anatomy in coronal view. Arrows depict flow of sperm and ejaculate. (By permission of the American Society of Reproductive Medicine)
3051_Seifer_02_p10-23 11/27/01 3:43 PM Page 12
12
K.A. Spear
FIGURE 2–2. Measuring the length of a testicle with a Seager orchidometer. (From Goldstein, 1995, by permission of W.B. Saunders)
testicle in the scrotum—must be identified (Fig. 2–3). A varicocele can cause abnormalities in gonadal function. The scrotal contents should be palpated with the patient in both the supine and standing positions. Many varicoceles are not visible and may be discernible only when the patient stands or performs a Valsalva maneuver. Varicoceles often result in a smaller testis on that side. Ninety percent are left-sided, and any discrepancy in size between the two testes should arouse suspicion of a varicocele. A rectal examination is essential to assess prostate size, evidence of infection, and the presence of midline cysts. Look carefully for signs of hypogonadism, such as decreased body hair, gynecomastia, infantile genitalia, and decreased muscular development.
Laboratory Evaluation measured with calipers (Fig. 2–2) and the volume estimated with an orchidometer. Size is an important indicator of spermatogenic capability, as 85% of the testis is involved in sperm production. When there is damage to the testicular tubules, loss of mass occurs. The normal length of the testis is more than 4 cm and the volume more than 20 ml. Epididymal induration and irregularities should be noted. The presence of a vas must be documented, as 2% of infertile men have congenital absence of the vas. Varicoceles—dilated spermatic veins that present as a “bag of worms” above the
FIGURE 2–3. (A) Left visible (grade 3) varicocele. (B) dilated veins underneath the scrotal skin.
The laboratory is an integral part of a full-service infertility center. If an on-site laboratory is not available, specimens must be analyzed by a dedicated infertility laboratory. Data from a reputable laboratory are critical. Unfortunately, the semen analysis must be done locally because the specimen must be evaluated shortly after production. Most other studies can be sent out to any reputable laboratory.
Semen Analysis The primary laboratory test is the semen analysis. It must be emphasized that semen analysis is not a test for fertility. It does not separate patients into sterile and fertile groups; it does give diagnostic information and allows a directed evaluation and treatment. At least two semen analyses must be obtained to establish a baseline. The specimen should be collected with a consistent abstinence of 2–3 days. The specimen container must be clean, not necessarily sterile, and wide-mouthed to minimize collection error. The preferred technique of collection is by masturbation, although coitus interruptus or use of a special condom devoid of spermatocidal agents may be used. The specimen must be evaluated within 2 hours of collection. The standard semen analysis allows evaluation of semen volume, pH, density (sperm per milliliter), motility, measurement of forward progression of sperm, and sperm morphology. The semen is examined also for evidence of sperm agglutination, hyperviscosity, and the presence of white
3051_Seifer_02_p10-23 11/27/01 3:43 PM Page 13
2. Evaluation of the Male for Infertility TABLE 2–2. WHO Criteria for Normal Semen Analysis Semen parameter Volume Density Motility Forward progression Morphology Leukocytes Agglutination Hyperviscosity
Value 2.0–5.0 ml 20 million/ml 50% 2 (scale 1–4) 30% normal forms 1 million/ml None None
Source: World Health Organization, 1992.
blood cells. The World Health Organization (WHO) range of values for normal semen analysis is given in Table 2–2. Some laboratories use computer-assisted semen analyses, which are of some value for measuring sperm motility; however, they should be used only as a source of supplemental information. Attention has been turned to a more accurate manual analysis of sperm morphology. Using strict criteria (Kruger criteria) for defining “normal” morphology, in patients undergoing in vitro fertilization (IVF), a significantly higher fertilization rate may be achieved from semen specimens with more than 4% normal forms.
Adjunctive Semen Studies White Blood Cell Staining Leukocytes in semen have significant effects on sperm function. They modulate an autoimmune response, adversely affect motility and fertilizing capacity, and deter sperm transport in the female reproductive tract. The semen of most men contains some immature sperm forms (round cells), which ordinarily cannot be distinguished from white blood cells (WBCs). This often leads to an erroneous diagnosis of pyospermia or infection. Special immunohistochemical stains identify WBCs. These stains should be employed if more than 1 million round cells/ml or more than 1 million WBCs/ml are reported on routine semen analysis. The peroxidase stain can be employed: It stains polymorphonuclear leukocytes brown. Monoclonal antibodies directed against the leukocyte CD45 or HLE-1 antigen are the current “gold standard.” Although more accurate, they are expensive and labor-intensive. In most clinical cases, a cytochemical stain is sufficient. Semen cultures are not indicated in asymptomatic patients, as they are essentially always negative. Routine cultures for atypical organisms are unwarranted because they
13
are not always accurate, are labor- and cost-prohibitive, and have not been shown to have a clinical impact. For the few patients with symptoms of urinary or genital tract infections cultures should be prepared. The specific cultures obtained depend on the individuals’ symptoms and examination but should include cultures of urine, expressed prostatic secretions, and a postprostatic massage urine sample. It has been demonstrated that exotoxins of Escherichia coli can significantly affect sperm motility and may also decrease sperm production. Common sexually transmitted organisms such as Chlamydia, Mycoplasma, and Ureaplasma have been implicated in reproductive failure. Patients with active prostatitis or other urinary tract infections frequently have decreased sperm count and motility.
Fructose With low-volume oligospermia or low-volume azoospermia, one should be concerned about retrograde ejaculation and ejaculatory duct obstruction. The assessment for ejaculatory duct obstruction may incorporate a test for seminal fructose, a sugar produced in the seminal vesicles. Its absence may indicate the possible absence of the seminal vesicles or obstruction of the ejaculatory ducts. Problematically, the fructose test is not entirely accurate and hence is unreliable. The state of the art now is transrectal ultrasonography (TRUS) to detect ejaculatory duct obstruction or seminal vesicle aplasia.
Anti-sperm Antibodies Great attention has been focused recently on immunologic infertility, resulting in a better understanding of the etiology and biology of anti-sperm antibodies. The incidence of anti-sperm antibodies in the infertile man range from 8% to 21%. In contrast, only 0.9–4.0% of fertile men and women have detectable antibodies. Aggregate evidence documents that anti-sperm antibodies comprise significant infertility factor. In men only antibodies present on the sperm surface are clinically important. Anti-sperm antibodies have implications at various stages in the fertilization process. Clarke et al. showed that sperm agglutination is significantly higher in men with positive immunobead tests. Thus sperm agglutination is a definite sign of antisperm antibodies. Others have found that antibodies decrease motility. Poor sperm penetration into cervical mucus has been noted in many of these patients. Additionally, the acrosome reaction may be impaired in patients with antibodies attached to
3051_Seifer_02_p10-23 11/27/01 3:43 PM Page 14
14
K.A. Spear
the sperm head. Of great importance is evidence that anti-sperm antibodies may cause impairment of zona binding and fertilization. In Zonari et al.’s study, IVF cycles with no fertilization showed a lack of zona binding and antibodies on the sperm head. Witkin et al. studied unsuccessful IVF cycles and found a high correlation between sperm-bound antibodies and low fertilization rates. Risk factors for the development of sperm-bound antibodies include previous testicular surgery, trauma, or infection, as does a history of torsion, cryptorchidism, and genitourinary infections. Additionally, obstructive azoospermia (possibly due to obstruction from a previous hernia repair, congenital absence of the vas deferens, or vasectomy) can induce sperm autoimmunity. No prevasectomy reversal evaluation is required, as only serum antibodies can be assessed. Serum antibodies are nonspecific and cannot accurately predict postoperative results. Selective testing for anti-sperm antibodies is important. Patients who should be evaluated include those with the previously mentioned risk factors as well as those with sperm agglutination noted on semen analysis, low sperm motility, abnormal cervical mucus penetration test, or multiple failed intrauterine insemination (IUI) or IVF cycles, and couples with unexplained infertility. There is no good correlation between serum antisperm antibodies and the presence of sperm-bound antibodies. Additionally, it is the sperm-bound antibodies that cause abnormalities in reproductive function, which is where testing should be focused. Direct assays measure sperm-bound antibodies. Indirect tests are serum studies. The preferred test is the direct immunobead test (IBT), but it requires motile sperm. Results show the percent of sperm bound, the antibody isotype, and the binding location. The clinically significant range is 20–50% of sperm demonstrating immunobead binding. Immunoglobulin G (IgG) and IgA antibodies are assessed. It is unlikely that IgM immunoglobulin will be found in the male genital tract, so testing for this subclass is unwarranted. In instances where this level of sophisticated testing is not available or a screening test is desired, Sperm Mar (Ortho Diagnostic Systems, Beerse, Belgium) is a commercially available assay that does not require sperm processing.
Sperm Function Tests Sperm–Cervical Mucus Interaction The postcoital test assesses the sperm in the partner’s cervical mucus and the interaction between the two. The test is performed just prior to ovula-
tion. A specimen of cervical mucus, obtained within a few hours of intercourse, is examined under a microscope. More than 10 sperm per high power field, most of which demonstrate progressive motility, constitutes a normal study. Indications for postcoital testing include hyperviscous semen, unexplained infertility, and lowvolume semen with good sperm density. This test is contraindicated for patients with poor quality semen specimens. Inherent poor reproducibility and the fact that there are specimens from both parties make the study difficult to interpret. If an abnormal result is obtained, an in vitro cervical mucus penetration test may be performed. These tests have been developed to standardize and isolate semen factors. Several commercially available tests allow measurement of sperm migration and penetration through standard (usually bovine) cervical mucus. An example of this type of test is the Penetrak (Serono Diagnostics, Braintree, MA). These test results usually correlate with the quality of the semen specimen, but there are patients who have abnormal results and normal semen parameters. In these individuals, look for the presence of antisperm antibodies. Currently, the definitive role of cervical mucus penetration tests in the evaluation of the infertile male is not clear.
Sperm Penetration Assay The sperm penetration assay is a sophisticated test that measures the physiologic ability of the human sperm to enter a zona-free hamster egg and begin the fertilization reaction. The zona pellucida is the barrier to cross-species fertilization. When hamster eggs are rendered zona-free and penetrated by human spermatozoa in vitro, they serve as a substitute for human ova in a preliminary assessment of fertilizing capacity. For successful penetration, sperm must be able to undergo capacitation, the acrosome reaction, fusion with the oolema, and incorporation into the ooplasm. Scoring is based on the percentage of ova penetrated, or number of penetrations per ovum. The lower limit of normal is 10–30% of ova penetrated. Results are expressed as the mean number of penetrations per ovum, which Lipshultz’s laboratory has termed the sperm capacitation index (SCI). An SCI of less than 5 is abnormal. Although interpretation of this study is controversial, the results generally correlate with IVF success rates. The test may be useful is if one is contemplating IUI versus IVF/ICSI (intracytoplasmic sperm injection) or IVF versus ICSI. If the sperm penetration assay is normal, IUI would be logical in the IUI versus IVF/ICSI case, and IVF
3051_Seifer_02_p10-23 11/27/01 3:43 PM Page 15
2. Evaluation of the Male for Infertility
would be indicated in the IVF versus ICSI case. Familiarity with the laboratory performing the assay is critical to allow proper interpretation.
Hormonal Screening A brief review of male reproductive endocrine physiology is essential. The testes are dual organs. There is an endocrine (hormonal) component consisting of Leydig cells, Sertoli cells, and germ (sperm) cells. This component is necessary for male sexual differentiation and maturation, normal potency and ejaculatory capability, and spermatogenic maturation. Endocrine and spermatogenic compartments are anatomically and functionally integrated. Proper hormone balance is initiated by a pulsatile hypothalamic release of gonadotropinreleasing hormone (GnRH). This causes pituitary release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), which have a direct action on the testis. FSH acts on Sertoli cells to provide a favorable milieu for spermatogenesis. LH stimulates the Leydig cell to secrete testosterone, providing the locally high concentration required for spermatogenesis. Serum testosterone reflects Leydig cell function and provides an indication of intratesticular testosterone. There is a diurnal rhythm, with the peak during early morning. Consequently, it is optimal to perform serum testosterone evaluations in the morning. Additionally, when monitoring an individual patient it is optimal if the tests are done at a relatively consistent time of day. Serum testosterone includes both bound and unbound (free) fractions. The free fraction is the biologically active component and comprises 2% of the total testosterone. Alterations in the sex hormone-binding globulin (SHBG) may give spurious estimates of the biologically active unbound testosterone, as changes in SHBG are reflected in the total testosterone. SHBG is increased by estrogens, thyroid hormone administration, and cirrhosis; it is decreased by androgens, growth hormone, and obesity. For example, in obese men the total testosterone may be lowered secondary to a decrease in SHBG, whereas the free testosterone may be within normal limits. Furthermore, testosterone is aromatized in peripheral tissue to estrogen. There is increased aromatization in the presence of alcoholism, chronic liver disease, testis tumors, and obesity. Most importantly, if the serum testosterone does not correlate with the clinical situation or is equivocal, the free testosterone should be assayed. The endocrine workup should be tailored to the
15
individual to allow a cost-conscious, efficient evaluation. Fewer than 3% of infertility cases are due to a primary endocrinopathy. Sigman studied 1034 men to determine what hormonal workup should be done and which patients should be studied. He found that by limiting screening to men with sperm densities less than 10 million/ml only one case of endocrinopathy would have been missed. A higher degree of confidence and detection results when patients with higher sperm counts are screened, although the likelihood of discovering a significant abnormality is low. What studies are appropriate? It is uncommon to find clinically important abnormalities in LH or testosterone if the FSH is normal. In Sigman’s study, no significant endocrine aberrance would have been missed by screening FSH and testosterone alone. Evaluation of FSH and testosterone seems to be the most efficient, cost-effective, and revealing hormonal survey. If the FSH is abnormal, or the testosterone is low, the serum LH should be assayed. Also, consider a free testosterone assay in equivocal cases or in clinical situations such as obesity. If the LH and testosterone levels are low, prolactin should be evaluated. Hyperprolactinemia causes LH suppression, which in turn lowers serum testosterone. Low serum testosterone decreases libido and may cause infertility. Certain patient historic factors raise suspicions of given entities. With hypogonadotropic hypogonadism, or Kallmann syndrome (congenital form), there is failure of GnRH secretion; clinical signs include anosmia (lack of smell) and delayed puberty. Hyperprolactinemia may manifest with impaired visual fields and severe headaches secondary to a prolactin-secreting pituitary tumor. The patient may also complain of impotence. Be aware that gonadotropin production is inhibited by negative feedback from estrogens and androgens at the hypothalamus and pituitary. A hypogonadal state is induced by androgen excess, either exogenous or endogenous. Exogenous sources include testosterone supplementation and anabolic steroids, each of which has a contraceptive effect. Congenital adrenal hyperplasia is the most common cause of endogenous androgen excess. These patients have a history of precocious puberty, short stature, and underdeveloped testes. Urinary 17-ketosteroids should be measured in these individuals. Of note is the fact that patients with hypothyroidism do not present primarily with infertility, and routine thyroid-stimulating hormone (TSH) screening is not indicated. Table 2–3 depicts the various hormonal patterns and their corresponding clinical entities.
3051_Seifer_02_p10-23 11/27/01 3:43 PM Page 16
16
K.A. Spear
TABLE 2–3. Hormonal Patterns and Corresponding Clinical Status Clinical status Normal Testicular failure Germinal aplasia Hypogonadotropic hypogonadism
FSH
LH
T
Normal Elevated Elevated Low
Normal Elevated Normal Low
Normal Normal or low Normal Low
FSH, follicle-stimulating hormone; LH, luteinizing hormone; T, testosterone.
Genetic Testing Genetic testing should be considered in the man with severe oligospermia or azoospermia. This becomes important especially when ICSI is being contemplated. It has been demonstrated by Page and others, that men with Y chromosome deletions, such as AZFc, will likely transmit the deletion and infertility to their sons who were conceived by ICSI. Several laboratories proficient in this testing include Boston University School of Medicine Center for Human Genetics (617-638-7083) and the Genetics and IVF Institute Molecular Genetics Laboratory in Fairfax, VA (800-654-4363) Genetic screening is mandated in patients with bilateral congenital absence of the vas deferens. Cystic fibrosis gene screening is required as discussed in this chapter.
Diagnostic Studies Scrotal Ultrasonography The use of ultrasonography to image organs and vessels and to measure blood flow is beneficial during evaluation of the infertile man. Its principal application regarding male factor infertility is for the diagnosis of varicoceles. Varicocele is usually diagnosed by physical examination, although the physical examination is sometimes complicated by body habitus and is sometimes equivocal. Some investigators believe that small varicoceles are as important as large ones. Whether nonpalpable or subclinical varicoceles are clinically significant remains a subject of controversy. Several adjuncts in the diagnosis of varicocele are available. Portable, pencil-probe directional Doppler units can be utilized in the office to assist in varicocele detection. This modality detects changes in blood flow (reflux) during a Valsalva maneuver, but the accuracy and reproducibility of this technique are limited. Standard scrotal ultrasonography is readily available, familiar to urologists and infertility clinicians, noninvasive, and relatively inexpensive. The diag-
nosis is based on a venous diameter of 3.5 mm or more with the patient at rest so he can be scanned in the supine position. Subclinical varicoceles are approximately 3 mm in diameter. Color flow Doppler allows determination of the direction and magnitude of blood flow. To detect the change in flow, or reflux, the patient must perform the Valsalva maneuver and may require examination in the standing position. This positioning allows adequate assessment of reflux in the testicular veins, although the accuracy and clinical significance are not absolute. Scrotal ultrasonography and color duplex Doppler are excellent adjuncts in patients with equivocal examinations.
Transrectal Ultrasonography In the past, evaluation of patients with low-volume ejaculates, especially those with azoospermia, included postejaculate urinalysis and subsequent vasography. Historically, surgical vasotomy with vasography were required to image the seminal vesicles and ejaculatory ducts to diagnose ejaculatory duct obstruction. Vasography is an invasive surgical procedure, and there is a risk of vasal scarring and obstruction. Transrectal ultrasonography (TRUS) is now being used to detect varying degrees of ejaculatory duct obstruction. It is essentially a noninvasive, inexpensive office procedure that is readily available. Patients do not require pre-TRUS preparation, antibiotics, or enemas. Urologists are comfortable with this technique, as it is used routinely for the evaluation and diagnosis of prostate carcinoma. Transrectal images of the prostate and seminal vesicles are vastly superior to those obtained with transabdominal imaging. High-resolution images using a 7.5 MHz rectal probe are produced in transverse and sagittal planes. Ejaculatory duct obstruction is easily diagnosed, and the results are highly accurate when using TRUS in azoospermic patients with low ejaculate volume. Obstruction is documented by the presence of dilated seminal vesicles more than 1.5 cm in diameter seen on transverse imaging. Additional findings indicating obstruction
3051_Seifer_02_p10-23 11/27/01 3:43 PM Page 17
2. Evaluation of the Male for Infertility
17
technique. Patients are prepared with an oral fluoroquinolone, one dose the night prior and a second dose the morning of the procedure. A Fleets enema is self-administered the morning of the aspiration. Interpretation of TRUS in the oligospermic patient is more difficult, and the entity of partial ejaculatory duct obstruction is not definitive. The seminal vesicle aspiration technique mentioned above may prove useful in this scenario. The role of TRUS in infertile men is evolving and currently provides a specific, accurate diagnosis in a select group of patients.
Postejaculate Urinalysis FIGURE 2–4. Transverse view of the prostate (within cursors) with a large midline cyst (hypoechoic lesion within prostate), as seen by transrectal ultrasonography (TRUS). (From Goldstein, 1995, by permission of W.B. Saunders)
include midline intraprostatic cystic structures and intraprostatic calcifications along the projected course of the ejaculatory ducts (Figs. 2–4, 2–5). The absence of seminal vesicles and ampulla of the vas is diagnostic of congenital abnormalities. Jarow has demonstrated that sperm are not normally noted in the seminal vesicles in an unobstructed state immediately after ejaculation. Fluid can be aspirated from the seminal vesicles via transrectal ultrasonic guidance to confirm ejaculatory duct obstruction. A 15-cm, 18- or 20-gauge disposable Echotip Turner biopsy needle (Cook) is well suited for this
FIGURE 2–5. Transverse view of the prostate with a calcification (arrow) in the region of the ejaculatory ducts, as seen by TRUS. (From Goldstein, 1995, by permission of W.B. Saunders)
A postejaculate urinalysis to detect retrograde ejaculation should be obtained in patients with an ejaculation (no antegrade ejaculate), those with low-volume azoospermia, and all others with lowvolume semen samples, including those with oligospermia and normal concentration. The patient voids to completion, produces anejaculate, and then immediately voids into a specimen container. The unspun voided specimen is then evaluated. A diagnosis of retrograde ejaculation is confirmed when more than 10 sperm are noted per high power field. The sample is then centrifuged and evaluated, by semen analysis, to obtain concentration and motility values.
Testis Biopsy Historically, testis biopsy has been used to diagnose a variety of impaired male fertility disorders. With the advent of hormonal screening and noninvasive imaging modalities, testis biopsy and operative vasography have assumed a limited role. Testis biopsy is reserved for patients who have azoospermia, essentially normal-size testes, palpable vas deferens and epididymis, and a normal volume of semen. In these cases, testis biopsy allows the differentiation between patients with microtubular obstructive disease who are candidates for microsurgical repair and patients with disorders of sperm development. In the age of intracytoplasmic sperm injection (ICSI), testicular biopsy has taken on an increased role. Patients who were previously untreatable are now candidates for extraction of testicular sperm. In the past it was stated that if an individual has an FSH level more than three times normal, testicular failure is present, and no treatment is available. However, in 50% of patients with an elevated FSH level up to three times the normal value, sperm or spermatids are noted on testicular biopsy. The
3051_Seifer_02_p10-23 11/27/01 3:43 PM Page 18
18
K.A. Spear
sperm is extracted from the testicular tissue in the laboratory and used in conjunction with ICSI. Testicular biopsy can be performed in the office under local anesthesia. Plain 1% lidocaine is used to infiltrate the anterior scrotal skin and dartos layers. With the testicle firmly held in position and with the epididymis in a posterior position and the anterior surface up against the scrotal wall, a 1 cm incision is made down to the tunica vaginalis. Holding stitches are placed in the tunica vaginalis, and it is opened sharply the length of the incision. An eyelid retractor is placed and additional 1% lidocaine is dripped on the tunica albuginia. A holding stitch is placed in the tunica albuginia, which is then incised approximately 0.5–1.0 cm in length. Testicular tubules extrude from the opening and are excised with tenotomy scissors. The tissue is placed in support medium, such as human tubular fluid or Hamm’s F-10, for transport to the laboratory. The biopsy is best done where intravenous sedation can be administered. Testicular biopsy remains the gold standard in regard to diagnosis when one is searching for a small number of sperm. When extraction of testicular sperm is to be utilized with ICSI, testicular biopsy affords a better chance of obtaining sperm than testicular aspiration. Furthermore, testicular tissue can be frozen to be utilized in the future. ICSI pregnancies and good fertilization rates have been reported using cryopreserved testicular sperm. Testicular aspiration can be performed in the office setting. Start with 1% lidocaine local infiltration at the puncture site. A spermatic cord block may aid with anesthesia. The lidocaine is injected perivasally. A 23-gauge needle and the Fratzen apparatus for fine-needle aspiration is used. An alternative is a syringe with a three-pronged handle. The needle is inserted into the testicle, and negative pressure is exerted on the syringe (plunger is pulled back) while moving the needle up and down within the testicle to obtain a sample. This technique is limited because the chance of obtaining sperm is low, the yield is low, and currently it must be coordinated with egg retrieval. There are no reports of cryopreserved aspirates resulting in ICSI pregnancies. Therefore, aspiration must be performed in a coordinated fashion with egg retrieval, and donor sperm are required for backup.
Results of Evaluation Evaluation of the infertile male categorizes patients. Not only can diagnoses be made (Table 2–4), treatment plans can be discussed and initiated. Both part-
TABLE 2–4. Diagnoses After Evaluation Diagnosis Varicocele Idiopathic Obstruction Anti-sperm antibodies Testicular failure Pyospermia/infection Ejaculatory dysfunction Endocrinopathies
Patients (%) 37–42 20–25 6–14 3–9 1–9 1–5 1–3 1
ners should be present during the initial visit and any subsequent visit during which treatment decisions are made. Each case must be individualized with male partner issues, female partner issues, success rates for treatment options, costs, morbidities, and the couple’s expectations being addressed. In the office, various treatment options can be initiated. In cases where surgery is indicated, explanation of the procedure and its potential outcome is required. The following is a review of the treatment for infertile males in the office environment.
Treatment Medical Therapy Hormonal Causes In patients with hypogonadotropic hypogonadism, treatment is highly effective. The congenital form, Kallman syndrome, is a result of failure of GnRH secretion. Thus FSH, LH, and testosterone are all low. Treatment consists of hCG 2000 IU given intramuscularly three times a week. This dosage adequately virilizes the man, although spermatogenesis proceeds to completion in only 20% of patients. In most patients, after 6 months one-half of a 75 IU ampule of pergonal is administered three times a week to supply FSH. Sperm counts below 10 million/ml, with good sperm motility, are usually noted. Many of these patients are able to conceive despite the decreased sperm density. Individuals with hyperprolactinemia require computed tomography (CT) or magnetic resonance imaging (MRI) of the head, with attention to the sella turcica, to rule out a pituitary tumor. Patients with mild elevations of prolactin need repeat testing for prolactin to confirm a significant elevation, as prolactin production is stress-related and levels vary. Repeat studies are important in cases where the prolactin level is less than 30 ng/ml. Serum prolactin levels over 300 ng/ml are diagnostic of a pituitary adenoma; a level of over 100 ng/ml is usually
3051_Seifer_02_p10-23 11/27/01 3:43 PM Page 19
2. Evaluation of the Male for Infertility
caused by an adenoma. If a pituitary tumor is found, neurosurgery, irradiation, or bromocriptine is required. If a tumor cannot be delineated on imaging studies or a microadenoma (10 mm) is found, bromocriptine is the therapy of choice. Begin with a 1.25 mg dose by mouth at bedtime to minimize the side effects of nausea, vomiting, fatigue, nasal stuffiness, and postural hypotension. The dosage is increased to an average of 2.5 mg twice a day. Prolactin levels return to normal in virtually all patients within days of achieving the full therapeutic dose, which usually is 5.0–7.5 mg. Consequently, prolactin levels should be monitored 4–7 days after dosage changes to determine the therapeutic response. The effects of bromocriptine are usually not permanent, but one-sixth of patients maintain normal prolactin levels after cessation of the drug. This is evident in patients with idiopathic hyperprolactinemia, when no tumor is noted. Bromocriptine can be withdrawn yearly to determine if the abnormality persists. Testosterone levels rise in about 3 months; and as with most therapy, semen analyses are delayed until 3 months after initiation to allow completion of spermatogenesis. Congenital adrenal hyperplasia, the most common cause of endogenous androgen excess, is usually detected prior to any infertility problems. It is treated with glucocorticoids. In an oligospermic patient with low testosterone and nonelevated LH, clomiphene citrate (Clomid) is beneficial. It is of note that if an individual has a low LH level, a prolactin assay should be performed. Clomiphene citrate is an antiestrogen– estrogen receptor blocker that prevents negative feedback of estrogens to the pituitary and hypothalamus. Estrogen is present in men, and it plays an important role in the pituitary–hypothalamic– gonadal axis. Ablation of feedback inhibition causes augmentation of GnRH and of LH and FSH secretion. Increased LH stimulates the Leydig cell production of testosterone. Possibly, the increase in FSH enhances sperm production. A clomiphene citrate dose of 25 mg daily is initiated. Serum testosterone should be tested 2–4 weeks after initiation of treatment and every 3 months thereafter to avoid excessive serum testosterone levels. Some authors recommend monitoring estradiol levels, as testosterone is converted peripherally, and elevated estrogens may be detrimental to sperm production. Because the spermatogenic cycle takes 74 days, semen analysis is undertaken 3 months into therapy. Clomiphene citrate is well tolerated in men, and side effects such as gastrointestinal (GI) upset, changes in libido, weight gain, and visual disturbances are rare.
19
Empiric Therapy Despite extensive evaluation, as many as 25% of infertile men have no obvious demonstrable cause for their infertility. Such patients are categorized as having “idiopathic” infertility. A variety of empiric therapies have been utilized for these patients. There is no convincing evidence that any empiric therapy is beneficial. Data from placebo-controlled studies of clomiphene citrate show little or no benefit. Other agents have been assessed, including other antiestrogens such as tamoxifen, aromatase inhibitors such as testolactone, gonadotropins, kallikrein, indomethacin, pentoxifylline, zinc, and antioxidants including vitamins C and E. There is a paucity of data to document the benefit of any of these agents in the idiopathic setting. Evaluation of treatment regimens for idiopathic infertility is complicated when many etiologies are classified together. Various drugs and dosages are utilized, placebo-controlled studies are lacking, and various outcomes are assessed including semen parameters and pregnancy rates. Additionally, treatment-independent pregnancy rates must be considered. At this point there is no individual treatment that can predictably improve sperm function or fertility in men with idiopathic infertility. Therefore empiric therapy for these patients is not recommended. If one chooses to attempt a trial of empiric therapy, consideration of side effects, costs, and potential detriment to fertility must be considered.
Anti-sperm Antibodies Options for therapy are limited for those with antisperm antibodies. The washing and dilution techniques currently available are inadequate owing to the high affinity of antibodies. Corticosteroid therapy is controversial, and few controlled studies are available. One controlled study showed benefit of immunosuppression, but a definitive answer is lacking. One problem is the risk profile of corticosteroids, which includes mood changes, glucose intolerance, ulcers, GI bleeding, and (most severe) aspetic necrosis of the hip. Because of the controversial nature of this treatment and the inherent risks, it is not the treatment of choice. If one chooses to use this therapy, an appropriate regimen consists of prednisolone 20 mg twice a day on days 1–10 of the partner’s cycle, followed by a 5 mg dose twice a day on days 11 and 12. This treatment cycle should be continued for at least 6 months. Hendry found statistically significant improvement in pregnancy rates between the treatment and control arms after 6 months of treatment.
3051_Seifer_02_p10-23 11/27/01 3:43 PM Page 20
20
K.A. Spear
The other well controlled study, by Haas, had a treatment period of 3 months, and no significant difference was noted. The longer, 6-month treatment may be advantageous and required. The best results are obtained when the regimen is used in conjunction with stimulated IUI cycles. In vitro fertilization is not a good therapeutic option, as fertilization rates are markedly decreased when sperm-bound antibodies are present. The treatment of choice is ICSI. Studies have shown excellent, standard fertilization rates and pregnancy and birth rates. ICSI has an associated cost burden that must be factored into the assessment and plan. An additional modality is donor insemination. Couples should be counseled regarding their options, along with risk/benefit and cost profiles.
Pyospermia If a significant number of white blood cells (1 million/ml) are noted in a semen sample, treatment is indicated. Treatment consists of: (1) frequent ejaculation, once every other day; (2) doxycycline, 100 mg twice a day; and (3) an over-the-counter nonsteroidal antiinflammatory drug (NSAID). Begin treatment at the start of the partner’s menstrual cycle and discontinue it several days after ovulation. This regimen may be administered in a cyclic fashion. Treatment is monitored by semen analysis, with the sample given a few days after ovulation or several days prior to a scheduled IUI. Studies indicate a marked decrease in leukocytospermia with this regimen. In the few patients who have symptoms and positive cultures, appropriate antibiotics are employed. Nitrofurantoin (Macrodantin) should be avoided because of adverse affects on spermatogenesis.
Retrograde Ejaculation With retrograde ejaculation, incomplete closure of the bladder neck during ejaculation leads to retrograde flow of semen into the bladder. Patients present with low-volume semen, oligospermia (decreased sperm count), or azoospermia. This condition commonly occurs in men with diabetes mellitus or those who have undergone retroperitoneal or pelvic surgery that disrupts the sympathetic nerves required for normal ejaculation. The condition is confirmed by finding large numbers of sperm in the postejaculate urine. These patients can be treated effectively with sympathomimetic such as pseudoephedrine hydrochloride (Sudafed) 60 mg four times a day. Alternative agents are ephedrine 25–50 mg four times a day or phenylpropanolamine (Ornade) 75 mg twice
a day. The drugs are taken for 10–14 days before assessing their effectiveness. If one of the three compounds is ineffective, try imipramine (Tofranil) 25 mg twice a day. If this is not efficacious, try a combination of one of the first three drugs and imipramine. This treatment is most effective in patients with diabetes. If medical therapy fails, one can retrieve semen from a postejaculatory urine specimen to be used in conjunction with an assisted reproductive technique (ART). To optimize the quality of the specimen, two methods are available: alkalization of the urine and catheterization with instillation of buffered solution. To alkalize the urine, administer sodium bicarbonate tablets 650 mg four times a day or one or two tablespoons of baking soda mixed in a glass of water every 6 hours. This regimen should begin at least 24 hours prior to sperm retrieval. Also, optimize the urine osmolality in the range of 300–380 mosm/L, as it is in semen. This is accomplished by increasing or restricting fluids. In general, the patient voids 1 hour prior to the planned ejaculation and then drinks 300–500 ml of fluid. The patient then ejaculates and voids into a container with buffered medium. An additional method is to catheterize the individual prior to ejaculation. Drain the bladder and then instill 50–100 ml of a physiologic solution such as human tubule fluid or Hamm’s F-10. The patient then masturbates and urinates into a specimen container. These specimens are processed and used in the appropriate ART (i.e., IUI, IVF).
Anejaculation Some patients who have undergone retroperitoneal or pelvic surgery or who had a spinal cord injury suffer from anejaculation, rather than retrograde ejaculation, which is a total absence of ejaculatory function. Although these patients occasionally respond to sympathomimetics such as pseudoephedrine, with the regimen as described, most require vibratory stimulation, electroejaculation, or surgical extraction of sperm from the vas or epididymis to obtain sperm for the ART procedure. Vibratory stimulation of ejaculation is easily performed in the office and is most successful in patients with upper spinal cord lesions. This technique uses a vibrator, the commercial Acuvibe model 6001 or a small hand-held unit with a cone tip that is sold in drugstores as a foot/body massager. The unit is applied to the frenulum of the penis and then may be moved to the dorsum of the glans. Patients who respond to this therapy do so
3051_Seifer_02_p10-23 11/27/01 3:43 PM Page 21
2. Evaluation of the Male for Infertility
within 5–10 minutes. Usually pelvic floor contractions, and possibly lower extremity contractions, are demonstrated prior to ejaculation. Most patients who respond exhibit antegrade ejaculation, but catheterization may be performed to retrieve the retrograde component. No anesthesia is required, but patients with lesions above T6 and those with a history of autonomic dysreflexia are pretreated with 10 mg sublingual nifedipine. Additional pretreatment includes one of the two methods described, alkalization or catheterization, to optimize the quality of the specimen obtained from the bladder. Also, if the patient self-catheterizes, has a Foley catheter, or has a history of voiding dysfunction, a urine culture should be obtained prior to therapy and antibiotics instituted. Patients who respond consistently with an antegrade specimen can learn to perform this technique with the aid of their partner. Pregnancies have been reported by utilizing this technique with intravaginal insemination. Electroejaculation utilizes a rectal probe that electrically stimulates contraction of the seminal vesicles and vasal ampullae, resulting in discharge of semen into the urethra. The model 12 electroejaculator, developed and refined by Seager, is distributed by the National Rehabilitation Hospital, Washington, DC. Electroejaculation can be performed in an office or procedure room in select patients with spinal cord injuries. No anesthesia is required. Keep autonomic dysreflexia in mind for patients with lesions above T6. The sample is processed to be used in conjunction with IUI or IVF.
21
ligation, all of which are outpatient procedures. Open surgical ligation, performed under local anesthesia with or without intravenous sedation, is the preferred method. A subinguinal incision is an excellent approach. Its small size translates into superb patient comfort postoperatively. This technique is cost-effective and low risk. A microsurgical approach may be advocated so the vasal and testicular arteries and the lymphatics are spared. The literature confirms that varicocelectomy improves fertility rates. A compilation of controlled studies demonstrates significantly improved pregnancy rates, and an international WHO study supports the influence of varicoceles on fertility. A prospective, randomized, crossover study by Madgar et al. clearly demonstrated significant improvement in fertility in patients undergoing varicocelectomy versus patients who were simply observed.
Ejaculatory Duct Obstruction Ejaculatory duct obstruction can be treated with transurethral resection of the ejaculatory ducts. Prior to treatment it is optimal if the obstruction is verified by transrectal aspiration of the seminal vesicles or by vasography. These studies also confirm the presence of sperm, ruling out proximal obstruction. Figure 2–6 illustrates potential sites of obstruction in the reproductive tract, including the ejaculatory duct. Published results of treatment show that one-half of patients have sperm in the ejaculate postoperatively, and 25% of all those undergoing treatment contribute to a pregnancy. Complications include (1) impairment of semen parameters due to urine pooling in the prostatic
Surgical Therapy Although a concise description of surgical techniques is beyond the scope of this chapter, an understanding of the breadth of corrective procedures available is imperative. The major techniques utilized are briefly addressed, with an emphasis on outcomes and expectations.
Varicocele A varicocele is an abnormal dilation of the testicular veins in the scrotum. It is the most common cause of male infertility, with a 15% incidence in the general population and a 40% incidence in infertile men. Among men with secondary infertility, there is an 80% incidence. Treatment results in semen improvement in 70% of men and pregnancies in 40% of couples. Repair is done by open surgical ligation of the vessels, transvenous embolization of the internal spermatic vein, or laparoscopic
FIGURE 2–6. Sites of potential obstruction in the male reproductive tract. Sagittal view. (By permission of Bayer Corp.)
3051_Seifer_02_p10-23 11/27/01 3:43 PM Page 22
22
K.A. Spear
TABLE 2–5. Time Since Vasectomy Related to Results After Reversal Time since vasectomy (years)
Sperm noted after reversal (%)
Partners pregnant (%)
3 3–8 9–14 15
97 88 79 71
76 53 44 30
Source: Belker et al., 1991.
fossa and mixing with semen and (2) urinary reflux into the ejaculatory ducts. Many of these men have a yellow, watery ejaculate. They should dilute the urine by increasing fluid intake and alkalinizing the urine by taking sodium bicarbonate tablets (650 mg four times a day) or Poly-citra (5 ml every 8 hours starting a day prior to planned ejaculation).
Microtubular Obstructive Disease Between 5% and 10% of patients with normalvolume azoospermia have microtubular obstruction. Prior vasectomy and de novo epididymal obstruction are the most common causes. Both of these entities can be corrected with sophisticated microsurgical techniques. The vasovasostomy study group demonstrated that the length of time since vasectomy is the most important predictor of success of a reversal (Table 2–5). Vasoepididymostomy results in an approximately 70% patency rate with pregnancy rates reported in the 30–50% range. The average length of time before a pregnancy occurs after vasectomy reversal is 1 year. Regarding vasoepididymostomy, most patients have sperm in their ejaculate 3–6 months after surgery, but the surgery should not be considered a technical failure until 18 months postoperatively, as it may take that long for sperm to appear.
Congenital Absence of the Vas Deferens Among azoospermic patients, 1.4% are found on physical examination to have bilateral congenital absence of the vas deferens. Sperm can be obtained from these patients by microsurgical epididymal sperm aspiration (MESA). This procedure has the best chance of success and highest yield. Percutaneous epididymal or testicular aspiration has several drawbacks, including inconsistent success, low yield, and inability to cryopreserve the sperm. The sperm can be utilized with ICSI. Cystic fibrosis (CF) and congenital absence of the vas deferens are different ends of a phenotypic spectrum resulting from deletions in the CF gene. Prior to MESA, both
partners should undergo CF mutation analysis from a serum sample to estimate their risk of transmitting CF or congenital absence of the vas to offspring. If the couple is at risk and proceeds with an ART procedure, amniocentesis, chorionic villous sampling, or preimplantation genetics should be considered.
Assisted Reproductive Techniques A variety of ART techniques have been used to treat male factor infertility. It must be pointed out that an ART should not be considered primary therapy for male factor infertility. The most cost-effective treatment with the highest success rate, combined with low patient morbidity, is the goal. An ART technique should be combined with treatment of the infertile man to gain the highest possible pregnancy rates. Schelegel has reported extensive cost analysis studies comparing varicocelectomy and vasectomy reversal with primary ART. He convincingly showed the cost-effectiveness of treating infertile men.
Conclusions Infertility is a major health concern for a large proportion of reproductive-age patients. Recognizing this entity as a “couple” problem is essential to successful treatment. Advances in the understanding, diagnosis, and treatment of male factor infertility is advancing at a rapid pace. Health professionals treating the infertile man are an integral part of the team addressing couple fertility.
Suggested Reading Acacio BD, Gottfried T, Israel R, et al. Evaluation of a large cohort of men presenting for a screening semen analysis. Fertil Steril 2000;73:595–597. Amer M, Haggar SE, Moustafa T, et al. Testicular sperm extraction: impact of testicular histology on outcome, number of biopsies to be performed and optimal time for repetition. Hum Reprod 1999;14:3030–3034. Belker AM, Thomas AJ Jr, Fuchs EF, et al. Results of 1469 microsurgical vasectomy reversals by the Vasovasostomy Study Group. J Urol 1991;145:505. Chuang AT, Howards SS. Male infertility: evaluation and nonsurgical therapy. Urol Clin North Am. 1998;25: 703–713. Clarke GN, Elliott PJ, Smaila C. Detection of sperm antibodies in semen using the immunobead test: a survey of 813 consecutive patients. Am J Reprod Immunol Microbiol 1985;7;118–123. Cram DS, Ma K, Bhasin S, Arias J, Pandjaitan M, Chu B, Audrins P, Saunders D, Quinn F, deKretser D, McLachlan R: Y chromosome analysis of infertile men
3051_Seifer_02_p10-23 11/27/01 3:43 PM Page 23
2. Evaluation of the Male for Infertility and their sons conceived through intracytoplasmic sperm injection: vertical transmission of deletions and rarity of de novo deletions, Fertil Steril 74:909, 2000. Goldenberg RL, White R. The effect of vaginal lubricants on sperm motility in vitro. Fertil Steril 1975; 26:872. Goldstein M. Surgery of Male Infertility. Philadelphia: Saunders, 1995. Haas GC Jr, Manganiello P: A double-blind, placebo controlled study of the use of methylprednisolone in infertile men with sperm-associated immunoglobulins, Fertil Steril 47:295, 1987. Hellstrom WJ, Overstreet JW, Samuels SJ, et al. The relationship of circulating antisperm antibodies to sperm surface antibodies in infertile men. J Urol 1980;140: 1039. Hendry WF: The significance of antisperm antibodies: measurement and management, Clin Endocrinol 36: 219, 1992. Honig SC, Oates RD. Infertility. In: Krane RJ, Siroky MB, Fitzpatrick IM (eds) Clinical Urology. Philadelphia: Lippincott, 1994;1102–1142. Honig SC, Lipshultz LI, and Jarow J. Significant medical pathology uncovered by a comprehensive male infertility evaluation. Fertil Steril 62:1028, 1994. Jarow IP. Seminal vesicle aspiration of fertile men. J Urol 1996;156:1005–1007. Kamischke A, Nieschlag E. Analysis of medical treatment of male infertility. Hum Reprod 1999;14(suppl 1):1–23. Kleiman SE, Yogev L, Hauser R, Botcham A, Lessing JB, Paz G, et al. Genetic evaluation of infertile men. Hum Reprod 14:33, 1999. Kruger TF, Acosta AA, Simmons KE, et al. Predictive value of abnormal sperm morphology in in vitro fertilization. Fertil Steril 1988;49:112. Lamb EJ. Prognosis for the infertile couple. Fertil Steril 1972;23:320. Lipschultz LI. Cryptoorchidism in the subfertile male. Fertil Steril 1976;27:609. Lipschultz LI, Howards SS. Infertility in the Male, 3rd ed. St. Louis: Mosby-Year Book, 1996. Lubs HA Jr. Testicular size in Klinefelter’s syndrome in men over fifty. N Engl J Med 1962;267:326. Madgar I, et al. Controlled trial of high spermatic vein ligation for varicocele in infertile men. Fertil Steril 1995;63:120.
23
McClure RD. Male infertility. In: Tanagho EA, McAninch JW (eds) General Urology. Norwalk, CT: Lange, 1992:669–695. Muller CH. Rationale, interpretation, validation, and uses of sperm function tests. J Androl 2000;21:10–30. Ohl DA, Naz RK. Infertility due to antisperm antibodies. Urology 1995;46:591–602. Schlesinger MS, Nagler HM. Treatment outcome after varicocelectomy. Urol Clin North Am 1994;21:517. Page DC, Silber S, Brown LG. Men with infertility caused by AZFc deletion can produce sons by intracytoplasmic sperm injection, but are likely to transmit the deletion and infertility. Hum Reprod 14:1722, 1999. Schlegel PN: Is assisted reproduction the optimal treatment for varicocele-associated male infertility? A costeffectiveness analysis. Urology, 49:83, 1997. Sigman M, Howards SS. Male infertility. In: Walsh PC, Retik AB, Stamey TA, Vaughan ED (eds) Campbell’s Urology. Philadelphia: Saunders, 1992:661–705. Sigman M, Lipshultz LI. Male infertility. In: Stein BS, Caldamone AA, Smith JA (eds) Clinical Urological Practice. New York: Norton, 1995:1219–1270. Silber SJ, Alagappan R, Brown LG, Page DC. Y chromosome deletions in azoospermic men undergoing intracytoplasmic sperm injection after testicular sperm extraction. Hum Reprod 13:3332, 1998. Witkin SS, David SS. Effect of sperm antibodies on pregnancy outcome in a subfertile population. Am J Obstet Gynecol 1988;158:59–62. Witkin SS, Viti D, David SS, et al. Relation between antisperm antibodies and the rate of fertilization of human oocytes in vitro. J Assist Reprod Genet 1992;9:207– 210. World Health Organization. WHO Laboratory Manual for the Examination of Human Semen and SpermCervical Mucus Interaction, 3rd ed. New York: Cambridge University Press, 1992. Yanagimachi R, Yanagimachi H, Rogers BJ. The use of zona-free animal ova as a test system for the assessment of the fertilizing capacity of human spermatozoa. Biol Reprod 1976;15:471. Zonari R, deAlmeida M, Rodrigues D, et al. Localization of antibodies on spermatozoa and sperm movement characteristics are good predictors of in vitro fertilization success in cases of male autoimmune infertility. Fertil Steril 1993;59:606–612.
3051_Seifer_03_p24-38 11/5/01 9:35 AM Page 24
3 Detection and Therapeutic Approaches to Age-Related Infertility Fady I. Sharara, Richard T. Scott Jr., and David B. Seifer
Two social factors, delayed childbearing and an increase in the prevalence of divorce followed by remarriage, are contributing to a growing number of women in their mid to late thirties who desire fertility at a time when fecundity is declining. One of the most difficult challenges is the evaluation and treatment of these women, who desire fertility but have diminished ovarian reserve. The latter is due to the fact that they frequently do not produce enough quality oocytes to take full advantage of the various options offered by assisted reproductive technologies. In addition, pregnancy rates during natural and assisted cycles are dramatically reduced, and the rate of spontaneous miscarriages is markedly increased. The challenge of increasing miscarriages with diminished ovarian reserve was highlighted in a retrospective study examining the influence of maternal age on pregnancy loss rates after early documentation of fetal cardiac activity by transvaginal ultrasonography in women undergoing ovulation induction for infertility. A spontaneous abortion rate of 2% was observed for maternal ages 35 years but increased to 16% for those 36 years old following documentation of fetal cardiac activity.1 The development of diminished ovarian reserve generally reflects the age-related decline in reproductive performance.2 As such, diminished ovarian reserve represents a natural physiologic occurrence noted in most women during their mid to late thirties. This presents a particular challenge to the practicing clinician, who must attempt to identify those women with markedly reduced ovarian reserve prior to embarking on expensive, invasive treatments. If women have diminished ovarian reserve, they should be counseled to consider oocyte donation or adoption. Although these options frequently are 24
disappointing, they do represent realistic options for many couples. For couples unwilling to consider these options, the next step may be to optimize their treatment as much as possible. These patients require more aggressive stimulation and treatment protocols and continue to have relatively decreased pregnancy rates compared to women with undiminished ovarian reserve. This chapter reviews various methods for ovarian reserve screening and considers treatment approaches for optimizing chances for women with diminished ovarian reserve to become a biologic parent.
Follicle-Stimulating Hormone Basal FSH Levels The traditional techniques used to estimate a patients’ ovarian reserve are of limited clinical value because of poor predictive values, invasiveness, or expense. A parameter that is easily measurable, minimally invasive, and inexpensive and that has good predictive value is needed. The basal follicle-stimulating hormone (FSH) level on cycle day 3 has been described by some as meeting these criteria.3–6
Age-Related Changes in FSH Levels A series of studies during the 1970s and 1980s characterized the endocrinologic aspects of the transition through the climacteric.7–10 Sherman and colleagues documented that women with normal ovulatory cycles commonly begin to have subtle elevations in their FSH levels in their midthirties.9,10 Further studies confirmed these findings and consistently demonstrated that the first eleva-
3051_Seifer_03_p24-38 11/5/01 9:35 AM Page 25
3. Detection and Therapeutic Approaches to Age-Related Infertility
tions occur during the early follicular phase.7,8 Although these studies did not evaluate the relation between the FSH level and ovarian reserve, they documented that FSH levels increase at the same general time the incidence of diminished ovarian reserve increases. The physiologic basis for the increase in basal FSH with aging has received renewed vigor. Batista et al. evaluated luteinizing hormone (LH), FSH, 17-estradiol inhibin, progesterone, PP-14, and endometrial biopsies (EMBs) in young (age 20–30) and older (age 40–50) volunteers.11 FSH levels were increased, and inhibin levels (Monash assay) were decreased in the older group. None of the other parameters were different; in particular, the incidence of out-of-phase EMBs was similar among the two groups. More recently, Klein and coworkers could not find any decrease in estradiol, progesterone, LH, or total immunoreactive inhibin (Monash assay) levels with reproductive aging.12 These investigators were able to show that the older group (age 40–45) had accelerated follicular development leading to a shortened follicular phase compared to the younger group (age 20–25). The same investigators also measured the 24-hour mean FSH and LH levels during the early follicular and midluteal phases of the cycle in both the younger and older groups. The 24-hour mean FSH levels were significantly higher in the older group during both phases of the cycle than in the younger group, whereas no differences were noted for LH. These investigators suggested that elevated FSH levels seen with reproductive aging may represent a primary neuroendocrine change rather than an ovarian one. More recently the same investigators evaluated the correlation between follicular FSH, estradiol, and inhibin A and B using a newly developed dimeric (bioactive) inhibin assay and found an inverse correlation between follicular FSH and inhibin B levels in the two groups of women described above (young versus older).13 This observation suggests that reproductive aging is primarily of ovarian origin. Furthermore, there are data to support the hypothesis that both diminished follicular quantity and quality occur in women with diminished ovarian reserve, as is discussed in the next section. These follicles have diminished capacity for steroidogenesis and inhibin production; they have fewer cells, and these cells have a good chance of undergoing apoptosis.14
Basal FSH Levels and Pregnancy Rates The earliest description of pregnancy rates and basal FSH levels was in a study by Muasher et al.,
25
who was evaluating the relation between gonadotropin-releasing hormone (GnRH) stimulation test results and the ovarian response to gonadotropins.15 Evaluation of the pregnancy rates following in vitro fertilization (IVF) cycles revealed high pregnancy rates in groups in whom FSH levels were relatively low, whereas no pregnancies occurred in groups in whom the basal FSH values were higher. Although the small number of patients in the study precluded a meaningful evaluation of basal FSH levels and pregnancy rates, it indicated the need for a larger, more detailed study. Scott et al. found in a large retrospective study of 758 IVF cycles that pregnancy rates decreased markedly as FSH levels rose.5 Ongoing pregnancy rates were highest in women whose FSH levels were 15 IU/L and fell to less than 5% in those whose basal FSH levels were over 25 IU/L. This reduction in pregnancy rate was attributed to diminished ovarian reserve, as these patients developed fewer follicles, produced fewer oocytes, and had fewer embryos transferred. Significantly, age would not have predicted the differences in clinical response because the ages of the women in the various groups were equivalent (mean age approximately 35 years). Thus assessment of basal FSH levels provided a means of predicting ovarian responsiveness and eventual pregnancy rates prior to assuming the risks and expense of treatment. Another study from the same center evaluated the relative predictive values of basal FSH levels and age in 1478 consecutive IVF cycles. Although there was a definable decline in pregnancy rate as age increased, basal day 3 FSH levels provided much better predictive values for both pregnancy and cancellation rates.6 This finding was confirmed in other studies. The precise physiologic basis for basal FSH screening is the subject of intense investigation. Originally several researchers postulated that because these elevations occur when circulating estradiol levels are at their nadir, differences in FSH levels could reflect differences in inhibin activity. Studies comparing inhibin levels in women of different ages provide little support for that specific mechanism. Hughes et al. found that although there was an age-related decline in peak inhibin levels during complex ovulation induction, those levels were not different earlier in the cycle (basal).16 Other authors found differences between inhibin levels in high and low responders during complex ovulation induction cycles, but again basal levels were not different.17 It is important to note that the above studies used the Monash assay to measure total immunoreactive inhibin, which is based on a
3051_Seifer_03_p24-38 11/5/01 9:35 AM Page 26
26
F.I. Sharara, R.T. Scott, Jr., and D.B. Seifer
heterologous double-antibody radioimmunoassay based on purified 31-kDa bovine follicular fluid inhibin, which also binds to the free -subunit and its precursors. Using a newly developed dimeric inhibin assay, which measures specific forms of bioactive inhibins (A and B) by enzyme-linked immunosorbent assay, the rise in early follicular FSH with reproductive aging correlates with a fall in inhibin B levels.13 Hopefully, introduction of this assay will allow investigators to examine the relative contributions of estradiol and inhibins A and B to controlling FSH secretion. It has been reported that luteinized granulosa cells from women with elevated day 3 FSH levels produce less steroids, are less viable in culture, have a reduced mitotic index, and produce decreased quantities of insulin-like growth factor (IGF-I and IGF-II). Moreover, it has been demonstrated that preovulatory follicles from women with diminished ovarian reserve contained fewer number of luteinized granulosa cells and have a higher percentage of cells undergoing apoptosis compared with women with uncompromised ovarian reserve undergoing superovulation for in vitro fertilization–embryo transfer (IVF-ET).14 More importantly, these investigators reported that the secretion of total and dimeric inhibin A (using a specific assay) was lower in granulosa cell cultures obtained at IVF from patients with high basal FSH, but no significant differences in either estradiol or progesterone concentrations were seen. This hopefully provides one explanation for the long-sought physiologic reason for the increase in basal FSH in women with diminished ovarian reserve.18
Inhibin Seifer et al.19 examined assisted reproductive technology (ART) outcomes in women characterized as having low or high day 3 serum inhibin B concentrations (45 pg/ml vs. 45 pg/ml). Women with low day 3 serum inhibin B demonstrated 70% of the estradiol response, 66% of the number of occytes retrieved, 28% of the clinical pregnancy rate per initiated cycle and three times the cancellation rate per initiated cycle than women with a day 3 inhibin B level 45 pg/ml. After controlling for age, day 3 serum FSH, day 3 serum estradiol, patient cycle number, and ART method, day 3 serum inhibin B 45 pg/ml was noted to be prognostic of the number of oocytes retrieved and the clinical pregnancy rate. These data suggest that women with low day 3 serum concentrations of inhibin B have less ovarian reserve, as demonstrated by a poor response to ovulation induction
and a reduced probability of conceiving a clinical pregnancy through ART than women with high day 3 inhibin B. Danforth and coworkers evaluated luteal phase inhibin A and follicular phase inhibin B levels and noted an inverse relation with advancing age. Also noted was a decline in inhibin A and inhibin B before the monotropic FSH rise. Additional data support the observation that day 3 serum inhibin B levels decline before the monotropic FSH rise. Seifer and coworkers studied women undergoing ART who demonstrated a poor response to stimulation as measured by increased ampules of gonadotropins for stimulation yielding a higher cancellation rate, a lower estradiol response, fewer oocytes retrieved, and lower clinical pregnancy rate. They found that this group of women also had lower inhibin B levels than women undergoing ART with normal ovarian responsiveness, despite both groups having similar nonelevated day 3 FSH levels. In addition to confirming the inverse relation between declining inhibin levels and rising FSH levels, Santoro and colleagues demonstrated an increase in activin A, which may also contribute to the FSH elevation. The results of these studies call for follow-up investigations with larger patient populations. If future investigations confirm the above findings, dimeric inhibin measurements along with day 3 FSH may provide a better screening test than either test alone.
Intercycle and Intracycle Variability in Basal FSH Levels If basal FSH levels are to be used to counsel patients regarding their chances for conception, a number of questions regarding the reproducibility of the test must be addressed. One is defining the magnitude of the intercycle variation in basal FSH levels. Scott et al. evaluated the intercycle variability in basal FSH levels in 81 women undergoing multiple IVF cycles.20 The mean deviation was 4.2 0.4 IU/L, with a range that extended from 1 IU/L to 42 IU/L. However, the patients with normal basal FSH levels (15 IU/L) had low intercycle variations (mean 2.6 0.2 IU/L). In contrast, patients with elevated basal FSH levels had a much higher degree of variation (mean 7.4 0.9 IU/L). Scott et al. noted that the intercycle variability in basal FSH levels generally did not affect the patients’ prognostic category and therefore should have a minimal impact on clinical decision-making. In the same study, 28 patients had an intercycle variability in basal FSH values that resulted in the patient having a basal FSH value in the normal or
3051_Seifer_03_p24-38 11/5/01 9:35 AM Page 27
3. Detection and Therapeutic Approaches to Age-Related Infertility
intermediate range during one cycle and elevated in another. If basal FSH levels reflect the overall metabolic activity of the developing cohort of follicles, it seemed possible that reproductive performance would be enhanced during cycles when the basal FSH levels were lower. Perhaps patients needed to be monitored from cycle to cycle and then stimulated during the cycle when their FSH levels were normal. A paired analysis of the high and low FSH cycles in these patients revealed no differences in stimulation quality, number of oocytes retrieved, or fertilization rates. Interestingly, the patients all behaved as low responders in both cycles. These data indicate that by the time patients develop more variability in their basal FSH concentrations they have already had a significant diminution in ovarian reserve. Furthermore, it strongly suggests that serial screening of FSH levels to select the optimal cycle for stimulation would be of limited clinical value. This study was limited, however, because information regarding pregnancy outcome was not available. Selection criteria for entry into the study required patients to have had repeated ART cycles without successful pregnancy. Martin et al.21 examined the pregnancy outcomes of four cohorts of couples regarding intercycle variability of the day 3 serum FSH level. More than 1850 cycles of women who underwent IVF were categorized as follows: only 20 mIU/ml; always 20 mIU/ml; current 20 mIU/ml but one previous 20 mIU/ml; and current 20 mIU/ml but two or more previous 20 mIU/ml. No pregnancies occurred in 53 cycles with day 3 FSH only 20 mIU/ml. In 1750 women whose day 3 FSH levels were always 20 mIU/ml, the pregnancy rate per cycle was 16.5%. For 54 cycles in which day 3 FSH was 20 mIU/ml one time only but 20 mIU/ml during the treatment cycle, the pregnancy rate as 5.6%. For 11 cycles where two or more previous FSH determinations were 20 mIU/ml but with a current day 3 FSH 20 mIU/ml, no pregnancy occurred. Based on these results the investigators came to the conclusion that patients with day 3 serum FSH 20 mIU/ml should be strongly discouraged from proceeding with IVF. The 5.6% pregnancy per cycle rate with one previously elevated FSH supports the concept that once a patient has an elevated FSH level she is unlikely to be successful during further IVF cycles regardless of what future day 3 FSH values may be. Another study examined intracycle variability in a healthy population of women with regular menstrual cycles. It noted serum FSH on days 2–5 to be similar.22 This result appears to have been confirmed by other investigators.12
27
Basal FSH Screening in Women with One Ovary Because basal FSH level screening is believed to reflect the activity of the developing cohort of follicles as a whole, there was considerable concern as to whether the predictive value of the test would be maintained in women with one ovary. There is a decrease in the size of the initial cohort of follicles in these patients, but there is not necessarily a corresponding decrease in their quality. Khalifa et al. compared the basal FSH levels in women with one or two ovaries and evaluated the predictive values of the test in each group.23 The 162 women with one ovary had higher mean basal FSH levels and correspondingly had a poorer response to gonadotropin stimulation than the 1066 patients with two ovaries. After controlling for the basal FSH level, however, there were no differences in gonadotropin responsiveness or pregnancy and delivery rates. These data indicate that basal FSH screening retains its predictive value in women with one ovary, even when using the same thresholds for defining an abnormal test.
Estradiol Levels and Basal Day 3 FSH Levels The validity of FSH screening depend on the time during the cycle the sample is collected. Timing is considered optimal when circulating estradiol (E2) levels are at their nadir, which is typically around cycle day 3. Some patients have inappropriately high E2 levels on day 3, which suggests that they may be farther into their follicular phase than is clinically apparent. In these circumstances, it is possible that the higher circulating E2 level is suppressing FSH levels back into the normal range even if the patient has diminished ovarian reserve. The original studies evaluating the relation between basal E2 and FSH levels in an effort to determine if there was a threshold value above the predictive value of a normal FSH level was lost.5 No such threshold value could be identified. More recently, two investigators revisited this question. Licciardi et al. determined that progressive increases in basal day 3 E2 levels were associated with declining ovarian responsiveness and pregnancy rates.24 After controlling for FSH levels, however, there was no difference in pregnancy rates in women with normal or “elevated” basal E2 levels. Thus the authors were unable to demonstrate that the E2 levels added information beyond that seen with FSH levels alone. In contrast, Smotrich et al. demonstrated a sig-
3051_Seifer_03_p24-38 11/5/01 9:35 AM Page 28
28
F.I. Sharara, R.T. Scott, Jr., and D.B. Seifer
nificant decline in pregnancy rates with elevated E2 levels, even after controlling for the FSH levels.25 These authors chose a higher threshold E2 value for defining a significant elevation (80 pg/ml compared to 45 pg/ml in Licciardi et al.’s paper), although no data regarding the comparability of the assays are available. In aggregate, these data suggest that patients with elevated E2 levels may have reduced reproductive potential. Further studies are needed to define more clearly the appropriate threshold values and to determine exactly how they should alter interpretation of circulating FSH concentrations.
Basal FSH/LH Ratios Although extensive data are available regarding the high level of specificity of basal FSH levels, the fact remains that the test may have limited sensitivity. Stated otherwise, patients with abnormal levels are typically low responders with poor pregnancy rates (highly specific), but a substantial group of patients have normal levels and still respond poorly to stimulation with associated poor pregnancy rates. This led some investigators to seek more sensitive tests (i.e., FSH/LH ratios, dimeric inhibin, E2 as previously mentioned) to determine if a given patient has diminished ovarian reserve. Mukherjee et al. reported that patients with elevated FSH/LH ratios (indicating disproportionally more FSH secretion) were low responders with lower peak E2 levels and fewer oocytes recovered.26 The authors evaluated 74 patients with normal basal FSH and E2 who underwent IVF, 14 of whom had an FSH/LH ratio 3.6. The cancellation rate in that group was 12 of 14, compared to a significantly lower cancellation rate of 6 of 60 if the FSH/LH ratio was 3.6. It is of note that pregnancy rate in patients with an FSH/LH ratio 3.6 was 25% (neither of the two patients with an FSH/LH ratio 3.6 conceived). Obviously a larger sample size is needed before this ratio can be used clinically as a marker of diminished ovarian reserve. In a review of the basal FSH/LH ratios and pregnancy outcome data from the Saint Barnabas Medical Center program in Livingston, NJ, there were no definable differences in pregnancy or implantation rates among 336 patients with normal basal FSH levels and varying FSH/LH ratios. More data are needed to determine if evaluation of this relation can provide clinically meaningful information.
Current Status of Basal FSH Screening Elevated basal day 3 FSH concentrations are highly predictive of diminished ovarian reserve as defined
by poor gonadotropin responsiveness and pregnancy rates in patients undergoing complex ovulation induction or one of the assisted reproductive technologies.5,6,15–18,20,23–25 The test is simple, inexpensive, and routinely available. The studies performed to date are limited to clinical circumstances requiring complex ovulation induction. No data are currently available to assess the predictive value of basal FSH screening during spontaneous ovulatory cycles or in women from a general infertility population.
Clomiphene Citrate Challenge Test The clomiphene citrate (CC) challenge test (CCCT) was described in 1987 by Navot et al. as a means of assessing ovarian reserve in women 35 years of age and older.27 This simple test consists of measuring serum FSH concentrations on cycle day 3 (basal) and then again on cycle day 10 following administration of 100 mg of CC on cycle days 5 through 9. In the original study, reported prior to any of the studies addressing the value of basal FSH levels, an abnormal test was defined by an elevated level in the day 10 sample. Obviously, an abnormal value on cycle day 3 also results in the test being considered abnormal. Similar to the information regarding basal FSH levels, the precise physiology of the CCCT has not been clearly defined. The premise of the test is that in women with normal ovarian reserve the overall metabolic activity of the developing follicles should be able to overcome the impact of CC on the hypothalamic-pituitary axis and suppress FSH levels back into the normal range by cycle day 10. Addition of CC creates a “provocative” test that unmasks patients who might not be detected by basal FSH screening alone. Investigators have demonstrated different serum inhibin B concentrations in normal versus abnormal CCCTs, supporting the concept that diminished granulosa cell inhibin B production may be responsible for an abnormal CCCT.
CCCT and Pregnancy Rates In its original description, the CCCT was used to evaluate 51 infertile women over age 35.27 All 51 of these women had normal basal FSH concentrations, but 18 had elevated values following CC administration and were categorized as having diminished ovarian reserve. Demographically, the patients with diminished reserve were similar to those with adequate reserve at equivalent ages, durations of infertility, and requirements for augmentation of ovulation. However, only 1 of the 18
3051_Seifer_03_p24-38 11/5/01 9:35 AM Page 29
3. Detection and Therapeutic Approaches to Age-Related Infertility
(6%) patients with diminished reserve conceived, whereas 14 of 33 (42%) of the adequate reserve group became pregnant. Following this initial report, several groups evaluated the predictive value of the CCCT for screening patients participating in ART programs.28 Tanbo et al. studied 91 women over age 35 and found abnormal CCCTs in 37.29 Of these 37 patients, 20 also had an elevated basal FSH concentration on cycle day 3. Only one patient had an abnormal value on day 3 and a normal value on day 10. The predictive value of an abnormal test was 85% for cycle cancellation due to poor ovarian responsiveness and 100% for failing to conceive. In contrast, cancellation rates were much lower (31.5%) and the pregnancy rates much higher (11%) in patients with normal tests. Most significantly, approximately twice as many patients were identified using the CCCT compared to basal FSH screening alone. Loumaye et al. also evaluated the CCCT but defined an abnormal test by adding the day 3 and day 10 FSH values together.28 In their series of 114 patients a threshold effect was evident, with pregnancy rates remaining equivalent until the summed FSH concentrations exceeded 26 IU/L, when they became zero. Here again the predictive value of an abnormal test for failing to become pregnant was 100%.
CCCT for Screening the General Infertility Population The data generated during the initial evaluation of the CCCT were similar to those obtained when evaluating basal FSH levels alone. The CCCT evaluates the predictive value of the test in ART programs or for patients undergoing complex ovulation induction. Although the test is clearly useful for identifying patients with a poor prognosis in that setting, the results may not be readily extrapolated to the general infertility population. There were legitimate concerns that because the CCCT reflected the inability of the developing cohort of follicles to suppress FSH levels into the normal range, the test would be predictive only of the quality of the cohort as a whole. If a single follicle in a cohort has good reproductive potential (even if the others did not), the natural processes of recruitment and selection could lead to ovulation of the highest-quality follicle, and the predictive value of the CCCT would be diminished. Scott et al. completed a long-term prospective evaluation of CCCT screening in women from the general infertility population.30 Approximately 10% of the 236 patients who were evaluated and
29
followed for a minimum of 1 year had an abnormal CCCT. The incidence of abnormal tests rose with age and was 3% when the woman was 30 years, 7% at 30–34 years, 10% at 35–39 years, and 26% for women 40 years. Most importantly, the pregnancy rates in the patients with diminished ovarian reserve were markedly lower (9%) than those with adequate reserve (43%). The pregnancy rates were still significantly decreased after controlling for age. It is of note that only 7 of the 23 patients with abnormal tests had an elevated day 3 FSH level, again suggesting that the CCCT may be substantially more sensitive than screening with day 3 samples alone. An examination of the E2 response between days 3 and 10 failed to reveal any correlation differentiating those women with normal or abnormal FSH responses. Evaluation of the relation between the eventual clinical diagnoses and CCCT results in these 236 couples revealed a high incidence of abnormal tests in the patients with unexplained infertility. In fact, the incidence of abnormal CCCTs was highest among patients with unexplained infertility (38%) and was unaffected by age.30 This finding suggests that diminished ovarian reserve should be considered an etiology of infertility, and that couples with abnormal tests should no longer be considered to have unexplained infertility.
Predictive Value of Age and the CCCT The data from the studies described above clearly define that the CCCT has been predictive values for pregnancy rates than does age alone. In clinical practice both age and CCCT results are now available. Scott et al. performed a life-table analysis of the pregnancy rates of 589 couples from the general infertility population who were followed for up to 45 months.31 Analysis of the patients with abnormal CCCTs revealed that the pregnancy rates were uniformly poor independent of the patient’s age. This finding provides further support to the contention that diminished ovarian reserve is a specific etiology of infertility. In contrast, evaluation of the patients with adequate ovarian reserve (normal tests) revealed a significant diminution in pregnancy rates with increasing age. This underscores the importance of considering the patients’ age when counseling them regarding their long-term chances for conception, even when their CCCT results are normal. Pearlstone et al. noted similar findings when evaluating the combined predictive value of age and basal FSH concentrations in women over age 40 who were undergoing complex ovulation induction.4 The poor predictive value of a normal test result
3051_Seifer_03_p24-38 11/5/01 9:35 AM Page 30
30
F.I. Sharara, R.T. Scott, Jr., and D.B. Seifer
in women over age 40 emphasizes that there are changes in the reproductive system that are not detected by a CCCT that may significantly limit the reproductive potential of individual patients.2 As noted previously, there are definable changes in the nonovarian components of the reproductive system that could theoretically account for some of the agerelated decline in reproductive potential. The fact that tubal transfer of donor eggs produces equivalent pregnancy rates in all age groups suggests that the most significant component of the age-related decline in reproductive potential relates to gamete quality. Taken in aggregate, it appears that the development of an abnormal CCCT is in fact a late finding, and that a significant oocyte-related diminution in reproductive potential occurs prior to the development of an abnormal test. A test predicting oocyte quality would obviously be of significant clinical importance.
Smoking and the CCCT Women who smoke cigarettes go through menopause 1–4 years earlier than nonsmokers, and a direct relation between the number of cigarettes smoked and early menopause has been noted.32,33 It suggests that smokers deplete their pool of follicles at an accelerated rate, suggesting that these women may have an onset of diminished ovarian reserve at an earlier age. Sharara et al. examined the relation between cigarette smoking and the prevalence of diminished ovarian reserve.34 They evaluated women over age 35 because it is unlikely that women at younger ages, even if they were depleting their pool of follicles at an accelerated rate, would have depleted enough of their follicles to manifest diminished reserve. This was confirmed in two studies where the mean age of smoking women was 35.35,36 In our study, women who smoked cigarettes had a significantly higher prevalence of abnormal CCCTs, implicating smoking in the loss of reproductive potential at an earlier age. It may be appropriate to add loss of reproductive potential to the already long list of health hazards induced by smoking in reproductive-age women. This information is of critical importance when counseling smoking women. Other environmental and endogenous factors (e.g., galactosemia) that may affect ovarian reserve are being investigated.
Current Status of CCCT Screening An abnormal CCCT has excellent predictive value for diminished ovarian reserve and poor long-term pregnancy rates during natural cycles, during ovu-
lation induction, and with IVF.27–30,34 Although the test is specific, it has limited sensitivity, with a significant age-related diminution in reproductive potential occurring even among women with normal test results.2 The CCCT may be superior to basal FSH screening because it is two to three times more sensitive than basal FSH screening alone. Although abnormal day 3 FSH values appear to be accompanied by abnormal day 10 values in most cases, the current literature does not contain enough data to recommend omission of the day 3 sample, and the authors continue to screen patients with both day 3 and day 10 FSH levels. Specific screening guidelines are described below.
Ovarian Reserve Screening Threshold Values When applying the tests to a given patient population, the practicing clinician is critically dependent on the validity of the assay results and the threshold values used for counseling. The importance of validating any given assay system is described below. The broader issue of selecting a threshold value for normal and abnormal is also important. In some of the early reports, authors used the distribution of results among healthy and apparently normal women to determine the 95% confidence interval of anticipated results. Values above this range were considered abnormal. Although this approach is intuitively logical, it is not appropriate for validation of this type of test result. For example, if the women screened were all in their early twenties, it would be illogical and probably incorrect to assume that 5% of them had a degree of diminished ovarian reserve adequate to compromise their fertility. Similarly, if a group of women in their early forties were evaluated, the number with diminished ovarian reserve would greatly exceed the 5%, which would be defined as abnormal. Clearly, defining threshold values by creating a general population confidence interval is inappropriate. The threshold values for normal and abnormal tests should be based on clinically defined endpoints. Because the specific changes that account for the loss of reproductive potential remain undefined, all the studies reported to date are observational in nature. The only way to determine a threshold value is to perform the screening test in a large group of women and then follow them clinically to determine who is able to conceive. An eval-
3051_Seifer_03_p24-38 11/5/01 9:35 AM Page 31
3. Detection and Therapeutic Approaches to Age-Related Infertility
uation of the distribution of these data may then be used to define normal and abnormal test results. For centers that do not have a large clinical volume or that want to apply these screening tests without waiting the required time to accumulate all the follow-up data, comparison of their assay system with those from one of the centers where the original research was done is indicated.
31
Seifer et al.38 reported a technique for quantitatively translating the results obtained at different institutions. They derived an equation that allowed them to predict the values obtained in one system based on the results obtained in the other (r 0.99). These data suggest that institutions may compare their assay to those used at centers that have validated their threshold levels based on clinical performance.
Assay Variability Immunoassays of LH and FSH are intrinsically difficult and imprecise, reflecting the fact that LH and FSH are glycoprotein hormones composed of a protein dimer backbone with variable degrees of glycosylation. Because these hormones have a common chain, the specificity of their actions is determined by the unique chain. The amino acid sequences of the and chains are believed to remain constant, although the degree of glycosylation varies substantially throughout the menstrual cycle. The different degrees of glycosylation affect the bioactivity and circulating half-lives of both LH and FSH and may also substantially influence the immunoassayability of these hormones. This is one of the main factors that explains the varying discrepancy between bioassay and immunoassay hormone levels in samples collected throughout the menstrual cycle. Differences in the antibodies used to measure gonadotropin levels also contribute to the imprecision of these assays. Most of the commercially available assay systems use polyclonal antibody systems that bind differently to different haptens on the glycoprotein hormone. It is important to recognize that immunoassays do not measure the total quantity of the glycoprotein present but, rather, the overall number of binding sites recognized by the antibodies used in the system. Consequently, as the distribution of the various isoforms changes throughout the menstrual cycle, the ability of any single assay to recognize the gonadotropins present may differ substantially. Obviously, this problem would be amplified when using another system with different antibodies that may recognize a different set of haptens. For all of these reasons, comparison of results among different assay systems may be difficult.37 The problems go beyond simple calculation of proportionality because an assay that reports a relatively higher value with one set of isoforms could present a lower value when measuring another. Additionally, different assays may be calibrated against different reference preparations, adding further variability to the results reported.
Morphologic Tests Investigators have attempted to quantify potential ovarian responsiveness using ultrasonographic measurements of various morphologic ovarian characteristics. An example is correlating antral follicle counts with ART outcomes. It has been observed that the number of antral follicles detected by transvaginal ultrasonography decreases with advancing age. Antral follicle counts have been found to correlate well with ovarian responsiveness to stimulation and pregnancy outcomes. Transvaginal ultrasonographic ovarian volume measurement represents another morphologic test of ovarian reserve. Syrop and coworkers39 examined ovarian volumes and noted that total ovarian volume and the volume of the smallest ovary were predictive of a woman’s response to gonadotropin stimulation and ART success. Specifically, large ovarian volumes were predictive of good ART outcome, whereas small ovarian volumes were associated with poor ART outcomes.
Recommendations for Ovarian Reserve Screening Based on the data currently available in the literature, it is possible to recommend guidelines about who should be screened for evidence of diminished ovarian reserve. All infertile women over age 30 should be screened because the rise in the incidence of diminished ovarian reserve begins at approximately that time. We believe that women should be screened early in their overall infertility evaluation, as the test is simple and inexpensive, and it provides valuable prognostic information. Additionally, younger women with unexplained infertility should be screened because the incidence of abnormal tests approaches 50% among these patients independent of their age. Perhaps the most important aspect of using the various tools available for assessing ovarian reserve is the way in which the information is applied to patient counseling. These tests do not have absolute
3051_Seifer_03_p24-38 11/5/01 9:35 AM Page 32
32
F.I. Sharara, R.T. Scott, Jr., and D.B. Seifer
sensitivity or specificity. Patients with abnormal values should be counseled that their chances for conception are poor and that they may want to consider other options, such as oocyte donation or adoption. These patients have excellent pregnancy rates in oocyte donation programs, indicating that the remainder of their reproductive system usually functions normally. The results of these tests, however, should not be used to exclude patients from care. This information is similar in nature to that provided by a semen analysis. Just as men with severe oligoasthenospermia occasionally father a child, women with evidence of diminished ovarian reserve occasionally conceive. The information is best used to counsel patients regarding their individual chances for conception. Decisions about how to apply that information is a personal decision made by the infertile couple and their clinician. Finally, the absolute dependence of these tests on clinically determined threshold values makes it imperative that clinicians have confidence in the significance of the results from their own laboratory. This may be achieved by evaluating clinically defined endpoints in their own population or by parallel comparison with the results obtained in an established laboratory.
Treatment of Women with Diminished Ovarian Reserve Prior to the advent of intracytoplasmic sperm injection (ICSI), it was believed that the major obstacle to treatment of the infertile couple was the male factor. Now the greatest limitation to treating a couple with infertility is diminished ovarian reserve of the female. This limitation has been studied extensively since investigators began describing dramatically lower success rates in in vitro fertilization (IVF) patients who have diminished ovarian reserve as reflected by an elevated day 3 serum FSH level. Strategies to improve outcomes have included increasing the dose of exogenous gonadotropins, decreasing the dosage of GnRH analogues, supplementing ovulation induction protocols with growth hormone, transferring back an increased number of embryos, and selective assisted hatching. Improvements in overall responsiveness have been demonstrated with virtually every protocol for some patients. Despite this fact, the incremental improvement in pregnancy rates has generally been small. These data continue to emphasize the importance of the qualitative changes in these patients’ oocytes, as many have sufficient improvements in the quantity of oocytes recovered to have routine numbers of embryos transferred.
For these reasons, it may not be sufficient simply to evaluate various treatment regimens by comparing peak E2 levels, the number of follicles that develop, the number of oocytes recovered, or the number of embryos available for transfer. Although pilot studies may legitimately compare ovarian responsiveness, any meaningful, definitive evaluation must also include an assessment of implantation and pregnancy rates.
Increased Gonadotropin Dosage The first and perhaps simplest approach to increasing the magnitude of the ovarian response is to increase circulating gonadotropin levels during stimulation. Higher circulating levels may reliable be achieved by increasing the quantity of gonadotropins being administered. Patients who responded poorly to low doses (150 IU FSH; 2 ampules per day) may commonly produce more follicles when given 300 IU or 450 IU per day.40 These enhanced responses lead to an increase in the number of oocytes obtained and the number of embryos transferred; and a significant number of pregnancies have been attained. Despite improvements in some patients, there are clear limits on the effectiveness of this strategy. At some point saturation kinetics are attained, and the ovarian response is determined more by the number of follicles available for recruitment than the circulating gonadotropin levels. This point is particularly important because low responders generally have markedly diminished numbers of follicles available for recruitment. It has been demonstrated that doses above 450 IU per day rarely produce a meaningful improvement in ovarian response or the ensuing pregnancy rates. Land et al. found no improvement in pregnancy rates with doses above 225 IU per day.40 Although the dose necessary to optimize ovarian responsiveness varies from patient to patient and should certainly be optimized, it is likely that clinically meaningful improvements are only rarely obtained with doses over 450 IU per day (6 ampules). It remains to be seen whether the introduction of recombinant FSH can alter the pregnancy rate for women with diminished ovarian reserve.
GnRH Agonist Down-Regulation The introduction of stimulation protocols containing GnRH agonists during the late 1980s provided new opportunities to stimulate patients who previously had limited responses to gonadotropins.41 Initial reports indicated that some low responders were stimulated better following luteal phase adminis-
3051_Seifer_03_p24-38 11/5/01 9:35 AM Page 33
3. Detection and Therapeutic Approaches to Age-Related Infertility
tration of a GnRH agonist.41 Subsequent clinical experience has provided disappointing results. In fact, many patients who are low responders may be completely refractory to stimulation after being down-regulated with a GnRH agonist.42 Whereas concurrent use of a GnRH agonist approaches being the standard for follicular stimulation in most ART programs, the enhancement of peak E2 levels, oocytes obtained, and pregnancy rates generally reflect the near-elimination of premature LH surges and the longer and more aggressive stimulation protocols that are possible. The fact that these are usually not the limiting factors in low responders may explain the generally unfavorable clinical results obtained with these protocols. There has been some question as to the direct impact of GnRH-a on ovarian responsiveness. GnRH receptors have been demonstrated in the ovary, although their role in follicular development is not understood. Feldberg et al. demonstrated increased ovarian responsiveness in low responders with elevated day 3 serum FSH levels who were maintained on lower doses of GnRH-a following pituitary suppression (minidose GnRHa).43 Although these preliminary data are provocative, prospective randomized dose response studies are clearly needed to address the issue of GnRH-a dose and ovarian performance adequately. Experience in our center continues to demonstrate that a number of patients are refractory to stimulation following down-regulation with GnRH-a at any dose (R.T. Scott et al., unpublished data). It is obvious that low responders represent a heterogeneous population of patients, and responses to various protocols are likely to vary widely.
GnRH Agonist Flare Because one goal in optimizing stimulation in women with diminished ovarian reserve was to increase the quantity of circulating gonadotropins, several investigators administered GnRH agonists to their patients beginning during the early follicular phase.44–46 The endogenous gonadotropin flare that occurred in response to the GnRH agonist was used to augment the exogenous gonadotropins. The duration of this endogenous gonadotropin flare has not been completely characterized, but pituitary desensitization is generally achieved within 5 days of initiating therapy. Therefore the patients are still protected from premature LH surges. Although many patients demonstrated an enhanced ovarian responsiveness using flare-up protocols, these protocols had some drawbacks. Some patients produced degenerate or low quality oocytes. Others
33
rescued the corpus luteum from their prior cycle and produced large levels of progesterone during the early follicular phase. The impact of these elevations on folliculogenesis, endometrial development, and subsequent implantation rates has not been adequately studied. Finally, the overall impact on pregnancy rates has been mixed. Although flareup protocols are certainly not as successful for the average ART patient as the luteal phase suppression protocols, they do offer an opportunity to obtain controlled ovarian hyperstimulation in some patients who cannot be stimulated with other protocols.42
Microdose GnRHa Flare-up There have been no reported dose-response studies of the pharmacodynamics of GnRH agonists during flare-up ovulation induction cycles. The doses have generally been taken from treatment protocols for men with prostate cancer, where minimizing the duration and effect of the endogenous gonadotropin flare would be desirable. Navot et al. reported in 1991 that the rate of pituitary desensitization and ovarian down-regulation was significantly prolonged using 1% of the normal dose of histerelin.47 They subsequently extended their findings in the primate model by demonstrating that the pituitary could respond with supraphysiologic gonadotropin release in response to low doses of GnRH-a for prolonged intervals without inducing desensitization. These data demonstrated that the rate of pituitary desensitization to GnRH-a stimulation may be dose-dependent. These investigators did not evaluate the potential clinical impact of those findings to determine if they could be used to alter or enhance ovarian responsiveness during controlled ovarian hyperstimulation cycles. Scott et al. studied the impact of microdose GnRH agonist administration by giving patients who were low responders 20 g of leuprolide acetate (1/50 the normal dose) every 12 hours beginning on cycle day 2 and continuing until the administration of human chorionic gonadotropin (hCG).48 These patients also received exogenous gonadotropins beginning on cycle day 4. Most patients demonstrated a marked improvement in ovarian responsiveness, as indicated by higher peak E2 levels, an increase in the number of developing follicles, and recovery of more oocytes at the time of retrieval. Pituitary sensitivity was not serially tested, but it is likely that densensitization was attained by the completion of the stimulation because none of the patients had detectable premature LH surges. Of more importance is that sev-
3051_Seifer_03_p24-38 11/5/01 9:35 AM Page 34
34
F.I. Sharara, R.T. Scott, Jr., and D.B. Seifer
eral pregnancies were attained in this previously refractory group. We have extended this study. The protocol has been modified, and we now use leuprolide acetate 50 g bid with the onset of exogenous gonadotropins on day 3. These patients almost uniformly achieve higher peak E2 levels and require fewer ampules of gonadotropins. Additionally, in 85% a larger number of follicles are recruited. Pregnancy results have been mixed. Patients who are low responders but who have normal ovarian reserve screening have clinical pregnancy rates of 40%. In sharp contrast, patients with abnormal FSH levels generally have higher peak E2 levels and may produce additional follicles, but pregnancy rates are still poor (5%). Thus it appears that a microdose agonist flare-up protocol may increase the quantitative follicular response in many patients, but it may not significantly enhance the quality of the developing cohort of oocytes. Schoolcraft et al. reported their results using a modification of the microdose protocol.49 The authors evaluated 32 patients (mean age 36.8 years) who were cancelled in a prior IVF cycle secondary to a poor response. By using leuprolide acetate 40 g bid with the onset of exogenous gonadotropins 3 days after discontinuing oral contraceptive pills (taken for 21 days), adding 4 IU of growth hormone per day until hCG administration, and performing assisted hatching on all the transferred embryos, the authors showed a marked improvement in ovarian response with a higher E2 level on day 5, higher peak E2, more oocytes retrieved, an implantation rate of 25% (3.7 embryos/ET), and a pregnancy rate of 50%. The cancellation rate was 12.5%.49 The authors claimed that pretreatment with oral contraceptives was a significant factor in their successful outcomes by eliminating a corpus luteum rescue prior to the initiation of gonadotropins. The role of growth hormone (GH) supplementation is controversial (see below). These results are encouraging despite being based on a small number of patients. Larger series addressing the role of microdose GnRH are clearly needed.
Growth Hormone A detailed discussion of the GH–IGF–insulin-like growth factor-binding protein (IGFBP) axis is beyond the scope of this chapter, but, there are now extensive data demonstrating the critical importance of the IGF-IGFBP family (growth factors IGF-I and IGF-II and their binding proteins) to follicular development.50,51 In particular, IGF-I is GHdependent and is involved in potentiating the effect of FSH. This led several investigators to evaluate
the effect of GH administration as an adjunct during follicular stimulation. GH most likely acts directly on GH receptors in granulosa cells (GCs) rather than through augmentation of follicular IGFI,52 as IGF-I mRNA and receptors are not expressed in GCs of the dominant follicles (IGF-II mRNA and receptors are, however, expressed abundantly in the dominant follicle, the significance of which needs further investigation because IGF-II is not GH-dependent).53 Early trials were promising, with some reporting substantial improvements in follicular responsiveness and pregnancy rates. Other studies also suggested benefit.54,55 Unfortunately, follow-up studies have been less encouraging, and some controlled studies have been unable to demonstrate clinical benefit.56–59 Considering the large expense and the discouraging results in controlled trials, it must be concluded that there is no well established clinical role for GH in the treatment of low responders at the current time. Further studies directed at defining the dose of GH and determining if select populations can benefit from treatment (e.g., hypogonadotropic and polycystic ovary patients) are currently ongoing.
Increasing Number of Embryos at Time of Transfer A retrospective study found that a subset of women 40 years undergoing in vitro fertilization/ embryo transfer (IVF/ET) would respond to ovarian stimulation well enough to result in four or more embryos available for transfer. In such cases, pregnancy rates were similar to that observed in young patients (34.4% vs. 47.7% per embryo transfer), although delivery rates were higher among women 40 years old compared with women 40 years old (38% vs. 21%). The multiple gestation rate was lower in women 40 than in those 40 years old (7.5% vs. 32%), and all multiple births were twins in the older group. Spontaneous miscarriage rates often mitigated the pregnancy rates, as women 40 years enrolled in this study had a miscarriage rate of 44.8% compared to 22.0% in those 40 years old. Selective reduction is a possible option in the unlikely event that more than two embryos implant. However, prospective studies are needed to realize whether multiple-order embryo transfer is a credible option for women with diminished ovarian reserve.60
Increased Luteal Phase Progesterone Support Meldrum reported correction of impaired uterine receptivity in infertile women 40 years old under-
3051_Seifer_03_p24-38 11/5/01 9:35 AM Page 35
3. Detection and Therapeutic Approaches to Age-Related Infertility
going oocyte donation using increased progesterone replacement.61 Despite the same mean age of donors and recipients and same duration of infertility, women over age 40 receiving progesterone 100 mg per day had a marked increase in successful pregnancies similar to that observed in women under age 40 receiving 50 mg per day (54% of 35 women over age 40 receiving progesterone 100 mg per day had pregnancies compared with 21% of 24 women over age 40 receiving 50 mg progesterone and 46% of 28 women under age 40 receiving 50 mg progesterone. The use of luteal phase progesterone support as an effective adjunct in improving outcomes in women with diminished ovarian reserve awaits further well designed studies.
Assisted Hatching Some of the treatments designed to enhance pregnancy rates in low responders have not been directed toward improving ovarian responsiveness. Cohen et al. reported in 1992 that the use of selective assisted hatching in women with borderline FSH levels improved their implantation and ongoing pregnancy rates.62 This work was extended by Schoolcraft et al., who specifically studied patients previously identified as low responders.63 They found substantially higher pregnancy rates among the women whose embryos were hatched. Hu and coworkers applied nonselective assisted hatching in 258 consecutive patients.64 In women older than 38 years the authors achieved a live birth rate of 24% (10/42) for couples with no male factor and 14% (1/7) for couples with male factor infertility. These numbers are small, but most ART programs performing assisted hatching use this technique in older women. These data indicate that the embryos from women who are low responders may have impaired ability to produce a hatching enzyme (the putative factor responsible for dissolving an opening in the zona pellucida at the time of natural hatching), or their zona pellucida may be hardened or thickened. In either event, the data available at this time indicate that some benefit may be obtained through application of this technique.
Future Treatment It is now clear that women with diminished ovarian reserve have quantitative factors (e.g., low number of oocytes, peak E2 levels) and qualitative factors (e.g., reduced implantation rate per embryo transferred) that limit their reproductive performance. Although efforts to increase the number of
35
follicles available for recruitment and development during any given treatment cycle will undoubtedly continue, it is also logical to assume that future treatments will be directed toward correcting the intrinsic intracellular processes that limit the reproductive potential of the individual oocytes that do develop. Although no treatment directed at the qualitative deficiencies are currently available, there are a number of interesting (but untested) possibilities. The first deals with the high incidence of aneuploidy in the oocytes of women who have diminished ovarian reserve. Because aneuploidy is generally the result of an abnormal first meiotic division, the oocyte is already abnormal by the time of retrieval. Future treatments may require that we replace the chromosomal complement of the oocyte with an appropriate haploid complement (possibly some form of pronuclear transposition). In vitro maturation of immature oocytes with supplementation of deficient factors may seem rational if we consider that the granulosa cells that accompany older oocytes are compromised in their production of growth factors, steroids, and glycoproteins; and they lack proper “nutritional” support for their sibling germ cells. Many such factors (e.g., mitochondria or certain messenger RNAs that have been related to changes in reproductive competence65,66) could be replaced initially by cytoplasmic donation and later by replacement of any specific factors (i.e., glycoproteins or growth factors) that have been identified and characterized. Abnormal meiotic spindles have also been noted in older women, leading to altered temporal and spatial changes in chromosomal movement and alteration of specific regulatory elements during the early phases of meiosis.67 Although these areas are being actively investigated at the current time, their potential for improving the efficiency of reproduction in women with diminished ovarian reserve remains clinically untested.
Acknowledgment This chapter has been adapted and modified from an article by Sharara, FI, Scott, RT, Seifer DB: The detection of diminished ovarian reserves in infertile women. Am J Obstet Gynecol 1998;179:804– 812.
References 1. Smith KE, Buyalos RP. The profound impact of patient age on pregnancy outcome after early detection of fetal cardiac activity. Fertil Steril 1996;65:35– 40.
3051_Seifer_03_p24-38 11/5/01 9:35 AM Page 36
36
F.I. Sharara, R.T. Scott, Jr., and D.B. Seifer
2. Scott RT, Hofmann GE. Prognostic assessment of ovarian reserve. Fertil Steril 1995;63:1–11. 3. Cameron IT, O’Shea FC, Rolland JM, et al. Occult ovarian failure: a syndrome of infertility, regular menses, and elevated follicle-stimulating hormone concentrations. J Clin Endocrinol Metab 1988;67: 1190–1194. 4. Pearlstone AC, Fournet N, Gambone JC, Pang SC, Buyalos RP. Ovulation induction in women age 40 and older: the importance of basal follicle-stimulating hormone level and chronological age. Fertil Steril 1992;58:674–679. 5. Scott RT, Toner JF, Muasher SJ, et al. Follicle stimulating hormone levels on cycle day 3 are predictive of in vitro fertilization outcome. Fertil Steril 1989; 51:651–654. 6. Toner JP, Philput CB, Jones GS, Muasher SJ. Basal follicle stimulating hormone level is a better predictor of in vitro fertilization performance than age. Fertil Steril 1991;55:784–791. 7. Lenton EA, Sexton L, Lee S, Cooke ID. Progressive changes in LH and FSH and LH:FSH ratio in women throughout reproductive life. Maturitas 1988;10:35– 43. 8. Reyes FI, Winter JSD, Faiman C. Pituitary-ovarian relationships preceding the menopause. I. A crosssectional study of serum follicle-stimulating hormone, luteinizing hormone, prolactin, estradiol, and progesterone levels. Am J Obstet Gynecol 1977;129: 557–564. 9. Sherman BM, West JH, Korenman SG. The menopausal transition: analysis of LH, FSH, estradiol, and progesterone concentrations during menstrual cycles of older women. J Clin Endocrinol Metab 1976;42: 629–636. 10. Sherman BM, Korenman SG. Hormonal characteristics of the human menstrual cycle throughout reproductive life. J Clin Invest 1975;55:699–706. 11. Batista MC, Cartledge TP, Zellmer AW, et al. Effects of aging on menstrual cycle hormones and endometrial maturation. Fertil Steril 1995;64:492–499. 12. Klein NA, Battaglia DE, Fujimoto VY, et al. Reproductive aging: accelerated ovarian follicular development associated with a monotropic follicle-stimulating hormone rise in normal older women. J Clin Endocrinol Metab 1996;81:1038–1045. 13. Klein NA, Illingworth PJ, Groome NP, et al. Decreased inhibin-B secretion is associated with the menotropic FSH rise in older, ovulatory women: a study of serum and follicular fluid levels of dimeric inhibin-A and B in spontaneous menstrual cycles. J Clin Endocrinol Metab 1996;81:2742–2745. 14. Seifer DB, Gardiner AC, Ferreira KA, Peluso JJ. Apoptosis as a function of ovarian reserve in women undergoing in vitro fertilization. Fertil Steril 1996; 66:593–598. 15. Muasher SJ, Oehninger S, Simonetti S, et al. The value of basal and/or stimulated serum gonadotropin levels in prediction of stimulation response and in vitro fertilization outcome. Fertil Steril 1988;50: 298–307.
16. Hughes EG, Robertson DM, Handlesman DJ, et al. Inhibin and estradiol responses to ovarian hyperstimulation: effects of age and predictive value for in vitro fertilization outcome. J Clin Endocrinol Metab 1990;70:358–364. 17. McClachlan RI, Healy DL, Robertson DM, de Kretser DM, Burger HG. Plasma inhibin levels during gonadotropin induced ovarian hyperstimulation for IVF: a new index of follicular function? Lancet 1986;1:1233–1234. 18. Seifer DB, Gardiner AC, Lambert-Messerlian G, Schneyer AL. Differential secretion of dimeric inhibin in cultured luteinized granulosa cells as a function of ovarian reserve. J Clin Endocrinol Metab 1996;81:736–739. 19. Seifer DB, Lambert-Messerlian G, Hogan JW, et al. Day 3 serum inhibin-B is predictive of assisted reproductive technologies outcome. Fertil Steril 1997;67: 110–114. 20. Scott RT, Hofmann GE, Oehninger S, Muasher SJ. Intercycle variability of day 3 follicle-stimulating hormone levels and its effect on stimulation quality in in vitro fertilization. Fertil Steril 1990;53:297–302. 21. Martin JSB, Nisker JA, Tummon IS, et al. Future in vitro fertilization pregnancy potential of women with variably elevated day 3 follicle-stimulating hormone levels. Fertil Steril 1996;65:1238–1240. 22. Hansen LM, Batzer FR, Gutmann JN, et al. Evaluating ovarian reserve: follicle stimulating hormone and oestradiol variability during cycle days 2–5. Hum Reprod 1996;3:486–489. 23. Khalifa E, Toner JP, Muasher SJ, Acosta AA. Significance of basal follicle-stimulating hormone levels in women with one ovary in a program of in vitro fertilization. Fertil Steril 1992;57:835–839. 24. Licciardi FL, Liu HC, Rosenwaks Z. Day 3 estradiol serum concentrations as prognosticators of ovarian stimulation response and pregnancy outcome in patients undergoing in vitro fertilization. Fertil Steril 1995;64:991–994. 25. Smotrich DB, Widra EA, Gindoff PR, et al. Prognostic value of day 3 estradiol on in vitro fertilization outcome. Fertil Steril 1995;64:1136–1140. 26. Mukherjee T, Copperman AB, Lapinski R, et al. An elevated day three follicle-stimulating hormone: luteinizing hormone ratio (FSH:LH) in the presence of a normal day 3 FSH predicts a poor response to controlled ovarian hyperstimulation. Fertil Steril 1996;65:588–593. 27. Navot D, Rosenwaks Z, Margalioth EJ. Prognostic assessment of female fecundity. Lancet 1987;2: 645–647. 28. Loumaye E. Billion JM, Mine JM, et al. Prediction of individual response to controlled ovarian hyperstimulation by means of a clomiphene citrate challenge test. Fertil Steril 1990;53:295–301. 29. Tanbo T, Dale PO, Ludne O, Norman N, Abyholm T. Prediction of response to controlled ovarian hyperstimulation: a comparison of basal and clomiphene citrate-stimulated follicle stimulating hormone levels. Fertil Steril 1990;53:295–301.
3051_Seifer_03_p24-38 11/5/01 9:35 AM Page 37
3. Detection and Therapeutic Approaches to Age-Related Infertility 30. Scott RT, Leonardi MR, Hofmann GE, et al. A prospective evaluation of clomiphene citrate challenge test screening in the general infertility population. Obstet Gynecol 1993;82:539–545. 31. Scott RT, Opsahl MS, Leonardi MR, et al. Life table analysis of pregnancy rates in a general infertility population relative to ovarian reserve and patient age. Hum Reprod 1995;10:1706–1710. 32. Adeno M, Gallagher H. Cigarette smoking and the age of menopause. Ann Hum Biol 1982;9:121–130. 33. Jick H, Porter J, Morrison AS. Relationship between smoking and age of natural menopause. Lancet 1997;1:1354–1354. 34. Sharara FI, Beatse SN, Leonardi MR, Navot D, Scott RT. Cigarette smoking accelerates the development of diminished ovarian reserve as evidenced by the clomiphene citrate challenge test (CCCT). Fertil Steril 1994;62:257–262. 35. Hughes EG, Yeo J, Claman P, et al. Cigarette smoking and the outcomes of in vitro fertilization: measurement of effect size and levels of action. Fertil Steril 1994;62:807–814. 36. Sterazik K, Strehler E, De Santo M, et al. Influence of smoking on fertility in women attending an in vitro fertilization program. Fertil Steril 1996;65:810–814. 37. Hershlag A, Lesser M, Montefusco D, et al. Interinstitutional variability of follicle-stimulating hormone and estradiol levels. Fertil Steril 1992;58:1123–1126. 38. Seifer DB, Canick JA, Seltman HJ, Frishman GN, Berk CA. Abstract P368. In: 39th Annual Meeting of the Society for Gynecologic Investigation, San Antonio, TX, 1993. 39. Syrop CH, Dawson JD, Husman KJ, Sparks AE, Van Voorhis BJ. Ovarian volume may predict assisted reproductive outcomes better than follicle hormone concentration on day 3. Hum Reprod 1999;14:1752. 40. Land JA, Yarmolinskaya MI, Dumoulin JCM, Evers JLH. High-dose human menopausal gonadotropin stimulation in poor responders does not improve in vitro fertilization outcome. Fertil Steril 1996;65:961– 965. 41. Droesch K, Muasher ST, Brzyski R, et al. Value of suppression with a GnRH-a prior to gonadotropin stimulation for in vitro fertilization. Fertil Steril 1989;51:292–295. 42. Muasher SJ. Treatment of low responders. J Assist Reprod Genet 1993;10:112–114. 43. Feldberg D, Farhi J, Ashkenazi J, et al. Minidose gonadotropin-releasing hormone agonist is the treatment of choice in poor responders with high folliclestimulation hormone levels. Fertil Steril 1994;62: 343–346. 44. Garcia JE, Padilla SL, Bayati J, Baramki TA. Follicular phase gonadotropin-releasing hormone agonist and human gonadotropins: a better alternative for ovulation induction in in vitro fertilization. Fertil Steril 1990;53:302–305. 45. Padilla SL, Bayati J, Garcia JE. Prognostic value of the early serum estradiol response to leuprolide acetate in in vitro fertilization. Fertil Steril 1990; 53:288–294.
37
46. Padilla SL, Dugan K, Maruschak V, Shalika S, Smith RD. Use of the flare-up protocol with high dose human follicle stimulating hormone and human menopausal gonadotropins for in vitro fertilization in poor responders. Fertil Steril 1996;65:796–799. 47. Navot D, Rosenwaks Z, Anderson F, Hodgen GD. Gonadotropin releasing hormone agonist-induced ovarian hyperstimulation: low dose side effects in women and monkeys. Fertil Steril 1991;55:1069– 1075. 48. Scott RT, Navot D. Enhancement of ovarian responsiveness with micro-doses of GnRH-agonist during ovulation induction for in vitro fertilization. Fertil Steril 1994;61:880–885. 49. Schoolcraft W, Schlenker T, Gee M, Stevens J, Wagley L. Improved controlled ovarian hyperstimulation in poor responder in vitro fertilization patients with microdose follicle-stimulating hormone flare, growth hormone protocol. Fertil Steril 1997;67:93– 97. 50. Adashi EY, Resnick CE, Hernandez ER, et al. Insulin like growth factor I as an intra-ovarian regulator: basic and clinical implications. Ann NY Acad Sci 1991;626:161–167. 51. Giudice LC. Insulin-like growth factors and ovarian follicular development. Endocr Rev 1992;13:641– 669. 52. Sharara FI, Nieman LK. Identification and cellular localization of growth hormone receptor gene expression in the human ovary. J Clin Endocrinol Metab 1994;79:670–672. 53. El-Roiey A, Chen X, Roberts VJ, et al. Expression of insulin-like growth factor-I (IGF-I) and IGF-II and the IGF-I, IGF-II, and insulin receptor genes and localization of the gene products in the human ovary. J Clin Endocrinol Metab 1993;77:1411–1418. 54. Menashe Y, Lunenfeld B, Pariente C, Frenkel Y, Mashiach S. Can GH increase after clonidine administration predict the dose of human menopausal hormone needed for induction of ovulation. Fertil Steril 1990;53:432–435. 55. Shoham Z, European and Australian Multicenter study. Cotreatment with growth hormone and gonadotropin for ovulation induction in hypogonadotropic patients: a prospective, randomized, placebo-controlled, dose-response study. Fertil Steril 1995;64: 917–923. 56. Bergh C, Hillensjo T, Wikland M, et al. Adjuvant growth hormone treatment during in vitro fertilization: a randomized, placebo-controlled study. Fertil Steril 1994;62:113–120. 57. Owen EJ, West C, Mason BA, Jacobs HS. Co-treatment with growth hormone of suboptimal responders in IVF-ET. Hum Reprod 1991;6:529–533. 58. Younis JS, Simon A, Koren R, et al. The effect of growth hormone supplementation on in vitro fertilization outcome: a prospective randomized, placebo controlled double blind study. Fertil Steril 1992; 58:575–580. 59. Suikkara AM, MacLachlan V, Koistinen R, Seppala M, Healy DL. Double-blind placebo controlled
3051_Seifer_03_p24-38 11/5/01 9:35 AM Page 38
38
F.I. Sharara, R.T. Scott, Jr., and D.B. Seifer
study: human biosynthetic growth hormone for assisted reproductive technology. Fertil Steril 1996; 65:800–805. 60. Wildra EA, Gindoff PR, Smotrich DB, Stillman RJ. Achieving multiple-order embryo transfer identifies women over 40 years of age with impaired in vitro fertilization outcome. Fertil Steril 1996;65:103–108. 61. Meldrum DR. Female reproduction aging-ovarian and uterine factors. Fertil Steril 1993;59:1–5. 62. Cohen J, Alikani M, Trowbridge J, Rosenwaks Z. Implantation enhancement by selective assisted hatching using zona drilling of embryos with poor prognosis. Hum Reprod 1992;7:685–691. 63. Schoolcraft WB, Schlenker T, Gee M, Jones GS, Jones HW. Efficacy of assisted hatching in poor prognosis IVF candidates. Fertil Steril 1994;62:551–554. 64. Hu Y, Hoffman DI, Maxson WS, Ory SJ. Clinical application of non-selective assisted hatching of human embryos. Fertil Steril 1996;66:991–994. 65. Flood JT, Chillik CF, van Uem JFHM, Iritani A, Hodgen GD. Ooplasmic transfusion: prophase germinal vesicle oocytes made developmentally competent by microinjection of metaphase II egg cytoplasm. Fertil Steril 1990;53:1049–1054. 66. Keefe DL, Niven-Fairchild T, Powell S, Buradagunta S. Mitochondrial deoxyribonucleic acid deletion in oocytes and reproductive aging in women. Fertil Steril 1995;64:577–583. 67. Battaglia DE, Goodwin P, Klein NA, Soules MR. Influence of maternal age on meiotic spindle assem-
bly in oocytes from naturally cycling women. Hum Reprod 1996;11:2217–2222.
Suggested Reading Chang M, Chiang C, Hsich T, et al. Use of the antral follicle count to predict the outcome of assisted reproductive technologies. Fertil Steril 1998;69:505. Hoffman G, Danforth D, Seifer D. Inhibin-B: the physiologic basis of the clomiphene citrate challenge test for ovarian reserve screening. Fertil Steril 1998;69:474. Reuss M, Kline J, Santos R, et al. Age and the ovarian follicle pool assessed with transvaginal ultrasonography. Am J Obstet Gynecol 1996;174:624. Santoro N, Tovaghogol A, Skurnick J. Decreased inhibin tone and increased activin A secretion characterize reproductive aging in women. Fertil Steril 1999;71:658. Seifer D, Scott R, Bergh P, et al. Women with declining ovarian reserve may demonstrate a decrease in day 3 serum inhibin-B prior to a rise in day 3 FSH. Fertil Steril 1999;72:63. Sharara F, McClamrock H. The effect of aging on ovarian volume measurements in infertile women. Obstet Gynecol 1999;94:57. Sharara F, Seifer DB. New Methods for Assessing Ovarian Reserve. OBG Management Volume 12, issue 10, pages 61–69, 2000. Welt C, McNicholl D, Taylor A, Hall J. Female reproductive aging is marked by decreased secretion of dimeric inhibin. J Clin Endocrinol Metab 1999;84:105.
3051_Seifer_04_p39-48 11/5/01 9:36 AM Page 39
4 Role of Ultrasonography in Infertility Theresa Widrich
Ultrasonography was first used in obstetrics and gynecology in 1958 by Donald, and it has undergone several developments since then. Both transabdominal and transvaginal ultrasonography (TVUS) are used in gynecology. The transabdominal approach gives a more panoramic view of the pelvis, but TVUS offers several advantages in gynecology. With TVUS the shorter distance of the ultrasound probe to the pelvic organs makes it possible to achieve a detailed delineation of the uterus with the cervix, uterine wall, and endometrium, ovaries, and fallopian tubes, even in obese patients. It does not require a full bladder, and so is more comfortable for the patient. Because of the proximity to the pelvic organs, high frequency transducers (5.0 or 7.5 MHz) may be used resulting in higher resolution and clearer images than transabdominal US. The combination of the pelvic examination and TVUS provides excellent information to the gynecologist. As a tool, TVUS has become indispensable for diagnosis and for selected treatments of infertility, such as evaluating the female pelvis, monitoring ovulation, and transvaginal oocyte pickup for in vitro fertilization.
Equipment Most ultrasound machines have B-mode (gray scale) imaging, M-mode (motion) and Doppler US (flow measurement at a single point of a vessel). Some machines also offer color Doppler making it possible to study the blood flow in a specific area. Various ultrasound probes are available. For TVUS there are mechanical probes with one oscillating element and electronic probes with phased
array or curvilinear transducers. Frequencies for TVUS are usually between 5.0 and 7.5 MHz and the angle of view may be between 60° and 360° (average 90°–150°) for endovaginal US. Smaller sectors make it possible to visualize details, such as small vessels and the heartbeat during early pregnancy. Wider angles allow an overview of the entire pelvis.
Technique of TVUS The patient must be informed about the procedure. Ideally she is positioned in the dorsal lithotomy position in stirrups. A bimanual examination precedes the US examination. The TVUS transducer is wiped with a disinfectant and is covered with a condom filled with gel. Coupling gel is placed on the tip of the transducer to ensure uninterrupted passage of the ultrasound waves from the probe into the pelvis. When scanning infertility patients at mid-cycle, one should be aware that some ultrasound gels and latex condoms have a spermicidal effect. In these cases polyethylene bags and paraffin oil can be used as an alternative. The transducer is inserted into the vaginal canal and images of the pelvic organs in the longitudinal and transverse plane are obtained. To get a 360° overview of the pelvis the US probe is rotated. Then the movement of the pelvic organs towards each other is tested. The examiner slightly moves the ultrasound probe and places his/her other hand on the abdominal wall and gently pushes towards the probe (like a bimanual exam using the ultrasound probe instead of one hand). If the pelvic organs do not slide this is an indirect sign of adhesions.
39
3051_Seifer_04_p39-48 11/5/01 9:36 AM Page 40
40
T. Widrich
Diagnosis of Infertility by TVUS
Endometrium
The first structures to be scanned are the uterus and cervix. It is useful to have performed a bimanual examination prior to this point to determine the position of the uterus (e.g. anteverted or retroverted). Its characteristic landmark is the endometrial stripe, surrounded by the homogeneous muscular layer of myometrium. Position and size of the uterus are noted (Fig. 4–1). Myomas are the most common pathology of the uterus and cervix. Smaller ones can be seen as round structures with high echogenicity on US. Larger ones distort the shape of the uterus or the endometrial stripe. Sometimes calcifications are seen within a myoma. When a leiomyoma is larger than 5 cm, the view obtained with TVUS may be obscured and in such cases it is more effective to carry out abdominal US. The position of the fibroid is important. Submucous myomas extend into the uterine cavity and may distort it, thereby inhibiting implantation of pregnancy. Müllerian abnormalities are estimated to occur in 2–3% of women. On TVUS a uterine septum can be seen as two endometrial stripes separated by a myometrial layer. The septum can result in inhibition of implantation and may be removed hysteroscopically. A bicornuate uterus is best discovered in transverse view; in the longitudinal view the intermediate myometrial layer is not continuous.
Circulating estrogen and progesterone influence the endometrial thickness and texture. US can clearly depict cyclic changes of texture and may indicate whether the appearance of the endometrium is related to the day of the menstrual cycle or to a suspected functional problem. During and shortly after menses the endometrium appears as a thin echogenic line. During the proliferative phase it thickens and becomes isoechoic. Toward ovulation the endometrium becomes more echogenic and develops a multilayered pattern. There is a thin hyperechoic line in the middle, surrounded by an inner hypoechoic layer and an outer echogenic layer that is secondary to stromal edema. This pattern seems necessary for normal pregnancy to develop (Fig. 4–2). Several studies have attempted to correlate endometrial thickness at the time of ovulation with pregnancy rates. It is now generally acknowledged that in the natural cycle, a thickness of 5 mm or less results in poor pregnancy rates, whereas 10 mm or more provides a good possibility of conception (Fig. 4–3). During the secretory phase the endometrium continues to thicken, reaching up to 14 mm, and becomes homogenic and hyperechoic on US. Beginning menstruation toward the end of the cycle may be seen as minimal hypoechoic spots in the endometrium. Polyps and other endometrial abnormalities may pose a problem. Endometrial polyps vary in size from less than a millimeter to several centimeters in diameter. Large polyps may interfere with implantation of the embryo and cause infertility. On
FIGURE 4–1. Saline infusion sonohysterography. Submucous myoma protrudes into the uterine cavity. Hysteroscopic removal is not possible in this case because the intramural part of the myoma is more than 50%.
FIGURE 4–2. Three layer pattern of the endometrium as seen around ovulation. (Courtesy of the Department of Gynecologic Endocrinology, University Hospital of Vienna, Austria.)
Conventional TVUS Uterus and Cervix
3051_Seifer_04_p39-48 11/5/01 9:36 AM Page 41
4. Role of Ultrasonography in Infertility
FIGURE 4–3. Secretory endometrium prepared for conception. This patient had a positive pregnancy test one day after this scan was performed. (Courtesy of W. Feichtinger, Institute for Sterility Treatment, Vienna, Austria.)
US, endometrial polyps typically appear as an unusually high degree of thickening of the endometrium and are best diagnosed early in the menstrual cycle when the proliferative endometrium is still thin.
Ovaries As many as 10–30% of women investigated for infertility do not ovulate regularly. TVUS can be used to monitor ovulation. Follicles can be observed on TVUS when they reach a diameter of 2–3 mm. During the natural cycle, a dominant follicle typically appears during days 8–12. Its growth is linear, about 2 mm per day, and it reaches a size of 18–24 mm before ovulation (mean 21.5 mm). It is rare for other follicles to be present during the natural cycle, but in such cases they usually do not exceed 14 mm in diameter, nor do they ovulate. The size of the dominant follicle correlates with the serum estrogen level, and its size is more predictive of ovulation than serum estrogen levels, although a combination of the two gives the best accuracy. E2 levels at ovulation are between 150 and 400 pg/ml. Ultrasonography can be useful to detect ovulation itself; or in cases of tubal damage on one side, it can help determine on which side ovulation will occur if intrauterine insemination is planned. Moreover, the shape of a follicle helps determine whether it will ovulate. Fukuda et al. showed that a healthy (type A) follicle contains a cloud in the shape of a cone. The base is positioned at the follicle wall; the tip points into the center of the follicle and has a light spot assumed to be the oocyte-cumulus complex (Fig. 4–4). This can be
41
seen when the follicle is in excess of 15 mm. Type B follicles show an echo free space and become atretic. Ovulation occurs 36–38 hours after the peak serum luteinizing hormone (LH) surge and is seen as a rapid reduction of follicle size. In most cases fluid is detected in the cul-de-sac. This may also be present before ovulation because of transudation. A corpus luteum is present from 45 minutes after ovulation, and on US appears as a round cystic structure with an irregular pattern due to blood clots. It changes rapidly over time. Polycystic ovary disease (PCO) is a type of menstrual dysfunction with anovulation, elevated androgens, and inappropriate gonadotropin secretion. Several causes lead to anovulation, and persistent anovulation leads to polycystic ovaries. Clinically, Balen et al. showed that obesity is associated with hirsutism and an elevated serum testosterone concentration; it is also correlated with increased rates of infertility and cycle disturbance. The rates of infertility and cycle disturbance also increase with serum LH concentrations 10 IU/L. A rising serum concentration of testosterone is associated with an increased risk of hirsutism, infertility and cycle disturbance. Sonographically, polycystic ovaries appear to be enlarged with a volume usually greater than 12 cm3. Several small follicles less than 10 mm are lined up under a thickened capsule. PCO indicates an increased risk of ovarian hyperstimulation syndrome, and in such cases US can play an important role in assessing the treatment plan. Endometriosis is a very common cause of infertility. Its prevalence is as high as 10% in the repro-
FIGURE 4–4. A healthy follicle in natural cycle shortly before ovulation. (Courtesy of the Department of Gynecologic Endocrinology, University Hospital of Vienna, Austria.)
3051_Seifer_04_p39-48 11/5/01 9:36 AM Page 42
42
T. Widrich
ductive age group and in 25–35% of infertile women. Common symptoms are secondary dysmenorrhea, secondary dyspareunia, diffuse or localized pelvic pain and low back pain, although women with endometriosis can be asymptomatic. On physical examination a retroverted, fixed uterus is suggestive of endometriosis. Nodularity in the cul-de-sac region or the sacrouterine ligaments is found in one-third of patients with endometriosis. Small foci of endometriosis can only be detected by laparoscopy but larger endometriomas are easily seen on TVUS. The classic sonographic appearance is the so called chocolate cyst, which appears homogenic and has the echogenicity of a fetal liver or lung. Some cysts are also partially solid and partially cystic. It can be difficult to differentiate between a corpus luteum cyst and an endometrioma. Often they can be distinguished only after several weeks: a corpus luteum cyst changes and eventually disappears.
Fallopian Tubes A healthy fallopian tube cannot be depicted sonographically unless there is some fluid around it, which, in a healthy woman may be present around ovulation or be due to ascites or inflammation. US may be helpful for detecting pelvic inflammatory disease (PID) or the chronic changes after PID, leading to the possible cause of infertility. Acute inflammation of the tube leads to thickening of the wall and free fluid in the pelvis. The tube is tender to the probe touch. Polycystic ovaries may be an indirect sign of acute PID. Chronic inflammation is seen as an accumulation of fluid in the tube and presents itself as an irregular, elongated mass filled with fluid or pus. It may initially appear circular like a stimulated follicle in one plane, but if the probe is turned through 90° the elongated structure becomes visible. The wall is thin and stretched. A tuboovarian abscess can be seen on TVUS as a conglomerate consisting of a complex cyst in the ovary surrounded by a dilated, fluid filled tube that is often tender on examination. Adhesions can seldom be depicted by ultrasound unless there is free fluid in the pelvis. They are suspected when there is no sliding of the uterus and ovaries, either to each other or in relation to the pelvic wall.
Fluid Enhanced TVUS Saline Infusion Sonohysterography One of the most exciting developments in vaginal sonography in recent years is the use of contrast agents. In 1993 Parsons and Lense developed the
technique of using saline as a negative contrast agent in the uterine cavity. Since then it has become widely used and mostly referred to as saline infusion sonohysterography (SIS). The technique is valuable for detecting any structural abnormalities, such as submucous myomas, endometrial polyps, and endometrial adhesions. The technique of SIS is as follows. After performing conventional TVUS the ultrasound probe is removed and an open-sided vaginal speculum is inserted. The cervix is cleansed with an antiseptic solution. Using a sterile uterine packing forceps, a small catheter is placed in the cervical os under direct visualization until the uterine fundus is reached. After removing the speculum a plastic syringe containing sterile saline is attached to the catheter. The ultrasound probe can then be reintroduced and saline is slowly infused into the uterus while observing for uterine distension. The uterine cavity can then be reevaluated. Submucous myomas can be defined as such after the instillation of saline and the relation of a fibroid to the uterine wall can be seen (Fig. 4–1). SIS also helps determine a suitable course of treatment because myomas with an intracavitary portion of more than 50% can be resected hysteroscopically. Submucous fibroids may also be diagnosed by hysteroscopy, but it is not possible to visualize the intramural part using this technique. Polyps when outlined by intracavitary fluid are seen as echogenic masses in the uterine cavity originating from the endometrium with a small or broad base. Adhesions or a septum are also easily seen when the uterine cavity is distended and they are outlined by the contrast agent. Several studies published over the last few years highlight some important advantages of using SIS. There are consistent findings that visualization of structural abnormalities is improved when saline is used, the procedure causes minimal discomfort and a low rate of complications. Two recent studies evaluated SIS for infertility patients: Soares et al. evaluated the diagnostic accuracy of SIS in uterine cavity diseases in 65 infertile patients, comparing its results with those of hysterosalpingography (HSG) and TVUS. Hysteroscopy was the gold standard and SIS had the same diagnostic accuracy for polypoid lesions and endometrial hyperplasia, with no equivocal diagnosis. For uterine malformations, SIS had a sensitivity of 77.8% and intrauterine adhesions a sensitivity of 75%. Gronlund et al. assessed the diagnostic value of SIS in an evaluation of metrorrhagia and infertility using hysteroscopy as the standard. The overall sensitivity and specificity for SIS was 90.9% and 100%, respectively. When examining the met-
3051_Seifer_04_p39-48 11/5/01 9:36 AM Page 43
4. Role of Ultrasonography in Infertility
43
rorrhagia and infertility groups separately the sensitivity and specificity and predictive values were 100% for all parameters in cases of infertility.
Hysterosalpingo-Contrast Sonography In 15% of cases the inability to conceive is due to tubal occlusion. The gold standard for evaluating the tubes is laparoscopy, but this has risks associated with general anesthesia. Another method is HSG, however this has the disadvantage of exposing the ovaries to radiation. A relatively new technique for assessing the status of fallopian tubes is hysterosalpingo-contrast sonography (HyCoSy). Deichert and Schlief first described this technique in 1989. Technique: An echogenic contrast medium (most authors use Echovist®) is administered through the cervix into the uterus using a balloon catheter, and its flow through the fallopian tubes observed in real time sonography. Each tube must be examined separately, and the flow of contrast media should be observed in three segments of the tube: isthmic, ampullary and fimbrial. The contrast agent will also become visible in the Cul-de-Sac region. Several studies have compared HyCoSy with HSG and Chromolaparoscopy. The results of HyCoSy are equal or slightly better than HSG; discomfort is comparable with about 10% of the patients reporting severe discomfort. Compared with laparoscopy the concordance was about 85%. Results become better when it is combined with Doppler flow studies in each tube (91% concordance). These results indicate that, if carried out by an experienced ultrasonographer, HyCoSy is a suitable first line procedure in patients with infertility disorders.
Monitoring Treatment of Infertility Ovulation Induction Normally more than one follicle appears during stimulated cycles. In this situation several follicles contribute to the level of serum estrogen. TVUS is used to assess the number and size of stimulated follicles (Fig. 4–5). Clomiphene citrate (CC) has a weak estrogenic effect and leads to increased secretion of follicle stimulating hormone (FSH) and LH through activation of the hypothalamic pituitary axis. Its main indication is absent or infrequent ovulation. Usually a CC dose of 50 mg PO is given on cycle days 5–9. In case of failure, the dosage may be increased up to 150 mg per day. Ultrasonography can be used to monitor the growth and number of follicles. When the dominant follicle reaches at least 20 mm in diameter, human chorionic gonadotropin (hCG)
FIGURE 4–5. Hyperstimulated ovary with several follicles at IVF oocyte harvesting. The tip of the suction needle can be seen in the collapsing follicle in the middle. (Courtesy of the Department of Gynecologic Endocrinology, University Hospital of Vienna, Austria.)
can be administered to trigger ovulation. Follicles larger than 14 mm may ovulate as well, whereas those less than 14 mm usually become atretic after administration of hCG. At 36 hours after hCG injection ovulation occurs, and intrauterine insemination (IUI) or intercourse should be scheduled 24–48 hours later. Arici et al. demonstrated that this timing can achieve higher pregnancy rates. The endometrial thickness after CC administration is usually less than in natural cycles (5–9 mm). Beneventi et al. observed that endometrial maturation is slower after application of CC for about 3 days. Controlled ovarian hyperstimulation with FSH can be used to achieve ovulation if CC treatment fails or if there is known malfunction of the hypothalamus or pituitary gland. Follicle stimulation is achieved by daily intramuscular injections through 7–14 days. Serum estrogen levels and frequent TVUS examinations are recommended to assess when hCG should be administered to induce ovulation. Usually a size of 18 mm for the dominant follicle is recommended. TVUS gives better information for the timing than estrogen levels because a larger number of small follicles may also produce a significant increase in serum estrogen levels. An estrogen level of 1000–1500 pg/ml is optimal; at a level over 2000 pg/ml, hCG should not be given because of the risk of ovarian hyperstimulation syndrome. Early signs of ovarian hyperstimulation on US are enlarged ovaries and free fluid in the pelvis.
In Vitro Fertilization More than 20 years have passed since the first child was conceived through IVF. Today indications not only include tubal disease and resistant anovulation
3051_Seifer_04_p39-48 11/5/01 9:36 AM Page 44
44
T. Widrich
but also male factor infertility, unexplained infertility, endometriosis, immunologic causes of infertility, cervical factor and some cases of premature ovarian failure. More follicles are stimulated with IVF than during controlled ovarian hyperstimulation. Several different protocols exist using FSH to induce follicular growth and GnRH Analogs to prevent premature LH surges. TVUS alone or in conjunction with serum estrogen level measurements is used to monitor the ovarian response and a linear growth of follicles of 2 mm per day can be expected. When at least two or three follicles reach 16–18 mm diameter, 5000 or 10,000 IU of hCG is administered to induce follicular maturation. Oocytes are harvested 34 to 36 hours later by fine needle aspiration.
Technique of Follicle Measurements It is usually easy to locate stimulated ovaries by directing the US probe lateral to the uterus. Follicles have an elliptic shape and should be measured in 3 dimensions and the mean diameter calculated. In the natural cycle and after stimulation with FSH, a follicle is considered mature from a diameter of 16–18 mm. After stimulation with CC a minimum of 20 mm is required. Measuring all 3 dimensions is also necessary to rule out that other structures are confused with follicles. A large vessel or a hydrosalpinx may appear round on one plane but will be identified when rotating the probe by 90°.
Endometrium in Stimulated Cycles In contrast to the natural cycle there is now general agreement that endometrial thickness cannot be used as a predictive factor for pregnancy rates in stimulated cycles. De Gruyter et al. found that pregnancy rates of assisted reproductive procedures are influenced only marginally by the degree of endometrial proliferation and treatment should not be cancelled because of inadequate endometrial thickness. Endometrial echogenicity is a more reliable parameter in stimulated cycles. Fanchin et al. found in a prospective study that when the endometrial echogenicity is measured objectively by a computer assisted system on the day of hCG administration, pregnancy and implantation rates fell progressively and significantly from the low echogenicity to the high echogenicity group in IVF cycles.
FIGURE 4–6. An early gestational sac has developed in the uterus. (Courtesy of W. Feichtinger, Institute for Sterility Treatment, Vienna, Austria.)
TVUS at the time of the missed menstrual period and grows rapidly reaching approximately 10 mm 40 days after the last menstrual period (Fig. 4–6). The presence of a yolk sac confirms the development of embryonic structures. Fetal cardiac activity may be observed on TVUS after the fifth week following the last menstruation. It usually confirms a normal intrauterine pregnancy. First trimester abortion is less than 2% after documentation of a heartbeat, although one study found that from a maternal age of 35 years or older there is a fivefold risk of early pregnancy loss even after a fetal heartbeat is documented. If correlated to serum hCG levels using the first international standard preparation, a gestational sac is visible on TVUS in all normal pregnancies above 1000 mIU/ml hCG, a yolk sac above 7200 mIU/ml and a visible embryo with a heartbeat with an hCG level greater than 10800 mIU/ml. With ectopic pregnancies, a pseudogestational sac may appear in the endometrium but does not develop embryonic echoes or a yolk sac. Also -hCG levels do not double every 2–3 days as they should with a normal pregnancy. If the fallopian tubes are carefully scanned, sometimes the ectopic pregnancy can be visualized, and even a heartbeat seen on US.
Treatment of Infertility Using TVUS
Early Pregnancy
Ultrasound-Assisted Puncture of Follicles During IVF
Serum measurements of hCG and US imaging are used to track the development of early pregnancy. A gestational sac of 2 mm becomes visible on
In the early years of IVF, oocytes were retrieved laparoscopically, exposing women to risks of general anesthesia and surgery. In 1982 Lenz and Lau-
3051_Seifer_04_p39-48 11/5/01 9:36 AM Page 45
4. Role of Ultrasonography in Infertility
ritzen were the first to report ultrasonographically guided transabdominal puncture for oocyte harvesting. The technique was then modified by Feichtinger and Kemeter to a transvesical and later a transvaginal approach. Needle guided vaginal puncturing for oocyte retrieval has now become the method of choice. Its advantages are the short distance to the ovaries with less probability of bowel injury or bleeding, better visualization of follicles, no adhesions to inhibit visualization of the follicles, no need for general anesthesia, an ambulatory setting for the procedure, and relatively few complications. Technique The entire procedure can be carried out in an outpatient setting. General anesthesia is not required; a sedative can be given if the patient is anxious but is not required in 50% of the cases. The patient is placed in the dorsal lithotomy position, and sterile drapes cover the legs and perineal area. The US probe is covered with a sterile condom or polyethylene bag, and a needle guide is attached to it. The vagina is cleansed with saline solution or IVF culture medium. Disinfecting solutions may be potentially harmful for the fertilization rate, and US gel on the outside of the transducer should also be avoided. The US probe is placed in the vagina and a biopsy line is generated on the US screen targeting the first stimulated follicle. A long 16 or 18 gauge needle is rapidly advanced through the vaginal wall into the follicle. The tip of the needle can be seen on the screen. The follicular fluid is aspirated under visualization and pulled into a collection chamber. The follicle collapses. Without withdrawing it, the needle is then carefully placed in the next follicle and suction is performed again. Some authors flush each follicle with medium, others do not. At the end of the procedure the pelvis is scanned to rule out bleeding.
45
Another application is US guided multifetal pregnancy reduction and salpingocenteses in cases of ectopic pregnancies. In both cases toxic substances (methotrexate or KCl) are injected to the gestational sac with a US-guided needle.
Recent Developments Doppler, Color Doppler and Color Power Angiography Doppler ultrasound allows measurements of blood flow by measuring the change of frequency that occurs when the ultrasound beam is reflected by moving erythrocytes. Spectral Doppler displays the frequency shift in waveform and allows the measurement of absolute velocity and resistance to flow (pulsatility index) at a certain point of the vessel (Fig. 4–7). Color Doppler (CD) displays the blood flow in an area and its direction: blood flow towards the ultrasound transducer is usually red, away from it is displayed as blue. Color power angiography (CPA) uses the amplitude of Doppler signals which represent the density of erythrocytes in the vessel being studied. This provides a more accurate display of tissue perfusion but gives no information about the direction of the flow. Doppler ultrasonography cannot yet be used to monitor stimulated cycles, nor can it be used to predict pregnancy outcome. There is growing evidence that studies of perifollicular vascularity will predict the development of a healthy oocyte. There is still dispute about a significant difference in the pulsatility index of the uterine artery between those women who became pregnant and those who did not after IVF treatment. This relationship has not been identified by all authors and Zaidi et al. offer a possible expla-
Risks Compared with laparoscopic oocyte harvesting, the complication rate using the transvaginal aspiration technique is low. Occasional bleeding from puncture sites or damage to the iliac vessels can lead to complications. Pelvic inflammation has also been seen after oocyte harvesting.
Other Uses of TVUS Needle aspiration can also be performed to reduce ovarian cysts. Even when carried out before oocyte harvesting, it does not seem to have an adverse influence on the pregnancy outcome.
FIGURE 4–7. Doppler measurement of the right ovarian artery in a stimulated ovary. (Courtesy of W. Feichtinger, Institute for Sterility Treatment, Vienna, Austria.)
3051_Seifer_04_p39-48 11/5/01 9:36 AM Page 46
46
T. Widrich
through very tortuous tubes which may improve our ability to assess tubal patency.
Conclusion
FIGURE 4–8. Three-dimensional-ultrasonography. A uterus duplex is displayed using multiplanar mode and Color Doppler. (Courtesy of A. Lee, Department of Prenatal Diagnosis and Treatment, University Hospital of Vienna, Austria.)
nation for this: They have been able to demonstrate a circadian rhythm of the pulsatility index in the uterine artery indicating that uterine perfusion is better in the morning. Future work may help standardize results. CD Ultrasound has been proven to be very useful in assessing tubal patency as described above.
Three Dimensional US A transvaginal three-dimensional scan has been developed that amplifies diagnostic potential (Fig. 4–8). Several two-dimensional images (slices) are taken and the three-dimensional picture is then calculated by the machine. When the volume is obtained it can be analysed in three different ways: reslicing, volume measurements and surface rendering. Reslicing has an advantage over two dimensional ultrasound because slices can be in any angle to the ultrasound probe. Jurcovic et al. have demonstrated the usefulness of this technique for displaying congenital abnormalities of the uterus. Volume measurements are gaining more importance in the measurement of the endometrium. Yaman et al. have demonstrated the reproducibility of endometrial volume measurements and Raga et al. have shown that the volume of the endometrium at implantation may predict pregnancy rates better than two dimensional thickness measurements. Surface rendering gives very impressive pictures of embryos and fetuses. Sladkevicius has also demonstrated its use in gynecology. By combining CPA with three-dimensional US he could obtain accurate pictures of the flow of contrast agent even
Ultrasonography and especially TVUS have become indispensable tools for the gynecologic infertility work-up as well as for monitoring and treating infertility. The use of contrast medium enhances its possibilities, making it possible to avoid laparoscopy and hysteroscopy in selected cases. Color Doppler, CPA, and three-dimensional US are the most recent developments with very promising possibilities although are yet to be evaluated in terms of their usefulness for infertility patients.
References and Suggested Reading Alatas C, Aksoy E, Akarsu C, et al. Evaluation of intrauterine abnormalities in infertile patients by sonohysterography. Hum Reprod. 1997;12:487–490. Ayida G, Chamberlain P, Barlow D, et al. Is routine diagnostic laparoscopy for infertility still justified? A pilot study assessing the use of hysterosalpingo-contrast sonography and magnetic resonance imaging. Hum Reprod. 1997;12:1436–1439. Bakos O, Lundkvist O, Wide L, Bergh T. Ultrasonographical and hormonal description of the normal ovulatory menstrual cycle. Acta Obstet Gynecol Scand. 1994;73:790–796. Balen AH, Conway GS, Kaltsas G, et al. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod. 1995;10:2107–2111. Beneventi F, Sampaolo P, Polatti F, et al. Ultrasonography endometrial patterns in different hormonal treatments to induce ovulation. Radiol Med (Torino). 1995; 90:278–283. Bernaschek G, Rudelstorfer R, Csaicsich P. Vaginal sonography versus serum human chorionic gonadotropin in early detection of pregnancy. Am J Obstet Gynecol. 1988;158:608–612. Blumenfeld Z, Yoffe N, Bronshtein M. Transvaginal sonography in infertility and assisted reproduction. Obstet Gynecol Surv. 1991;46:36–49. Bree RL, Edwards M, Bohm-Velez M, et al. Transvaginal sonography in the evaluation of normal early pregnancy: correlation with HCG level. Am J Roentgenol. 1989;153:75–79. Buttram VC Jr, Gibbons WE. Müllerian anomalies: a proposed classification. (An analysis of 144 cases). Fertil Steril. 1979;32:40–46. de Crespigny L, Kuhn R, McGinnes D. Saline infusion sonohysterosalpingography, an underutilized technique. Aust N Z J Obstet Gynaecol. 1997;37:206–209. De Geyter C, Schmitter M, De Geyter M, et al. Prospective evaluation of the ultrasound appearance of the
3051_Seifer_04_p39-48 11/5/01 9:36 AM Page 47
4. Role of Ultrasonography in Infertility endometrium in a cohort of 1,186 infertile women. Fertil Steril. 2000;73:106–113. DeCherney AH, Laufer N. The monitoring of ovulation induction using ultrasound and estrogen. Clin Obstet Gynecol. 1984;27:993–1002. Deichert U, Schlief R, van de Sandt M, Juhnke I. Transvaginal hysterosalpingo-contrast-sonography (Hy-CoSy) compared with conventional tubal diagnostics. Hum Reprod. 1989;4:418–424. Dickey RP. Doppler ultrasound investigation of uterine and ovarian blood flow in infertility and early pregnancy. Hum Reprod Update. 1997;3:467–503. Dijkman AB, Mol BW, van der Veen F, et al. Can hysterosalpingocontrast-sonography replace hysterosalpingography in the assessment of tubal subfertility? Eur J Radiol. 2000;35:44–48. Fanchin R, Righini C, Ayoubi JM, et al. New look at endometrial echogenicity: objective computer-assisted measurements predict endometrial receptivity in in vitro fertilization-embryo transfer. Fertil Steril. 2000; 74:274–281. Feichtinger W. Follicle aspiration with interactive threedimensional digital imaging (Voluson): A step toward real-time puncturing under three-dimensional ultrasound control. Fertil Steril. 1998;70:374–377. Feichtinger W. Results and complications of IVF therapy. Curr Opin Obstet Gynecol. 1994;6:190–197. Feichtinger W. Current technology of oocyte retrieval. Curr Opin Obstet Gynecol. 1992;4:697–701. Fleischer AC. Sonographic assessment of endometrial disorders. Semin Ultrasound CT MR. 1999;20:259– 266. Fukuda M, Fukuda K, Yding Andersen C, Byskov AG. Healthy and atretic follicles: vaginosonographic detection and follicular fluid hormone profiles. Hum Reprod. 1995;10:1633–1637. Fukuda M, Shimizu T, Fukuda K, et al. Transvaginal hysterosonography for differential diagnosis between submucous and intramural myoma. Gynecol Obstet Invest. 1993;35:236–239. Goldstein SR, Timor-Tritsch IE: Ultrasound in Gynecology 1st Ed. Churchill Livingstone Inc. 1995. Gronlund L, Hertz J, Helm P, Colov NP. Transvaginal sonohysterography and hysteroscopy in the evaluation of female infertility, habitual abortion or metrorrhagia. A comparative study. Acta Obstet Gynecol Scand. 1999;78:415–418. Grunfeld L. The uterus and endometrium. Clin Obstet Gynecol. 1996;39:175–187. Hackeloer BJ. Ultrasound scanning of the ovarian cycle. J In Vitro Fert Embryo Transf. 1984;1:217–220. Jurkovic D, Gruboeck K, Tailor A, et al. Ultrasound screening for congenital uterine anomalies. Br J Obstet Gynaecol 1997;104:1320–1321. Nicolaides KH, Kleinkauf-Houcken A, Huneke B, Lindner C, Braendle W. Combining B-mode ultrasound with pulsed wave Doppler for the assessment of tubal patency. Hum Reprod. 1997;12:2457–2460. La Torre R, De Felice C, De Angelis C, et al. Transvaginal sonographic evaluation of endometrial polyps:
47
a comparison with two dimensional and three dimensional contrast sonography. Clin Exp Obstet Gynecol. 1999;26:171–173. Lande IM, Hill MC, Cosco FE, Kator NN. Adnexal and cul-de-sac abnormalities: transvaginal sonography. Radiology. 1988;166:325–332. Laughead MK, Stones LM. Clinical utility of saline solution infusion sonohysterography in a primary care obstetric-gynecologic practice. Am J Obstet Gynecol. 1997;176:1313–1316. Lee A, Sator M, Kratochwil A, et al. Endometrial volume change during spontaneous menstrual cycles: volumetry by transvaginal three-dimensional ultrasound. Fertil Steril 1997;68:831–835. Orsini LF, Venturoli S, Lorusso R, et al. Ultrasonic findings in polycystic ovarian disease. Fertil Steril. 1985; 43:709–714. Parson AK, Lense JJ: Sonohysterography for endometrial abnormalities: preliminary results. J Clin Ultrasound 1993;21:87–95. Raga F, Bonilla-Musoles F, Casan EM, et al. Assessment of endometrial volume by three-dimensional ultrasound prior to embryo transfer: clues to endometrial receptivity. Hum Reprod. 1999;14:2851–2854. Schlief R, Deichert U. Hysterosalpingo-contrast sonography of the uterus and fallopian tubes: results of a clinical trial of a new contrast medium in 120 patients. Radiology. 1991;178:213–215. Schwimer SR, Rothman CM, Lebovic J, Oye DM. The effect of ultrasound coupling gels on sperm motility in vitro. Fertil Steril. 1984;42:946–947. Shalev J, Meizner I, Bar-Hava I, et al. Predictive value of transvaginal sonography performed before routine diagnostic hysteroscopy for evaluation of infertility. Fertil Steril. 2000;73:412–417. Sladkevicius P, Campbell S. Advanced ultrasound examination in the management of subfertility. Curr Opin Obstet Gynecol. 2000;12:221–225. Smith KE, Buyalos RP. The profound impact of patient age on pregnancy outcome after early detection of fetal cardiac activity. Fertil Steril. 1996;65:35–40. Soares SR, Barbosa dos Reis MM, Camargos AF. Diagnostic accuracy of sonohysterography, transvaginal sonography, and hysterosalpingography in patients with uterine cavity diseases. Fertil Steril. 2000;73: 406–411. Sohaey R, Woodward P. Sonohysterography: technique, endometrial findings, and clinical applications. Semin Ultrasound CT MR. 1999;20:250–258. Speroff L, Glass RH, Kase NG. The polycystic ovary. In: Clinical Gynecologic Endocrinology and Infertility. 6th Edition, Baltimore: Williams & Wilkins 1999. Strandell A, Bourne T, Bergh C, et al. The assessment of endometrial pathology and tubal patency: a comparison between the use of ultrasonography and X-ray hysterosalpingography for the investigation of infertility patients. Ultrasound Obstet Gynecol. 1999;14:200– 204. Strandell A, Bourne T, Bergh C, Granberg S, Thorburn J, Hamberger L. A simplified ultrasound based infer-
3051_Seifer_04_p39-48 11/5/01 9:36 AM Page 48
48
T. Widrich
tility investigation protocol and its implications for patient management. J Assist Reprod Genet. 2000; 17(2):87–92. Timor-Tritsch IE, Rottem S. Transvaginal ultrasonographic study of the fallopian tube. Obstet Gynecol. 1987;70:424–428. Ubaldi F, Wisanto A, Camus M, et al. The role of transvaginal ultrasonography in the detection of pelvic pathologies in the infertility workup. Hum Reprod. 1998;13:330–333. Van der Auwera I, D’Hooghe TM. Ultrasound covers and sonographic gels are embryo-toxic and could be replaced by non-toxic polyethylene bags and paraffin oil. Hum Reprod. 1998;13:2234–2237.
Widrich T, Bradley LD, Mitchinson AR, Collins RL. Comparison of saline infusion sonography with office hysteroscopy for the evaluation of the endometrium. Am J Obstet Gynecol. 1996;174:1327–1334. Wolman I, Groutz A, Gordon D, et al. Timing of sonohysterography in menstruating women. Gynecol Obstet Invest. 1999;48(4):254–258. Wu MH, Tang HH, Hsu CC, et al. The role of threedimensional ultrasonographic images in ovarian measurement. Fertil Steril. 1998;69:1152–1155. Yaman C, Sommergruber M, Ebner T, et al. Reproducibility of transvaginal three-dimensional endometrial volume measurements during ovarian stimulation. Hum Reprod. 1999;14:2604–2608.
3051_Seifer_05_p49-57 11/5/01 3:13 PM Page 49
5 Coping with Infertility: Practical Psychosocial Issues Dorothy A. Greenfeld
Three questions obsess infertile patients. “Am I ever going to be pregnant?” is heard with great frequency by physicians working with this population. Though patients may dread the answer, their longing for pregnancy and their fears that parenthood is forever out of reach compel them to ask the question. The other two questions are usually unspoken but are fueled by the ceaseless distress and anxiety patients suffer because of their inability to conceive: “Am I losing my mind?” and even more frightening “Is the distress that I feel preventing me from getting pregnant?” Physicians working with infertile individual(s) serve their patients well when they anticipate all three questions and when they include psychological support and counseling as an integral part of a comprehensive treatment plan. It has long been a common idea that infertility is “all in the mind,”1–3 so it is not surprising that patients fear they are the cause of their own infertility. Despite the long-standing myth that infertility has a psychiatric basis, studies on the psychological aspects of infertility have consistently demonstrated that infertile individuals are psychologically “normal” and that the experience of infertility rarely results in severe psychological sequelae or disabling psychiatric disorders.4–6 The emotional experience of infertility and its treatment, however, is generally concluded to be difficult and can have a profound impact on affected individuals and couples.6–8 Moreover, clinical data support the notion that participants in infertility treatment can benefit from psychological support and counseling, and that there is an important role for the mental health professional in this milieu.6,9,10 This chapter focuses on what clinicians who work with infertile patients can learn from studies
on the psychological aspects of infertility and how they can help patients cope with the typical psychosocial stressors associated with infertility. Some of the psychologically and ethically complex treatment decisions faced by infertile patients and the role of the mental health professional are discussed here. The chapter concludes with recommendations for clinicians dealing with couples and individuals faced with these difficult problems.
What Have We Learned from Research? Historically, infertility was thought to be a “woman’s problem,” and her psychological state was considered to be at the root of the problem. Indeed, papers on medical and psychological aspects of infertility from the first half of the twentieth century were generally in agreement that by unconsciously rejecting pregnancy, childbirth, and motherhood women caused their own infertility.1–3 This simplistic (and sexist) notion began to change during the late 1960s and early 1970s as studies appeared in the psychiatric and gynecologic literature that compared data from infertile women with data from matched controls (fertile women) and found no differences in their psychological state.11,12 At the same time, clinical reports began to emerge suggesting that there were certain predictable emotional responses to infertility and that infertile patients could benefit from psychological counseling and support.9,13–16 Studies using standard psychological measures have found that there are no differences in the psy-
49
3051_Seifer_05_p49-57 11/5/01 3:13 PM Page 50
50
D.A. Greenfeld
chological state between infertile couples and fertile controls.4,17,18 Nevertheless, these studies have continued to demonstrate that, although psychologically normal, infertile patients experience a high degree of emotional dysphoria and euphoria as a result of infertility and its treatment.5,6 For example, in a study of 59 infertile women, Downey et al. reported that 76% of the subjects through that infertility caused them serious psychological consequences.19 In another study of 63 infertile women and 37 infertile men, Mahlstedt et al.7 reported that subjects felt hopeless and depressed. In a study of 200 couples entering in vitro fertilization (IVF) treatment, Freeman et al.8 reported that 48% of the women and 15% of the men described infertility as the “worst experience of their lives.” Researchers have also considered whether patients’ coping strategies—how they cope with life in general—may serve as a predictor for how they endure a failed cycle of infertility treatment. For example, Litt et al.20 and Newton et al.21 reported that patients who demonstrated pretreatment depressive symptoms and pretreatment anxiety symptoms were more likely to have a poor emotional response to a failed cycle of IVF. The coping strategies that employ psychologically “distancing” oneself from the treatment appear to be the least effective. For example, in Litt et al.’s study the patients who had the most difficulty after a failed cycle were women who used “escape” as a coping strategy.20 In a similar report, Hynes et al. studied 100 infertile women and found that the women who used “avoidance” as a coping strategy were more likely to experience psychological distress after a failed treatment cycle.22 What can we learn from this research? Over the course of their infertility and its treatment patients typically experience a range of emotional responses, including guilt, anxiety, depression, and grief. These responses, which vary from patient to patient, are a normal part of the process. Although at times causing stress and symptoms, they do not in themselves suggest a psychologically unstable individual. The quality and content of the experience of infertility for most couples change over time.23 Nevertheless, there are certain practical psychosocial issues with which couples must cope as they go through the process—issues clinicians should keep in mind as they consider what is best for their patients. Such issues include the impact of the diagnosis, the impact of the treatment, gender differences in response to infertility and how they affect the way couples cope with the process, and coming to the decision to end treatment.
Practical Psychosocial Issues Impact of the Diagnosis Most people take their fertility for granted. In fact, a common complaint from individuals and couples when they have difficulty conceiving is “we were so careful to avoid pregnancy until we were ready.” Thus in what is commonly described as a “life crisis”10,16 couples go in short order from an assumption of assured fertility to one of absolute dismay at what is experienced as unfair and wholly unexpected infertility. The initial denial and “this can’t be happening to me” feelings may later change to intense remorse. The intensively painful experience of finding oneself defined as infertile in what appears to be a highly fertile world leads to feelings of isolation and guilt and the inevitable questions: “Why me”? Rosenthal24 described guilt as a primary emotional response common to many couples diagnosed with infertility: guilt about waiting too long to start a family, guilt about previous life events such as pregnancy termination or a sexually transmitted disease. The guilt can exacerbate feelings of remorse, leading to acute anxiety. Frequently the experience is to go from taking fertility for granted directly to an all-out aggressive attempt to achieve pregnancy—an emotional juxtaposition that forces entry into a world heretofore completely unknown to them. Infertile patients frequently complain that their lives have been completely “taken over” by their infertility, pervading their marital relationships, their sexual life, their relationships with their families, their social relationships (where everyone around them is getting pregnant and having babies). Once they begin treatment, infertility also can have a devastating effect on their financial life. The oftused phrase “the emotional roller coaster of fertility” aptly describes the euphoria and dysphoria so often associated with their experience. Over time, these feelings can become chronic23 as the length of the typical struggle with infertility and its treatment can lead to a growing sense of losing control of the process. All to often the result is a profound decline in the individual’s sense of integrity, competence, and feelings of self-worth. Mahlstedt described eight common losses associated with infertility.25 1. 2. 3. 4.
Loss Loss Loss Loss
of of of of
a (potential) relationship health status or prestige self-esteem
3051_Seifer_05_p49-57 11/5/01 3:13 PM Page 51
5. Coping with Infertility: Practical Psychosocial Issues
5. Loss of self-confidence 6. Loss of security 7. Loss of a fantasy or hope of fulfilling an important fantasy 8. Loss of something or someone of great symbolic value
Impact of Treatment In addition to the emotional impact of infertility are the rigorous, expensive, and often humiliating demands of the medical treatment. By its nature, the treatment necessarily involves a prolonged intrusion into the most intimate aspects of the infertile couple’s life. The charting of basal body temperatures, the precise timing of sexual intercourse, and the need to perform “sex on demand” to optimize the possibility of conception are only the first and most benign of these intrusions. Later requirements may include invasive surgical procedures, taking ovulation-enhancing hormones by injection, undergoing intrauterine inseminations, and ultimately, for some, participation in assisted reproduction techniques such as IVF. Clearly, the pace and scope of treatment varies from one couple to the next, but the experience for all feels lengthy. The extended and repetitive nature of what to the physician may seem like innocuous treatments can have a devastating cumulative impact on the couples’ sexual and marital relationship. The couple must try to maintain a semblance of normal life while trying to accommodate a grueling, often hectic treatment schedule—all at a time when they feel in a “limbo” of uncertainty about whether any of the efforts will succeed. Some patients jokingly say, “I have learned more about the reproductive system than I ever imagined I would need to,” whereas for others the treatment regimens are confusing and difficult to understand. Already socially isolated from their fertile family members and friends, they find themselves feeling intimidated and anxious about broaching questions to the treatment staff. As the treatment becomes more complex, couples may be distressed to find themselves unprepared but contemplating a treatment prohibited by their religion or one they find ethically troubling. For example, couples are asked to decide whether to freeze, destroy, or donate excess embryos, whether they would tolerate a risky multifetal pregnancy, or whether they would consider fetal reductions (aborting one or more of the fetuses) to increase the likelihood of survival of the remaining reduced number of fetuses.
51
Gender Differences in Response to Infertility As though the social, sexual, and financial impact of prolonged treatment on their relationship were not enough with which to contend, infertile couples must also confront the fact that they as individuals may have different responses to infertility and its treatment—differences related to gender. Without education and preparation to help them understand that this is normal, couples are often frightened by these differing responses and fear that it means they are losing everything, including their relationship. In fact, it is often quite the opposite. The experience of infertility often brings couples closer, strengthening the bonds between them. Because it is often true that they have different coping skills, the closeness resulting from the challenge of infertility can make them stronger as a team, although in the short run these differences can add to the couples’ difficulties.
Female Response to Infertility Many women worry about and doubt their fertility long before they try to conceive. When they are diagnosed as infertile they typically experience it as evidence of personal failure. (Interestingly, this is a typical reaction from women even when it is their male partner who is infertile.) Women typically see infertility as a punishment for their imagined previous “sins” (such as an abortion early in life). They frequently ruminate about time lost, time wasted, or experiences they “should not have had.” At the beginning of the workup phase, women are more likely to question their sexuality, to have increasing self-doubt, and to experience greater emotional distress than men.25–27 After prolonged infertility treatment women often report a decrease in sexual satisfaction and a loss of libido.23 Women are also typically much more affected by outside influences, such as who among their friends, relatives, and acquaintances is pregnant. No matter what the diagnosis, women report more feelings of role failure and diminished self-esteem. Though potentially more psychologically vulnerable to the “fertile world around them,” women nonetheless tend to show better coping skills in terms of reaching out to develop social networks with family and friends. It is often the woman who initiates and seeks out psychological support from a mental health professional and support groups.27
3051_Seifer_05_p49-57 11/5/01 3:13 PM Page 52
52
D.A. Greenfeld
Male Response to Infertility Men tend to assume that infertility is “a woman’s problem,” an assumption often reinforced by their female partners’ willingness to take on responsibility for the problem. This assumption may be inadvertently further compounded by the medical treatment team, who may not bother to perform a semen analysis until long after the female partner has been subjected to invasive diagnostic procedures. Men are less likely than women to question their fertility prior to treatment, and in many cases it comes as a shock to a man to learn that he is the infertile partner. These men report feelings of loss, diminished self-esteem, and a sense of being stigmatized.28 Nonetheless, their distress is generally not as severe as that of women. Men report feeling sad and disappointed but not devastated. In general, men appear to be more accepting of possible childlessness and are more willing then women to consider an end to treatment when infertility is due to a male factor. As a result, the man is usually the partner who is more reluctant to participate in an assisted reproductive technology program. (Women may interpret this reluctance as a lack of interest or a lack of agreement about family goals.) Whoever is the infertile partner, men more often tend to use distancing strategies to mute the intensity of their feelings of loss while at the same time remaining especially sensitive to their partner’s distress.27
Ending Treatment As treatment continues, the litany of anxieties and concerns among the infertile increasingly includes the question: “When is enough enough?” Obviously, at a time when it seems that the treatment possibilities are endless (i.e., the advent of advanced maternal age as a result of treatment with donated oocytes) this question is not easily answered. Infertile couples address this issue in many ways. For example, some couples go to the “end of the earth” to seek treatment and technology, and others decline any treatment. For some these decisions are made based on financial constraints, and for others they are based on religious or cultural taboos; but for all its worth attention from the treatment team. Though patients may hesitate, they want and appreciate discussion and guidance on this matter from their clinicians. Physicians can be most helpful when they give an ongoing honest assessment of the diagnosis, plan, and prognosis. Patients may raise their concerns about stop-
ping treatment as a way of putting the issue on the table; but merely raising the issue does not mean they are ready to stop immediately. Other patients want to have a plan for closure: for example, “We will try two more cycles of intrauterine inseminations and then we stop.” For all patients, stopping treatment involves a decision-making process and careful consideration. Some consider other options for parenthood such as adoption. Others explore third party reproduction, such as oocyte donation or a gestational surrogate. They also may consider not having children at all. The physician can be most helpful by taking a careful, guiding, but scrupulously neutral approach. What is not helpful is a statement such as, “You ought to consider adoption” as a euphemism for “This treatment is not going anywhere.”
Special Considerations of Pregnancy After Infertility Though the above practical psychological issues are experienced to some degree by everyone going through infertility treatment, not all patients need to spend a great deal of time looking at other options. After all, some do get pregnant. It might seem that, having achieved their goal, they would be pleased, grateful, and free of stress. Pregnancy itself, however, raises some specific issues that challenge the formerly infertile woman. All pregnant women worry about pregnancy loss and the health of their unborn child. These worries are often accentuated for the formerly infertile.
Pregnancy The issue of pregnancy is on the minds of these infertile women much if not most of the time. The result is a repetitive pattern of mood fluctuation with each menstrual cycle. During part of the cycle they are excited and optimistic, almost certain that this time conception has occurred. During this period they are completely focused on each bodily change, each nuance that may indicate the earliest stage of pregnancy. This heightened expectation of pregnancy is often compounded by symptoms caused by the infertility medications that mimic pregnancy (what Sandelowski et al. referred to as a “drug-induced pseudocyesis”).29 For example, these medications may cause patients to experience nausea, weight gain, and sore breasts or delayed menses, all of which can be interpreted as early signs or symptoms of pregnancy. Once menses
3051_Seifer_05_p49-57 11/5/01 3:13 PM Page 53
5. Coping with Infertility: Practical Psychosocial Issues
occurs, the patient’s mood plunges. She is not pregnant and, she fears, never will be. What happens when, after infertility, pregnancy is clearly documented? Olshansky described an “identity shift” experience by the formerly infertile woman. At first, while anxiously straddling the fence between infertility and pregnancy, she may have difficulty seeing herself as a “normal pregnant woman.”30 Bernstein et al. described the normal ambivalence and questions about competence that affects all pregnant women. The author stated that these questions and anxieties are typically intensified in the newly pregnant (formerly infertile) patient who may voice doubts about her self-worth and her competence as a mother.31 The anxiety associated with infertility and its treatment may carry over and continue into the pregnancy. Concerns about “defective reproductive machinery” may extend to fears about potential problems with the pregnancy or subsequent delivery. When in fact there are prenatal or neonatal problems, women tend to feel guilt and shame, which they associate with their former infertility. Lind et al. described the impact of prior infertility on parents whose newborn children required treatment in the newborn intensive care unit. Even when the child’s illness had no connection whatsoever with the infertility, the mothers experienced a profound sense of loss and grief that they associated with their “defective” state.32
Pregnancy Loss Many imagine that miscarriage would be the worst thing that could happen to patients who have finally conceived after a long, difficult effort. In fact, that is not what the evidence shows. Women who are lucky enough to conceive after infertility treatment often report feeling vulnerable and often worry intensely about losing the pregnancy (some preparation and much reassurance is called for at this point). However, if that pregnancy results in a miscarriage, the disappointment is lessened because the women are frequently relieved to know they can achieve pregnancy and they at least have had that experience. Harris et al. described the paradox that infertile couples grieving after a miscarriage may simultaneously experience a kind of relief, an “emotional gain” that is the result of just knowing that they were able, if only for a short while, to be a part of “the fertile world.”33 Nevertheless, pregnancy loss following infertility merits special consideration. One study reported increased levels of depression in women following pregnancy loss, and most at risk were the childless women.34
53
Multiple Pregnancy and Multifetal Pregnancy Reduction Rapid advances in the methods of assisted reproduction have led to an increase in multiple pregnancies.35 Patients who have been trying to conceive for years may not know that their medical treatment causes an increased risk of multiple pregnancy; and even if they are aware of that risk, they may welcome it, hoping to have more than one child.36 They may not fully understand the risks associated with multiple pregnancy, such as prematurity and infant mortality. In fact, pregnancies involving three or more fetuses constitute such a significant risk that it has led to the development of another treatment: multifetal pregnancy reduction. Because of the ethically complex issues associated with this treatment—one that may involve aborting one or more fetuses to save one or more fetuses—has raised concerns among clinicians. Two studies have considered the long-term psychological consequences of multifetal pregnancy reduction and have concluded that although women undergoing this procedure become distressed and suffer some short-term depression, most accept it as a painful necessity and report that they would willingly undertake it again.37,38
Pregnancy Following Treatment with Donor Gametes Although artificial insemination with donor sperm has been available to infertile couples for nearly a century, treatment of women with donor oocytes has been available only since 1984. Though conceptually similar, these treatments are significantly different. Treatment with donor oocytes is a more complicated, invasive, and expensive procedure than donor insemination. Furthermore, it has introduced a new cohort of patients into treatment, such as women with premature ovarian failure, women who have had surgically lost ovaries because of serious illness, and women of advanced reproductive age. Whether the couple is utilizing donor sperm or donated oocytes, however, the pretreatment preparation and many of the counseling issues remain the same. The couple must mourn the loss entailed by the fact that one of the parents is not genetically related to the potential child. The couple must also deal with the difficult decision as to whether they will utilize an anonymous or a known donor. Couples are also faced with questions about what to tell the potential child. What (if anything) and when should they tell the child about his or her conception?
3051_Seifer_05_p49-57 11/5/01 3:13 PM Page 54
54
D.A. Greenfeld
Role of the Mental Health Professional The identified psychological stresses of infertility treatment, the need to cope with demanding treatment protocols, and the expanding array of ethically complex issues have led to a steadily increasing appreciation of the role of the mental health professional on the infertility treatment team. Mental health professionals are utilized to assess and evaluate participants in infertility treatments, provide psychotherapeutic intervention and support, and serve as educators in a difficult and complex milieu.
Psychological Consultation and Evaluation Ideally, the mental health practitioner is an integral part of an interdisciplinary treatment team. In this context, routine evaluation by the mental health professional gives the patient the message that the demanding nature of the treatment requires a degree
of counseling, education, and support. Its routine nature suggests that the psychological stresses of treatment are “normal and expected.” Psychological consultation and evaluation give the patient an opportunity to express concerns he or she may have about the treatment as it allows the clinician an opportunity to form a picture of the participant. A medical practitioner with a small practice or who is incorporating infertility treatment into a gynecologic practice may not have a mental health practitioner available as part of the on-site team. In these instances it is important to obtain a thorough history that could include recommendations for referral to a mental health practitioner when appropriate. The assessment should be designed to determine whether further psychological evaluation is necessary. There are several models for the content of such an assessment. One such document is The Comprehensive History of Infertility (CPHI), developed by Burns and Greenfeld (1990) for the Mental Health Professional Group of the American Society for Reproductive Medicine (Table 5–1). The CPHI contains the reproductive history, psy-
TABLE 5–1. Comprehensive Psychosocial History of Infertility 1990 Reproductive History Infertility Current infertility: primary or secondary History of past infertility Pregnancy Living children (stepchildren, adopted, donor offspring, placed for adoption) Therapeutic abortion(s) Spontaneous abortion(s) Other perinatal loss: SIDS, death of child High-risk pregnancy History of genetic/chromosomal abnormalities Cancer of the reproductive tract and/or chemotherapy DES exposure Congenital abnormalities of the reproductive tract Family history of genetic disorders Mental Status Psychiatric history Hospitalization for psychiatric illness Psychiatric treatment Treatment with psychotropic medication Substance abuse Current mental status Symptoms of depression Symptoms of anxiety/panic attacks Symptoms of obsession Current use of psychotropic medications Current problem with substance abuse/addiction Change in mental status Exacerbation of prior psychiatric symptoms
Sexual History Frequency and response Function/dysfunction Religious or cultural influence on sexual patterns or procreation beliefs Sexual history Function/dysfunction Sexually transmitted disease Prior sperm donor/surrogate mother/consideration of use of donor gametes Homosexual or ambisexual patterns History of rape or incest Changes in any sexual patterns secondary to infertility or medical treatment. Relationship Status Marital History of marriages/divorces History of marital discord/therapy Extramarital relationships Current satisfaction/dissatisfaction Ambivalence about medical treatment and reproductive technologies Familial History of dysfunctional family of origin Recent deaths or births in family History of numerous familial losses Social Available support system Career disruptions or pressures History of or current legal problems Criminal conduct
(Reproduced from Burns LH, Greenfeld DA, for the Mental Health Professional Group. CPHI: Comprehensive Psychosocial History for Infertility. Birmingham, AL: American Society for Reproductive Medicine, 1990.)
3051_Seifer_05_p49-57 11/5/01 3:13 PM Page 55
5. Coping with Infertility: Practical Psychosocial Issues
chological history, marital history, sexual history, and social history. Findings suggesting that referral to a mental health professional is appropriate include a history (past and present) of psychiatric illness, a history of pregnancy complications and loss, a history of sexual abuse, past or current chemical abuse or dependence, or a chaotic social or familial situation. Of course, any patient who requests such a referral should be provided one.39 Many programs of assisted reproductive technology require pretreatment evaluation and assessment of patients to determine if they are prepared for the rigors of the treatment, if they understand and are able to give informed consent to the treatment, if they are psychologically stable. One such program developed a set of guidelines for psychological evaluation.40 The following is a checklist of areas for consideration during the pretreatment evaluation and assessment of participants in treatment. 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11.
Patient reliability Ability to provide informed consent Stability of the couple’s relationship Psychological issues for the infertile partner Expectations of infertility treatment Understanding the impact of the technology Current and past sexual functioning Level of social support Religious and cultural considerations Psychiatric status Legal history
Psychological Support and Counseling For patients who have a seriously troubled history or who are in immediate psychological distress, a referral for psychotherapy is indicated. Even the large number of patients who do not merit referral are likely to be reassured that psychological support is available if needed. Several modalities of psychotherapeutic intervention have been effective for treatment of infertile individuals and couples. Therapeutic sessions may be conducted individually, with the couple (or family) together, or with one or both partners as participants in a group treatment. The focus of therapy may be alleviation of distress and control of psychological symptoms, sex therapy, or grief management. The techniques may include supportive, cognitive, or psychodynamically oriented treatment. Most of the referrals are for brief treatment involving crisis intervention designed to provide short-term support and symptom relief. The choice of modality usually depends
55
on the nature of the problem, the patient(s) preferences, and the availability of each option. Though it is an individual’s or couple’s choice about the treatment modality, it is usually up to the referring clinician to initiate the referral, explaining the rationale for the recommendation. Whatever the choice of treatment focus or modality, one thing is clear: Gone are the days when physicians referred their infertile patients to psychotherapists for the purpose of helping them “work through unresolved conflicts impeding their changes for pregnancy.” Nowadays, the goal of psychotherapeutic intervention is to recognize that infertility is highly stressful and that dealing with it can enhance one’s ability to cope with the psychological and physical stresses of the problem.
Individual Therapy Many patients prefer individual treatment. It is the most private, secure, and common treatment modality, one that is likely to be most familiar and acceptable. When a patient has a clear preference for individual treatment, it should generally be honored unless there is a clear indication that another modality is indicated.
Couples Therapy Menning described the problem of infertility, no matter who is responsible for the diagnosis, as one that always affects the couple’s marriage, their friendship, and their sexual relationship.15 Hence couples treatment is often the most useful for infertile couples. It provides a safe forum where they can deal with conflicts, listen to each other, and deal with gender differences in response to the problem.
Group Therapy Many couples find group therapy especially useful. Groups of infertile couples can provide support, education, and the kind of empathy available only to those who are experiencing the same stresses. The experience of talking with others in the same predicament can help “normalize” the experience and provide a level of reassurance that makes the experience more tolerable. A prospective study of the effectiveness of support groups for the infertile concluded that they are “a highly acceptable and effective intervention in self-referred patients in alleviating psychological distress related to infertility.”40
3051_Seifer_05_p49-57 11/5/01 3:13 PM Page 56
56
D.A. Greenfeld
Recommendations for Physicians Infertile patients are surrounded by family and friends who advise them to “relax and you’ll get pregnant” (which of course only adds to their anxiety and distress). Obviously, it is helpful to patients when the medical team does not participate in that sort of advice. It is especially helpful to patients when their physicians reassure them that their anxiety is not preventing them from becoming pregnant. Moreover, physicians serve their infertile patients well when they communicate the fact that psychological stress is a temporary but inevitable part of the process. Physicians who have an indepth understanding of the psychological and emotional aspects of this complex problem can reassure and support patients, recognize when they need additional support, and help them find and use that support. Kingsberg41 listed the following recommendations for physicians treating infertile patients. 1. Educate and inform couples at each visit about their diagnosis, prognosis, and treatment options, even if it seems redundant. 2. Acknowledge and normalize the emotional aspects of these treatment options. 3. Encourage couples not to rush their decision about treatment. 4. Encourage couples to consult with a mental health professional.
References 1. Deutsch H (1944) The Psychology of Women. New York: Grune & Stratton. 2. Fisher IC. Psychogenic aspects of sterility. Fertil Steril 1953;4:466–471. 3. Benedek T. Infertility as a psychosomatic defense. Fertil Steril 1952;3:527–535. 4. Downey J, McKinney M. The psychiatric status of women presenting for infertility evaluation. Am J Orthopsychiatry 1992;62:196–205. 5. Berg BJ, Wilson JF. Psychiatric morbidity in the infertile population: a reconceptualization. Fertil Steril 1990;53:654–661. 6. Mazure CM, Greenfeld DA. Psychological studies of in vitro fertilization/embryo transfer participants. J In Vitro Fert Embryo Transfer 1989;6:242–49 7. Mahlstedt PP, MacDuff S, Bernstein J. Emotional factors and the in vitro fertilization and embryo transfer process. J In Vitro Fert Embryo Transfer 1987; 4:232–236. 8. Freeman EW, Boxer AS, Rickels K, et al. Psychological evaluation and support in a program of in vitro. Fertil Steril 1985;43:48–53.
9. Berger DM. The role of the psychiatrist in the reproductive biology clinic. Fertil Steril 1977;28:141– 145. 10. Covington SN. Psychosocial evaluation of the infertile couples: implications for social work practice. J Soc Work Hum Sexuality 1987;6:21–36. 11. Mai FM, Munday RM, Rump EE. Psychiatric interview comparisons between infertile and fertile couples. Psychosom Med 1972;12:46–59. 12. Noyes RW, Chapnick EM. Literature on psychology and infertility. Fertil Steril 1964;15:543–548. 13. Menning BE. The infertile couple: a plea for advocacy. Child Welfare 1975;54:545–560. 14. Menning BE. Resolve: a support group for infertile couples. Am J Nurs 1976;76:258–259. 15. Menning BE. Counseling infertile couples. Contemp Obstet Gynecol 1979;13:101–108. 16. Menning BE. The emotional needs of infertile couples. Fertil Steril 1980;34:313–319. 17. Adler JD, Boxley RL. The psychological reactions to infertility: sex roles and coping styles. Sex Roles 1985;12:271–279. 18. Connolly KJ, Edelmann RJ, Cooke ID, et al. The impact of infertility on psychological functioning. J Psychosom Res 1992;36:459–468. 19. Downey J, Yingling S, McKinney M, et al. Mood disorders, psychiatric symptoms, and distress in women presenting for infertility evaluation. Fertil Steril 1989;52:425–432. 20. Litt MD, Tennen H, Affleck G, et al. Coping and cognitive factors in adaptation to in vitro failure. J Behav Med 1992;15:171–187. 21. Newton C, Hearn M, Yuzpe A. Psychological assessment and follow up after in vitro fertilization: assessing the impact of failure. Fertil Steril 1990;54: 879–886. 22. Haynes GJ, Callan VJ, Terry DJ, et al. The psychological well-being of infertile women after a failed IVF attempt: the effects of coping. BMJ 1992;65: 269–278. 23. Berg BJ, Wilson JF. Psychological functioning across stages of treatment for infertility. J Behav Med 1991; 14:11–26. 24. Rosenthal MB. Psychiatric aspects of infertility and assisted reproductive technologies. Infertil Reprod Med Clinics of North Am 1993;4:471–482. 25. Mahlstedt PP. The psychological component of infertility. Fertil Steril 1985;43:335–346. 26. Daniluk JC. Strategies for counseling infertile couples. J Counsel Dev 1991;69:317–320. 27. Abbey A, Andrews FM, Halman LJ. Gender’s role in responses to infertility. Psych Women Q 1991;15: 295–316. 28. Natchtigall RD, Becker G, Wozny M. The effects of gender-specific diagnosis on men’s and women’s response to infertility. Fert Steril 1992;57:113–121. 29. Sandelowski M, Harris BG, Holditch-Davis D. Pregnant moments: the process of conception in infertile couples. Res Nurs Health 1990;13:273–282. 30. Olshansky EF. Psychosocial complications of preg-
3051_Seifer_05_p49-57 11/5/01 3:13 PM Page 57
5. Coping with Infertility: Practical Psychosocial Issues nancy after infertility. NAACOGS Clin Issu Perinat Womens Health Nurs 1990;1:342–347. 31. Bernstein J, Mattox JH, Kellner R. Psychological status of previously infertile couples after a successful pregnancy. J Obstet Gynecol Neonatal Nursing 1988; 12:404–408. 32. Lind RF, Pruitt RL, Greenfeld DA. Previously infertile couples and the newborn intensive care unit. Health Soc Work 1989;14:127–144. 33. Harris BG, Sandelowski M, Holditch-Davis D. Infertility: a new interpretation of pregnancy loss. Mat Child Nurs 1991;16:217–220. 34. Neugebauer R, Kline J, Shrout P, et al. Major depressive disorder in the 6 months after miscarriage. JAMA 1997;277:383–388. 35. Berkowitz R, Lynch L, Chitkara U, et al. Selective reduction of multifetal pregnancies in the first trimester. N Engl J Med 1988;16:318. 36. Lieblum SR, Kemmann E, Taska L. Attitudes toward multiple births and pregnancy concerns in infertile and noninfertile women. J Psychosom Obstet Gynaecol 1990;11:197. 37. Shreiner-Engel P, Walther VN, Mindes J, et al. Firsttrimester multifetal pregnancy reduction: acute and persistent psychologic reactions. Am J Obstet Gynecol 1995;172:541–547. 38. McKinney M, Downey J, Timor-Tritsch I. The psychological effects of multifetal pregnancy reduction. Fertil Steril 1995;64:51–61. 39. Burns LH, Greenfeld DA. The Comprehensive Psy-
57
chosocial History of Infertility (CPHI). Birmingham, AL: American Society for Reproductive Medicine, 1990. 40. Stewart DE, Boydell KM, McCarthy K, et al. A prospective study of the effectiveness of brief professionally-led support groups for infertility patients. Int J Psychiatry Med 1992;22:173–182. 41. Kingsberg SA. Assisted reproductive techniques and male factor infertility: psychological perspectives on the treatment recommendations of IUI, IVF, and ICSI. Syllabus from the course Male Infertility: The Medical and Psychological Team Approach to Treatment, sponsored by the American Society for Reproductive Medicine, 1996.
Suggested Reading Klock SC, Greenfeld DA. Psychological status of in vitro fertilization patients during pregnancy: a longitudinal study. Fertil Steril 2000;73:1159–1164. Milad MP, Klock SC, Moses S, et al. Stress and anxiety do not result in pregnancy wastage. Hum Reprod 1998; 13:2296–2300. Schover LR. Psychosocial aspects of infertility and decisions about reproduction in young cancer survivors: a review. Med Pediatr Oncol 1999;33:53–59. Infertility Counseling: A Comprehensive Handbook for Clinicians. Edited by Linda Hommer Kurns, Sharon N. Covington. New York: Parthenon Publishing Group, 1999.
3051_Seifer_06_p58-62 11/5/01 9:45 AM Page 58
6 Impact of Managed Care on Office-Based Infertility Practice Richard E. Blackwell
When young couples begin forming a family, they do not anticipate problems with reproduction.1 Often the patients who attend reproductive endocrine infertility clinics are educated, are highly motivated, and have yet to confront an adversity in life that could not be overcome with perseverance. Therefore they may present to the reproductive endocrinologist in a frustrated, angry, confused state. Their view of reproductive medicine may be tainted by articles in the news, sensational press releases, and magazine articles with titles such as, “The Frightening Future of Baby Making” or “High Tech Baby Making.” They see newspaper headlines showing quadruplet gestations with their family members, news articles indicating that gametes have been switched in the laboratory or perhaps sold commercially, and infertility treatment resulting in malignancy or other disease processes.2 There is tabloid exposure in places such as grocery store check-out lines touting titles such as “Animal and Human Sperm Bank Mix-up” and “Tragic Dog Baby Born: Hospital Orders Cover-up.” Although most of these concerns may have questionable relevance to reproductive endocrine practice, they do hit on many sensitive social issues. Perhaps these situations contribute to the fact that 43% of infertile couples never seek help, with approximately 12% seeking care per year. It should also be remembered that this type of lay press is not totally ignored by the insurance industry. Most of these articles confirm the executives’ worst fear about liability in the case of gamete mix-up, the cost of multiple births, and the risk of increasing the insured cancer population.3–8 In other words, it is safe to say that infertility does not exist in a social or political vacuum. Furthermore, infertility does not exist in a vacuum from a medical point of view, although several attempts have been made nationally to seg58
regate the infertility benefit from other disease processes for simplification and ease of projecting risk. Essentially three types of proposal have been presented for dealing with infertility: a capitated plan such as the one implemented by U.S. HealthCare, the infertility protocol presented by Bates Consulting,9 and the Lewin VHI algorithm.10,11 Under the U.S. HealthCare model, the basic infertility workup can be carried out by anyone designated a primary provider. It consists of a semen analysis, postcoital test, hysterosalpingography, and some assessment of ovulation (typically a midluteal progesterone or endometrial biopsy). When most patients have finished this segment of the workup they are referred directly to a limited number of reproductive endocrinologists, completely bypassing the obstetrician/gynecologist. Patients may visit two reproductive endocrine practices and at that juncture choose their tertiary care provider. A capitated arrangement is reached between the corporate entity and the provider, which is in the mid-four-figure region. Any means may be used to achieve conception, such as laparoscopic surgery, intrauterine insemination, gonadotropins, gamete intrafallopian transfer, or in vitro fertilization (IVF). The provider has 2 years to achieve the pregnancy and must maintain a low 20th percentile pregnancy rate to remain eligible for the plan. If conception occurs early during the workup, the provider receives the remainder of the capitated payment. The algorithm presented by Bates Consulting Company involves an initial evaluation of the history, physical examination, semen analysis, hormone evaluation in 35% of the patients, and hysterosalpingography in 30%. One-third of the patients are thought to have disorders of ovulation; this problem is treated by correcting body weight (if 95% or
3051_Seifer_06_p58-62 11/5/01 9:45 AM Page 59
6. Impact of Managed Care on Office-Based Infertility Practice
130% of ideal) and/or therapy with clomiphene citrate, bromocriptine, or prednisone for six cycles as indicated. If no pregnancy results, 30% of the patients undergo office hysteroscopy and then three cycles of IVF. Thirty percent of the patients have ovulatory disorders, and 24% of them undergo operative laparoscopy. Half are thought to have a good prognosis. They attempt pregnancy for 6 months; if no pregnancy results, approximately 40% undergo three cycles of IVF. If they are poor-prognosis patients (50% with extensive tubal disease), they undergo three cycles of IVF. Forty percent of the couples have male factor infertility; 80% are oligospermic, and varicocelectomy is used sparingly. If no pregnancy occurs following surgery, three cycles of IVF are carried out. The azoospermic patient (20%) undergoes six cycles of therapeutic donor insemination. If no pregnancy results, two cycles of IVF are attempted. It should be noted that in this algorithm the patient pays the cost of laboratory evaluation, the cost of all medications including gonadotropins, an additional charge for the IVF cycle, and the cost of donor insemination. The algorithm designed by Lewin VHI was prepared by a panel of infertility experts using a literature review and a modified delphi approach. Infertility was treated as being the result of a variety of disease processes including such entities as a pituitary tumor, central nervous system dysfunction, diabetes mellitus, other systemic disorders, endometriosis, fibroids, adhesions, and eating disorders, among others. The algorithm further depends on a working relationship between the obstetrician/ gynecologist and the reproductive endocrinologist, functioning together as a network. It continuously evolves based on an outcome analysis. It sets boundaries on therapy based on a literature review and outcome analysis. This algorithm is entirely different from a protocol concept, which is derived from an individual anecdotal practice experience that often leads to failure, increased cost, dissatisfied subscribers, and ultimately litigation. Algorithms can be used to improve care, control cost, use resources efficiently, and increase the availability of coverage because it allows the payer to predict the worst case scenario, which generally falls in the range of 0.40 to 0.50 per member per month. This is much lower than is generally thought by the insurance industry. The algorithm also has as its basis a number of facts that influence reproduction. Approximately 54 million women in the United States age 15–45 years who are trying to conceive show subfertility
59
rates in the range of 8.5–25.0%. Infertility acts against a background of changing age in both men and women, with the age of menopause normally ranging between 35 and 57 years (mean 51.4 years) in the U.S. population. By age 35 there is an exponential fall in the fecundity rate, with the fertility rate being approximately 100 per 1000 people at age 40.12 Furthermore, the number of clinically recognized trisomies rises exponentially at age 35, and by age 40 it represents approximately 25% of pregnancies.13 Likewise, the spontaneous miscarriage rate rises exponentially after age 35, and by age 40 it is approximately 30%.13 Ectopic pregnancies rise from 15% per 1000 pregnancies at age 25–34 to nearly 20% at age 35–44.14 In fact, every complication of pregnancy—including abortion, ectopic pregnancy, congenital malformations, prematurity, intrauterine growth retardation, macrosomia, perinatal mortality, fetal death, neonatal death, infant mortality, placenta previa, abruptio placentae, pregnancy-induced hypertension, chronic hypertension, diabetes labor dysfunction, cesarean section, maternal mortality, and maternal morbidity— increases markedly beyond age 35. In addition, the likelihood of conception is associated with agerelated male sexual dysfunction. The conception rate with partners under age 25 with 6 months of unprotected intercourse is 48.5%; at age 40 and over it is 22.7%. The frequency of intercourse decreases with age; and with intercourse occurring less than once per week, the conception rate is 16.7% over 6 months; at more than four times a week the conception rate is 83.3%. Finally, there is an exponential decrease in the number of orgasms per week and an exponential rise in the number of episodes of impotence, which begins at around age 35. All of these factors result in increased cost, decreased productivity of the couple, depression, marital discord, family discord, and isolation of the couple. These factors make powerful arguments for presenting an infertility benefit to providers. Furthermore, as a way of reducing cost, the algorithm stresses over and over again the use of accurate diagnosis, the maximization of pregnancy using low technology therapy, the appropriate use of laparoscopic surgery, and the appropriate use of assisted reproductive technology (ART) early during the workup if need be, all of which is cost-effective. Such an algorithm helps codify a standard of practice; it controls cost, limits other costs such as other surgery as for ectopic pregnancies, predicts outcome, and makes therapy finite. For example, clomiphene citrate ovulation induction is used for five ovulatory cycles, gonadotropin ovulation induction is used for six cycles, IVF is used for four
3051_Seifer_06_p58-62 11/5/01 9:45 AM Page 60
60
R.E. Blackwell
to six cycles. An infertility algorithm also sets the referral pattern; that is, move the patient to the reproductive endocrinologist early during the workup, which is again cost-effective.15
Payment for Services Payment for infertility services generally falls into three general categories: capitation, discounted fee for service, and self-pay. Most reproductive endocrine practices operate with some form of these payments. There is little experience with capitated plans in the area of infertility, and to my knowledge no prospective data have been presented. Our own prospective payment plan, designed for the VIVA program [University of Alabama at Birmingham (UAB)], uses the Lewin VHI algorithm to form the basis of the proposal. A figure of 0.47 per member per month was used to project our expenses and revenues. Eleven months into the first year this figure appears to be correct. The plan covers a semen analysis, postcoital test, hysterosalpingography or sonohysterography, hormone assays, and follicular monitoring by ultrasonography. It also covers surgical procedures to diagnose or treat infertility, ovulation induction including clomiphene and gonadotropin therapy, artificial insemination by donor or husband, and assisted reproductive technology including IVF and gamete intrafallopian transfer. There are exclusions, limitations, and stipulations including a maximum lifetime coverage of nine ovulation induction cycles of clomiphene, six gonadotropin cycles, three artificial insemination cycles, and four ART cycles. In addition to standard co-pay, any service related to hospitalization or outpatient surgical procedures has a 40% co-pay; any drug such as clomiphene, gonadotropins, and gonadotropin-releasing hormone (GnRH) analogues used for treating infertility has a 40% co-pay; and sterilization reversals are excluded under this plan. Our experience over less than a year suggests that there is not an unfavorable selection bias.16 Most of us are familiar with discounted fee for service. Currently, many practitioners receive between $0.30 and $0.50 on the dollar for services rendered. Other than in states that have mandated coverage for ART services, many commercial carriers discontinue therapy at the level of gonadotropins plus intrauterine insemination or following a limited number of treatment cycles with this mode of therapy. Many reproductive endocrinologists favor out-of-pocket payment. Such a philosophy pushes infertility services farther into the boutique
nitch, and it might be that this form of therapy will enjoy the same market dynamics as a cosmetic surgery.
Database and Outcome Analysis Following publication of the article, “Are we exploiting the infertile couple?”17 Congress began to focus effort on standardizing not only infertility but laboratory services. Subsequently, an outcome database was established by the Society for Reproductive Technology; and the Clinical Laboratories Improvement Act (CLIA) regulations were modified. At the same time, following the Clinton failed health care initiative, a marketplace-driven revolution in managed care occurred. Carriers began to insist on accurate databases and outcome analysis. The concept of disease management was simultaneously introduced by both the insurance and pharmaceutical industries. This concept insists that diseases are treated in an incremental manner with the most cost-effective therapy based on a literature review and outcome analysis.18–22 Although these concepts appeal to some and are rejected by others, they raise many difficult issues. We have all seen databases manipulated and outcomes skewed by patient selection and exclusion. Pregnancy rates are clearly diagnosis- and agedependent; and advanced therapies often yield impressive results when applied to those who perhaps do not need them. Furthermore, disease management raises licensure issues, for instance the criminal indictment of a physician-benefits manager by the state of Florida who was charged with practicing medicine in that state without a license. Although this particular physician was licensed to practice in another state, his direction of patient care in Florida was viewed by the courts as a licensure violation. The same issues have been raised with regard to satellite offices, various satellite affiliations, and telemedicine. Likewise, advertisements appearing on the web may fall under the same constraints.
Credentialing Another area that will undoubtedly come under intense focus involves licensure and credentialing. Individuals who practice medicine in any state, regardless of the form, will most likely be required to apply for a license in that state, be networked with physicians who are physically in the location, and be appropriately certified, particularly as we
3051_Seifer_06_p58-62 11/5/01 9:45 AM Page 61
6. Impact of Managed Care on Office-Based Infertility Practice
enter the area of virtual reality in the surgical arena. Certification in reproductive endocrinology will most likely be a requisite for a payment by insurance companies, and failure to be certified will probably result in deselection, as has already been seen in some communities. Payment for sonography will probably be dependent on being certified by the American Registry of Diagnostic Medical Sonographers (ARDMS, 600 Jefferson Plaza, Suite 360, Rockville, MD 20852). Laboratories will have to be certified by both CLIA and The American College of Pathology to be competitive for contract bids.
Networks Networking is one of the most difficult social and legal issues facing reproductive endocrinologists. For instance, many of us practice broad-based reproductive medicine, which means we function as primary, secondary, and tertiary providers for some of our patients. The issue of self-referral from one role to the other is perilous and is being watched intensely by the insurance industry and government. The whole area of networking creates a special dilemma for those of us in academic medicine, as plans such as that presented by U.S. HealthCare seem to strike at the very purpose of a residency training program because the better programs prepare residents to manage broad-based reproductive medicine and infertility problems, up to the stage of assisted reproductive technology utilization. To bypass the skills of so many of our colleagues seems to be an inefficient use of resources. The most efficient treatment of the patient with complex reproductive medicine problems seems to be an initial referral of this patient directly to the obstetrician/gynecologist by the primary care provider, who would work up the patient guided by algorithms and disease management concepts. He or she would consult frequently with the reproductive endocrinologist during the workup and refer the patient who fails to conceive to the reproductive endocrinologist in a timely manner. These steps seem to limit cost and maximize outcome.15 However, in this intense era of competition, the formation of working networks between the reproductive endocrinologist and the obstetrician/gynecologist is at times difficult because problems of ego, training, and practice often interfere with the successful function of these networks. The future of reproductive medicine will be dictated by the use of algorithms, which are no more than a codification of the guidelines of practice advocated by the sub-
61
specialty division of the American Board of Obstetrics and Gynecology. Another issue with which one must deal in networking is antitrust violation and the percentage of market control. Informal networks seem to attract the least attention from government antitrust forces. Under such arrangements individuals could be members of a number of networks, and admission to one would not exclude another. Networks have been described by Foy23,24 in these terms: “The effectiveness of a network is inversely proportional to its goal. A network needs to have a focus not a goal. A network needs a spider at the center, not a chairman. A network needs a note or a newsletter, not a journal. A network needs a good list of members more than a set of bylaws. A network needs groups, not committees. A network needs a phone number, not a building.” In other words, it is an informal network of providers who are willing to come together under a common philosophy and agree to treat patients accordingly. Such an organization, if made up of a strong group of obstetrician/gynecologists and reproductive endocrinologists, would have great appeal to insurance carriers looking for providers for their subscribers. Such networks would also allow the accumulation of enough data to furnish the payers meaningful outcome analyses. This process will always be dynamic as the pendulum of manage